Generated by All in One SEO v4.9.2, this is an llms.txt file, used by LLMs to index the site.

# BioAdvance Capital

Improving Human Health

## Sitemaps

- [XML Sitemap](https://bioadvance.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Insmed Provides Clinical and Business Update](https://bioadvance.com/insmed-provides-clinical-and-business-update/) - Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company
- [ImmunoGenesis Receives $10.8 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Accelerate the Clinical Development of IMGS-001 for Patients with Immune-Excluded Tumors with High Unmet Need](https://bioadvance.com/immunogenesis-receives-10-8-million-grant-from-the-cancer-prevention-research-institute-of-texas-cprit-to-accelerate-the-clinical-development-of-imgs-001-for-patients-with-immune-excluded-tumors/) - IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded a $10.8 million grant from
- [Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations](https://bioadvance.com/latus-bio-announces-ind-clearance-of-lts-101-for-cln2-disease-and-receipt-of-fast-track-orphan-drug-and-rare-pediatric-disease-designations/) - LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore the potential of LTS-101 to address a high unmet medical need PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus
- [Vittoria Biotherapeutics Announces Presentation of First-in-Human Interim Phase1 Data for VIPER-101 at ASH2025](https://bioadvance.com/vittoria-biotherapeutics-announces-presentation-of-first-in-human-interim-phase1-data-for-viper-101-at-ash2025/) - PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in a poster presentation at the
- [Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board](https://bioadvance.com/latus-bio-launches-ai-ml-strategy-to-transform-aav-gene-therapy-adds-two-leading-experts-in-peptide-and-protein-modeling-to-scientific-advisory-board/) - PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University of Toronto). The company’s AI/ML
- [DEBRA Research Invests in Eliksa Therapeutics to Advance ELK-003, a Biological Eye Drop for Epidermolysis Bullosa-Related Ocular Complications](https://bioadvance.com/debra-research-invests-in-eliksa-therapeutics-to-advance-elk-003-a-biological-eye-drop-for-epidermolysis-bullosa-related-ocular-complications/) - The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with DEBRA Chile has enrolled 18 patients to date, with no drug-related side effects observed among the first 8 participants who have completed treatment. The investment round by a
- [Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma](https://bioadvance.com/tolerance-bios-implanted-ipsc-derived-thymic-organoids-enable-in-vivo-positive-selection-of-human-t-cells-and-tumor-burden-reduction-in-melanoma/) - Patient-specific human immune system-bearing mouse model created by implanting human thymic cells derived from iPSC with Tolerance Bio’s proprietary process Human T cells educated in vivo by thymic organoids delayed melanoma tumor growth in a patient derived xenograft model Data support the development of Tolerance Bio’s thymic cells and pharmacological approaches for thymus regeneration in
- [Ascension Invests In Transforming Clinician Productivity and Experience](https://bioadvance.com/ascension-invests-in-transforming-clinician-productivity-and-experience/) - Healthcare is transforming rapidly, driven by technological advancements, evolving patient expectations and shifting demographics. While these changes propel our industry forward, significant gaps in access continue. As we enter this new era, it is critical that we partner with clinicians across the industry to constantly explore new ways to optimize. Continued transformation allows us to
- [Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten- ledaborbactam](https://bioadvance.com/basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic-2/) - Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical
- [Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate](https://bioadvance.com/kayothera-inc-nominates-kayo-1732-a-first-in-class-oral-inhibitor-of-the-retinoid-nuclear-receptor-pathway-in-type-2-diabetes-and-cardiometabolic-indications-as-a-development-candidate/) - SEATTLE--(BUSINESS WIRE) --Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development candidate. KAYO-1732 is a novel, orally-available, small molecule inhibitor of the Aldehyde dehydrogenase 1A3 (ALDH1A3) enzyme, developed for the treatment of type 2 diabetes
- [IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations](https://bioadvance.com/iview-therapeutics-is-pleased-to-announce-the-appointment-of-jeanette-stewart-rn-as-the-director-of-clinical-operations/) - IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO and cofounder of PRN Pharmaceutical
- [First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease](https://bioadvance.com/first-patient-dosed-in-phase-2b-clinical-trial-of-ivw-1001-for-dry-eye-disease/) - First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research Foundation in Newport Beach, California.
- [IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO](https://bioadvance.com/iview-therapeutics-presents-breakthrough-gvb-2001-gene-therapy-for-glaucoma-at-ccrvo/) - IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO [Chongqing, China – July 26, 2025] The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic
- [Summit Pharmaceuticals Signed an Exclusive Distributorship Agreement with Accelerated Biosciences](https://bioadvance.com/summit-pharmaceuticals-signed-an-exclusive-distributorship-agreement-with-accelerated-biosciences/) - Summit Pharmaceuticals Signed an Exclusive Distributorship Agreement with Accelerated Biosciences, US Cell Provider Summit Pharmaceuticals International Corporation (Headquarters: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama, hereinafter “SPI”) has signed an exclusive distributorship agreement with Accelerated Biosciences (Headquarters: Philadelphia, USA; CEO: Yuta Lee, hereinafter “AB”), a US-based company to expand and promote the use of
- [Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care](https://bioadvance.com/kayothera-named-as-a-winner-of-the-american-diabetes-associations-innovation-challenge-to-transform-type-2-diabetes-care/) - Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the winners of the American Diabetes
- [The Future of Healthcare Runs on AI-Powered Automation and Data — Here’s How One Company Is Making It a Reality](https://bioadvance.com/the-future-of-healthcare-runs-on-ai-powered-automation-and-data-heres-how-one-company-is-making-it-a-reality/) - Healthcare is entering a new era filled with opportunity. Hospitals are exploring smarter ways to care for patients with the staff they have. Pharmaceutical companies are rethinking how to bring therapies to market with greater speed and precision. Across the industry, one theme is clear: AI-powered automation and data are unlocking solutions that make healthcare
- [Investing in a Healthier Future: How Atalan Is Enabling Health Systems to Predict and Prevent Surprise Resignations and Protect Revenue](https://bioadvance.com/investing-in-a-healthier-future-how-atalan-is-enabling-health-systems-to-predict-and-prevent-surprise-resignations-and-protect-revenue/) - Atalan is Pioneering the Clinician Retention Intelligence (CRI) Category in Healthcare Healthcare systems thrive when clinicians do. Atalan, a healthcare workforce technology company, is leading the way in helping hospitals and health systems protect revenue, retain clinicians, and sustain high-quality patient care. With over 60% of physicians and nearly half of all nurses reporting symptoms
- [Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration](https://bioadvance.com/tolerance-bio-and-zipcode-bio-announce-strategic-rd-collaboration/) - Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics September 8, 2025 10:30 AM, PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and ZipCode Bio, a biotechnology company
- [Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic](https://bioadvance.com/basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic/) - Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to
- [Strados Labs Collaborates with Rutgers Robert Wood Johnson Medical School](https://bioadvance.com/strados-labs-collaborates-with-rutgers-robert-wood-johnson-medical-school/) - Strados Labs Collaborates with Rutgers Robert Wood Johnson Medical School, RWJBarnabas Health to Evaluate Wearable Respiratory Monitoring Cystic Fibrosis The pilot study explores the RESP® Biosensor’s potential to allow for low-effort home monitoring in patients with acute and chronic cystic fibrosis. by Strados Labs | Aug 28, 2025 | Press Releases Philadelphia, PA, August 28th, 2025 — Strados
- [Wellsheet launches multidisciplinary AI Copilot](https://bioadvance.com/wellsheet-launches-multidisciplinary-ai-copilot/) - Wellsheet launches multidisciplinary AI Copilot to reduce charting time by 50% AI improves chart summarization, multidisciplinary rounding coordination and streamlines discharge planning and documentation NEW YORK, July 17, 2025 /PRNewswire/ -- Wellsheet, a leader in AI clinical workflows and operations, today announced a new Care Team Copilot that combines chart summarization, multidisciplinary rounding and discharge, and AI-generated documentation into
- [ImmunoGenesis Announces the Formation of Scientific Advisory Board](https://bioadvance.com/immunogenesis-announces-the-formation-of-scientific-advisory-board/) - ImmunoGenesis Announces the Formation of Scientific Advisory Board Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies HOUSTON, July 01, 2025 (PR NEWSWIRE) -- ImmunoGenesis, a
- [Bainbridge Health Welcomes B. Braun](https://bioadvance.com/bainbridge-health-welcomes-b-braun/) - Bainbridge Health Welcomes B. Braun to the National Infusion Collaborative™ Bainbridge Health announced that B. Braun Medical Inc. (B. Braun) has joined the National Infusion Collaborative (NIC) PHILADELPHIA, PA, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- Bainbridge Health, a leading provider of medication safety and stewardship solutions, today announced that B. Braun Medical Inc. (B.
- [Latus Bio Strengthens Executive Team with Appointments](https://bioadvance.com/latus-bio-strengthens-executive-team-with-appointments/) - Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect our continued commitment to building
- [Vittoria Biotherapeutics to Share Trials-in-Progress Presentation](https://bioadvance.com/vittoria-biotherapeutics-to-share-trials-in-progress-presentation/) - Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting Trial is evaluating VIPER-101, a novel, gene-edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative therapies for hard-to-treat diseases, today
- [Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells](https://bioadvance.com/accelerated-biosciences-and-stemmatters-collaborate-to-offer-ipsc-derived-from-human-trophoblast-stem-cells/) - Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells PHILADELPHIA--December 16, 2024 (BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human trophoblast stem cells (“hTSC”). By utilizing Accelerated Bio’s innovative hTSC platform,
- [Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round](https://bioadvance.com/tolerance-bio-inc-announces-scientific-advisory-board-and-completion-of-20-2-million-seed-round/) - Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address immune diseases Pacific 8 Ventures
- [Vittoria Biotherapeutics Announces Dosing of First Patient in  Phase 1 Clinical Trial of VIPER-101](https://bioadvance.com/vittoria-biotherapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-viper-101/) - Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101 Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day manufacturing process PHILADELPHIA, Dec. 19, 2024
- [Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial](https://bioadvance.com/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial/) - Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs) to enroll approximately 15 subjects
- [Ossianix Receives Grant from The Michael J. Fox Foundation](https://bioadvance.com/ossianix-receives-grant-from-the-michael-j-fox-foundation/) - Ossianix Receives Grant from The Michael J. Fox Foundation to Advance TXP1 Brain Shuttle for Delivering TrkB Agonist Antibody in Parkinson’s Disease Therapy by PS, 09 Jan, 2025 Stevenage, UK – 9 January 2025 – Ossianix Inc., an antibody discovery and engineering company with a CNS focus, has been awarded a US$1.26 million grant by
- [Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial](https://bioadvance.com/palvella-therapeutics-announces-publication-of-results-from-phase-2-clinical-trial/) - Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies Publication reports 10% of participants wereither "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impresion of Change folowing 12-weks
- [IVIEW Therapeutics Completed A++ Round Financing](https://bioadvance.com/iview-therapeutics-completed-a-round-financing/) - IVIEW Therapeutics Completed A++ Round Financing to Advance its innovative Ocular Drug Development Programs [Cranbury, New Jersey January 17, 2025] IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the successful completion of its A++ round of financing. The funds raised will primarily be used to advance
- [Scorpius Holdings Announces Collaboration with KaloCyte to  Advance Manufacturing for ErythroMer™](https://bioadvance.com/scorpius-holdings-announces-collaboration-with-kalocyte-to-advance-manufacturing-for-erythromer/) - Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its collaboration with KaloCyte, a pioneering
- [The New Yorker: The Long Quest for Artificial Blood](https://bioadvance.com/the-new-yorker-the-long-quest-for-artificial-blood/) - The New Yorker: The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley See more here
- [IVIEW Therapeutics Announces Topline Results](https://bioadvance.com/iview-therapeutics-therapeutics-announces-topline-results/) - IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations of IVW-1001, a novel TRPM8
- [Strados Labs Collaborates with Beth Israel Deaconess Medical Center](https://bioadvance.com/strados-labs-collaborates-with-beth-israel-deaconess-medical-center/) - Strados Labs Collaborates with Beth Israel Deaconess Medical Center for Innovative Study in Pulmonary Edema The study will evaluate continuous lung sound monitoring for the early detection of pulmonary edema and prevention of complications in critically ill ICU patients. by Strados Labs | Feb 20, 2025 | Press Releases Philadelphia, PA, February 20, 2025 — Strados Labs, a medical technology
- [Latus Bio Announces Data Presentations](https://bioadvance.com/latus-bio-announces-data-presentations/) - Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics Conference in Palm Springs, California,
- [BioAdvance Capital Fuels Life Sciences Innovation with Nine New Investments](https://bioadvance.com/bioadvance-capital-fuels-life-sciences-innovation-with-nine-new-investments/) - BioAdvance Capital Fuels Life Sciences Innovation with Nine New Investments Expands Portfolio with Cutting-Edge Innovations in Gene Therapy, AI-Driven Drug Discovery, and Precision Medicine and Reaffirms Investments in Existing Portfolio Philadelphia, PA – February 25, 2025 – In 2024, BioAdvance Capital continued its mission to foster early-stage healthcare innovation in the greater Philadelphia and Mid-Atlantic
- [ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101](https://bioadvance.com/immunogenesis-doses-first-patient-in-phase-1-2-clinical-trial-of-imgs-101/) - ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy HOUSTON, March 6, 2025 /PRNewswire/ -- ImmunoGenesis,
- [Strados Labs Introduces Grant Initiative](https://bioadvance.com/strados-labs-introduces-grant-initiative/) - Strados Labs Introduces Grant Initiative to Accelerate Research into Continuous Lung Sound Monitoring The new program provides eligible research studies with in-kind support for the use of the RESP® Biosensor system. by Strados Labs | Mar 25, 2025 | Press Releases Philadelphia, PA, March 20, 2025 – Strados Labs, a medical technology company, is announcing the launch of a
- [Latus Bio Announces Multiple Oral and Poster Presentations](https://bioadvance.com/latus-bio-announces-multiple-oral-and-poster-presentations/) - Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting PHILADELPHIA--(BUSINESS WIRE)--Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, which is being
- [ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001](https://bioadvance.com/immunogenesis-expands-phase-1a-b-trial-of-imgs-001/) - Source: Cancer Focus Fund ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as Phase 1 dose escalation proceeds
- [Latus Bio Unveils AAV-Ep+ Capsid Variant](https://bioadvance.com/latus-bio-unveils-aav-ep-capsid-variant/) - Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant protein in NHPs and a
- [Latus Bio Announces Publication of Breakthrough Research](https://bioadvance.com/latus-bio-announces-publication-of-breakthrough-research/) - Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal ganglia diseases show robust potency
- [Waters Acquires Halo Labs](https://bioadvance.com/waters-acquires-halo-labs/) - Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from
- [Science: There Will Be Blood](https://bioadvance.com/https-www-bioadvance-com-media-science-adr4067-pdf/) - Science: There Will Be Blood Is mimicking the cells that carry hemoglobin the key to a blood substitute? See more here
- [PolyPid Announces Research and Development Collaboration with ImmunoGenesis](https://bioadvance.com/polypid-announces-research-and-development-collaboration-with-immunogenesis/) - PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) --PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based
- [Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals](https://bioadvance.com/palvella-therapeutics-announces-closing-of-merger-with-pieris-pharmaceuticals/) - Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately
- [Phrase Health Secures NIH SBIR Funding to Advance Innovative Analytics Solutions](https://bioadvance.com/https-www-bioadvance-com-media-082024-phrase-health-secures-nih-sbir-funding-to-advance-innovative-analytics-solutions-pdf/) - Phrase Health Secures NIH SBIR Funding to Advance Innovative Analytics Solutions Phrase Health, Inc. secures $2M NIH SBIR grant to develop innovative EHR workflow management solutions, advancing patient care through data-driven, continuous improvement. See more here
- [Wellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate](https://bioadvance.com/wellsheet-and-wolters-kluwer-collaborate-to-integrate-ai-powered-clinical-workflows-with-uptodate/) - Wellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate See more here
- [Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract](https://bioadvance.com/https-www-bioadvance-com-media-101023-venatorx-pharmaceuticals-awarded-a-third-antibiotic-barda-contract-pdf/) - Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis See more here
- [Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer](https://bioadvance.com/https-www-bioadvance-com-media-101923-immunome-appoints-bob-lechleider-m-d-pdf/) - Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer - Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies See more here
- [ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023](https://bioadvance.com/https-www-bioadvance-com-media-110723-enb-therapeutics-presents-top-line-results-from-phase-1b-enbolden-101-study-pdf/) - ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023 - ENB-003 in combination with KEYTRUDA (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) - Encouraging results support further development - Expansion cohort in primary
- [Immunome Appoints Jean-Jacques Bienaimé to Board of Directors](https://bioadvance.com/https-www-bioadvance-com-media-110823-immunome-appoints-jean-jacques-bienaime-to-board-of-directors-pdf/) - Immunome Appoints Jean-Jacques Bienaimé to Board of Directors - Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors See more here
- [Immunome Reports Third Quarter 2023 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-110923-immunome-reports-third-quarter-2023-financial-results-pdf/) - Immunome Reports Third Quarter 2023 Financial Results - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - Bob Lechleider, M.D., appointed as Chief Medical Officer - Jean-Jacques Bienaimé, former CEO of
- [Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.](https://bioadvance.com/https-www-bioadvance-com-media-110923-melinta-therapeutics-and-venatorx-pharmaceuticals-announce-licensing-agreement-pdf/) - Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S. See more here
- [ONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management.](https://bioadvance.com/https-www-bioadvance-com-media-110923-onco-inc-announces-strategic-partnership-with-oncora-medical-pdf/) - ONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management. See more here
- [VESTECK, Inc. "it is always someone's mom or dad, brother or sister."](https://bioadvance.com/https-www-bioadvance-com-media-111323-vesteck-inc-_it-is-always-someones-mom-or-dad-brother-or-sister-pdf/) - VESTECK, Inc. "it is always someone's mom or dad, brother or sister." See more here
- [Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies](https://bioadvance.com/https-www-bioadvance-com-media-111423-vittoria-biotherapeutics-secures-over-15-million-pdf/) - Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies Funds to support advancement of lead candidate, VIPER-101, to the clinic See more here
- [SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma](https://bioadvance.com/https-www-bioadvance-com-media-111523-sirpant-immunotherapeutics-receives-fda-orphan-drug-designation-for-sirpant-m-for-the-treatment-of-t-cell-lymphoma-pdf/) - SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma See more here
- [Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations](https://bioadvance.com/https-www-bioadvance-com-media-111623-palvella-therapeutics-announces-u-s-fda-pdf/) - Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations Microcystic Lymphatic Malformations is a chronically debilitating and lifelong genetic disease
- [Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis](https://bioadvance.com/https-www-bioadvance-com-media-112923-opsidio-announces-first-patient-dosed-in-phase-2a-trial-of-opscf-in-moderate-to-severe-atopic-dermatitis-pdf/) - Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis - OpSCF is a novel monoclonal antibody directed against the inflammatory form of stem cell factor See more here
- [Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications](https://bioadvance.com/https-www-bioadvance-com-media-120123-palvella-therapeutics-and-ligand-pharmaceuticals-pdf/) - Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than
- [Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma](https://bioadvance.com/https-www-bioadvance-com-media-120723-vittoria-biotherapeutics-announces-fda-clearance-pdf/) - Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma Initiating first-in-human Phase 1 trial in H1 of 2024 See more here
- [SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors](https://bioadvance.com/https-www-bioadvance-com-media-121223-sirpant-immunotherapeutics-announces-fda-pdf/) - SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors See more here
- [Immunome to Acquire Antibody-Related Assets and Materials from Atreca](https://bioadvance.com/https-www-bioadvance-com-media-122623-immunome-to-acquire-antibody-related-assets-and-materials-from-atreca-pdf/) - Immunome to Acquire Antibody-Related Assets and Materials from Atreca See more here
- [Immunome Appoints Carol A. Schafer to Board of Directors](https://bioadvance.com/https-www-bioadvance-com-media-010224-immunome-appoints-carol-a-schafer-to-board-of-directors-pdf/) - Immunome Appoints Carol A. Schafer to Board of Directors See more here
- [Immunome Appoints Phil Roberts as Chief Technical Officer](https://bioadvance.com/https-www-bioadvance-com-media-010424-immunome-appoints-phil-roberts-as-chief-technical-officer-pdf/) - Immunome Appoints Phil Roberts as Chief Technical Officer See more here
- [Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform](https://bioadvance.com/https-www-bioadvance-com-media-010824-immunome-exclusively-licenses-zentalis-ror1-antibody-drug-conjugate-and-proprietary-technology-platform-pdf/) - Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and
- [Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries](https://bioadvance.com/https-www-bioadvance-com-media-010924-venatorx-pharmaceuticals-and-menarini-group-enter-commercial-agreement-pdf/) - Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries See more here
- [SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.](https://bioadvance.com/https-www-bioadvance-com-media-012224-sirpant-immunotherapeutics-strengthens-board-of-directors-pdf/) - SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D. See more here
- ["Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024"](https://bioadvance.com/https-www-bioadvance-com-media-012624-dr-sean-lyden-professor-and-chairman-vascular-surgery-cleveland-clinic-on-the-mainstage-at-iset-pdf/) - "Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024" See more here
- [Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals](https://bioadvance.com/https-www-bioadvance-com-media-020624-immunome-to-acquire-al102-a-phase-3-asset-for-the-1-pdf/) - Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile See more here
- [Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers](https://bioadvance.com/https-www-bioadvance-com-media-021624-unite-us-and-ride-health-partner-to-improve-access-to-transportation-services-for-new-yorkers-pdf/) - Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers The Collaborative Initiative with Social Care Networks Will Overcome Obstacles to Vital Services Following New York State's Approval of the 1115 Medicaid Waiver See more here
- [New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection](https://bioadvance.com/https-www-bioadvance-com-media-022024-venatorx-nejm-publishes-positive-results-of-cefepime-taniborbactam-from-phase-3-certain-1-study-pdf/) - New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint Composite Efficacy Sustained at Late Follow-up Visit Safety Profile Consistent with Meropenem See more here
- [Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam](https://bioadvance.com/https-www-bioadvance-com-media-022324-venatorx-and-melinta-provide-update-on-status-of-u-s-new-drug-application-for-cefepime-taniborbactam-pdf/) - Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam No Clinical Safety or Efficacy Issues Identified No Requirement for Further Clinical Data or Trials See more here
- [Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer](https://bioadvance.com/https-www-bioadvance-com-media-022724-vittoria-therapeutics-announces-appointment-pdf/) - Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer See more here
- [IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024](https://bioadvance.com/https-www-bioadvance-com-media-022824-iview-announces-presentation-of-positive-topline-results-pdf/) - IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 See more here
- [iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease](https://bioadvance.com/https-www-bioadvance-com-media-031124-iview-therapeutics-announced-fdas-clearance-of-ind-application-1-pdf/) - iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease See more here
- [Venatorx Pharmaceuticals Expands Senior Leadership Team](https://bioadvance.com/https-www-bioadvance-com-media-031224-venatorx-pharmaceuticals-expands-senior-leadership-team-pdf/) - Venatorx Pharmaceuticals Expands Senior Leadership Team Key Hires in CMC/Technical Operations, Business Development, and Finance See more here
- [SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma](https://bioadvance.com/https-www-bioadvance-com-media-031224-sirpant-immunotherapeutics-announces-first-patient-dosed-pdf/) - SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma See more here
- [Melior Is Recognized as CRO of the Year by Life Sciences Review](https://bioadvance.com/https-www-bioadvance-com-media-031924-melior-is-recognized-as-cro-of-the-year-by-life-sciences-review-pdf/) - Melior Is Recognized as CRO of the Year by Life Sciences Review Life Sciences Review annually selects 10 preeminent CROs and has chosen Melior Discovery as the top CRO in 2023 The editors recognized Melior’s unique capabilities in the pre-clinical in vivo pharmacology space with its theraTRACE offering, its breadth of model offerings, and boutique
- [Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway](https://bioadvance.com/https-www-bioadvance-com-media-040524-concarlo-therapeutics-presents-novel-therapeutic-approach-for-er-metastatic-breast-cancer-targeting-the-cdk-pathway-2-pdf/) - Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway See more here
- [Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer](https://bioadvance.com/https-www-bioadvance-com-media-041624-vittoria-biotherapeutics-announces-keith-westby-pdf/) - Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer See more here
- [SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium](https://bioadvance.com/https-www-bioadvance-com-media-043024-sirpant-immunotherapeutics-to-participate-in-wells-fargo-virtual-private-biotech-symposium-pdf/) - SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium See more here
- [Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing](https://bioadvance.com/https-www-bioadvance-com-media-050224-mekonos-enters-partnership-agreement-with-accelerated-biosciences-pdf/) - Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing - Mekonos' silicon nanoneedle-based delivery platform will provide Accelerated Bio with high efficiency, high viability cell engineering – including the precise and gentle delivery of multiplexed genetic cargo into its pluripotent hTSCs - Accelerated Bio’s ethically
- [Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer](https://bioadvance.com/https-www-bioadvance-com-media-050824-coherus-announces-clinical-collaboration-pdf/) - Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer See more here
- [Venatorx Pharmaceuticals Announces Changes to Executive Leadership](https://bioadvance.com/https-www-bioadvance-com-media-051624-venatorx-pharmaceuticals-announces-changes-to-executive-leadership-pdf/) - Venatorx Pharmaceuticals Announces Changes to Executive Leadership See more here
- [Accelerated Biosciences and Spanios Partner to Advance Therapeutic Design Across Solid Tumor Cancers](https://bioadvance.com/https-www-bioadvance-com-media-051624-accelerated-biosciences-and-spanios-partner-pdf/) - Accelerated Biosciences and Spanios Partner to Advance Therapeutic Design Across Solid Tumor Cancers See more here
- [Accelerated Biosciences Announces License of its Human Trophoblast Stem Cells (hTSC) to Agathos Biologics for Development of Ethically Sourced Research and Biomanufacturing Platforms](https://bioadvance.com/https-www-bioadvance-com-media-060524-accelerated-biosciences-announces-license-of-its-human-trophoblast-stem-cells-htsc-to-agathos-biologics-pdf/) - Accelerated Biosciences Announces License of its Human Trophoblast Stem Cells (hTSC) to Agathos Biologics for Development of Ethically Sourced Research and Biomanufacturing Platforms See more here
- [IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease](https://bioadvance.com/https-www-bioadvance-com-media-062524-iview-therapeutics-inc-announces-dosing-of-first-patient-in-phase-12-clinical-trial-pdf/) - IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease See more here
- [Wellsheet AI-Powered Smart EHR UI Delivers Usability and ROI](https://bioadvance.com/https-www-bioadvance-com-media-062524-wellsheet-ai-powered-smart-ehr-ui-delivers-usability-and-roi-pdf/) - Wellsheet AI-Powered Smart EHR UI Delivers Usability and ROI - 94% of clinicians recommend for chart review - 6.3% reduction in length of stay - 8X+ ROI in first year, delivering ~$8M savings per hospital - 40%+ reduction in time spent in the EHR See more here
- [The UM BioPark is a beacon for early-stage technology ventures](https://bioadvance.com/https-www-bioadvance-com-media-062824-the-um-biopark-is-a-beacon-for-early-stage-technology-ventures-pdf/) - The UM BioPark is a beacon for early-stage technology ventures The research park’s perfectly matched location and array of startup-supporting resources makes it an invaluable pillar for a growing number of life science startups — and the entire Maryland ecosystem. See more here
- [Accelerated Bio and Pluristyx create Clinical Grade Induced Pluripotent Stem Cells from Reprogramming Human Trophoblast Stem Cells](https://bioadvance.com/https-www-bioadvance-com-media-071124-accelerated-bio-and-pluristyx-create-clinical-grade-induced-pluripotent-stem-cells-pdf/) - Accelerated Bio and Pluristyx create Clinical Grade Induced Pluripotent Stem Cells from Reprogramming Human Trophoblast Stem Cells See more here
- [Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology](https://bioadvance.com/https-www-bioadvance-com-media-072224-vittoria-biotherapeutics-announces-peer-reviewed-publication-in-science-immunology-pdf/) - Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology See more here
- [Strados Labs announces successful completion of pediatric asthma study](https://bioadvance.com/https-www-bioadvance-com-media-072324-strados-labs-announces-successful-completion-of-pediatric-asthma-study-pdf/) - Strados Labs announces successful completion of pediatric asthma study See more here
- [Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement](https://bioadvance.com/https-www-bioadvance-com-media-072424-palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement-pdf/) - Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including
- [Delve Health Partners with Strados Labs to Enhance Remote Patient Monitoring in Clinical Trials](https://bioadvance.com/https-www-bioadvance-com-media-080624-delve-health-partners-with-strados-labs-to-enhance-remote-patient-monitoring-in-clinical-trials-pdf/) - Delve Health Partners with Strados Labs to Enhance Remote Patient Monitoring in Clinical Trials See more here
- [The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes](https://bioadvance.com/the-pathogenic-role-of-retinoid-nuclear-receptor-signaling-in-cancer-and-metabolic-syndromes/) - The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes See more here
- [IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients](https://bioadvance.com/https-www-bioadvance-com-media-091724-iview-therapeutics-inc-completes-patient-recruitment-for-phase-1-2-trial-of-ivw-1001-pdf/) - IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients See more here
- [Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA)](https://bioadvance.com/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-the-u-s-food-and-drug-administration-fda/) - Palvella Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing Phase 3 trial evaluating
- [Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™](https://bioadvance.com/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-of-qtorin/) - Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) currently enrolling participants at leading
- [HueDx Transforms Point-of-Care Diagnostics  with AI-Powered Smartphone Solutions](https://bioadvance.com/huedx-transforms-point-of-care-diagnostics-with-ai-powered-smartphone-solutions/) - HueDx Transforms Point-of-Care Diagnostics with AI-Powered Smartphone Solutions HueDx's AI-powered platform improves point-of care diagnostics with enhanced accuracy, real-time data, and wider accessibility for rapid, reliable testing. See more here
- [Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases](https://bioadvance.com/tolerance-bio-inc-launches-with-17-2-million-in-seed-financing-to-advance-thymus-based-therapies-for-immune-mediated-diseases/) - Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases Financing led by Columbus Venture Partners, with participation by Criteria Bio Ventures, Sessa Capital,
- [Palvella Therapeutics Appoints Matthew E. Korenberg as Chief  Financial Officer](https://bioadvance.com/palvella-therapeutics-appoints-matthew-e-korenberg-as-chief-financial-officer/) - Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer Mr. Korenberg is a seasoned executive with signifcant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs See more here
- [Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting](https://bioadvance.com/vittoria-biotherapeutics-presents-positive-preclinical-data-at-66th-annual-ash-meeting/) - Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing in the development of innovative
- [Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates](https://bioadvance.com/vittoria-biotherapeutics-completes-25-million-in-private-financing-to-propel-groundbreaking-cell-therapy-candidates/) - Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-totreat diseases, today announced the successful completion of a $25 million private financing round. This funding is a $10 million extension to
- [InfraScan Announces First Patients Enroll in Clinical Trial in Brain Hematoma Detection](https://bioadvance.com/infrascan-announces-first-patients-enroll-in-clinical-trial-in-brain-hematoma-detection/) - InfraScan Announces First Patients Enroll in Clinical Trial in Brain Hematoma Detection Read more here
- [NuPathe Licenses Novel Drug Delivery Technology from University of Pennsylvania](https://bioadvance.com/nupathe-licenses-novel-drug-delivery-technology-from-university-of-pennsylvania/) - NuPathe Licenses Novel Drug Delivery Technology from University of Pennsylvania Read more here
- [InfraScan to Present at Medtech Insight and Windhover Information’s “Investment In Innovation (In3) WEST” Conference](https://bioadvance.com/infrascan-to-present-at-medtech-insight-and-windhover-informations-investment-in-innovation-in3-west-conference/) - InfraScan to Present at Medtech Insight and Windhover Information’s “Investment In Innovation (In3) WEST” Conference Read more here
- [Avid's Amyvid Recommended for Approval In Europe as Diagnostic Tool for Alzheimer's Disease](https://bioadvance.com/avids-amyvid-recommended-for-approval-in-europe-as-diagnostic-tool-for-alzheimers-disease/) - Avid's Amyvid Recommended for Approval In Europe as Diagnostic Tool for Alzheimer's Disease Read more here
- [InfraScan to Present at “Investment In Innovation (In3) WEST” Conference](https://bioadvance.com/infrascan-to-present-at-investment-in-innovation-in3-west-conference/) - InfraScan to Present at “Investment In Innovation (In3) WEST” Conference Read more here
- [Infrascanner™ Software Designer Wins the Design of Medical Devices Top Award](https://bioadvance.com/infrascanner-software-designer-wins-the-design-of-medical-devices-top-award/) - Infrascanner™ Software Designer Wins the Design of Medical Devices Top Award Read more here
- [Novartis to Acquire Protez for Up to $400 Million](https://bioadvance.com/novartis-to-acquire-protez-for-up-to-400-million/) - Novartis to Acquire Protez for Up to $400 Million Read more here
- [NuPathe Inc. CEO to Present at the Leerink Swann Emerging Technologies in Pain Medicine Conference](https://bioadvance.com/nupathe-inc-ceo-to-present-at-the-leerink-swann-emerging-technologies-in-pain-medicine-conference/) - NuPathe Inc. CEO to Present at the Leerink Swann Emerging Technologies in Pain Medicine Conference Read more here
- [Protez Pharmaceuticals to be Acquired by Novartis](https://bioadvance.com/protez/) - Protez Pharmaceuticals to be Acquired by Novartis Read more here
- [County Biopharmaceutical Firm Protez to be Bought](https://bioadvance.com/protez-2/) - County Biopharmaceutical Firm Protez to be Bought Read more here
- [Acuity Pharmaceuticals Announces Completion of Financing Round](https://bioadvance.com/acuity-pharmaceuticals-announces-completion-of-financing-round/) - Acuity Pharmaceuticals Announces Completion of Financing Round Read more here
- [Alteris Licenses Rights From Duke and Johns Hopkins to Cancer Vaccine](https://bioadvance.com/alteris-licenses-rights-from-duke-and-johns-hopkins-to-cancer-vaccine/) - Alteris Licenses Rights From Duke and Johns Hopkins to Cancer Vaccine Read more here
- [For Start-Ups, Support May be in Bigger Supply](https://bioadvance.com/for-start-ups-support-may-be-in-bigger-supply/) - For Start-Ups, Support May be in Bigger Supply Read more here
- [BioAdvance Invests In Midway Pharmaceuticals to Support Promising Development Program for GI Therapies](https://bioadvance.com/bioadvance-invests-in-midway-pharmaceuticals-to-support-promising-development-program-for-gi-therapies/) - BioAdvance Invests In Midway Pharmaceuticals to Support Promising Development Program for GI Therapies Read more here
- [Phoenix S&T Featured as a Member of the Keystone Innovation Zone Dedicated to Improving Human Health](https://bioadvance.com/phoenix-st-featured-as-a-member-of-the-keystone-innovation-zone-dedicated-to-improving-human-health/) - Phoenix S&T Featured as a Member of the Keystone Innovation Zone Dedicated to Improving Human Health Read more here
- [Phoenix S&T Announces Expanded Availability of Capillary LC Column Heaters and Controllers in US and EU](https://bioadvance.com/phoenix-st-announces-expanded-availability-of-capillary-lc-column-heaters-and-controllers-in-us-and-eu/) - Phoenix S&T Announces Expanded Availability of Capillary LC Column Heaters and Controllers in US and EU Read more here
- [LumenVu Lights It Up](https://bioadvance.com/lumenvu-lights-it-up/) - LumenVu Lights It Up Read more here
- [Protez Buys Influx, a Chicago Biotech Firm](https://bioadvance.com/protez-buys-influx-a-chicago-biotech-firm/) - Protez Buys Influx, a Chicago Biotech Firm Read more here
- [Ceptaris Announces Publication in JAMA Dermatology of Positive Clinical Results](https://bioadvance.com/ceptaris-announces-publication-in-jama-dermatology-of-positive-clinical-results/) - Ceptaris Announces Publication in JAMA Dermatology of Positive Clinical Results Read more here
- [Ceptaris Secures $10 Million in Series D-1 Financing](https://bioadvance.com/ceptaris-secures-10-million-in-series-d-1-financing/) - Ceptaris Secures $10 Million in Series D-1 Financing Read more here
- [Ceptaris Secures $15M in Venture Debt Financing](https://bioadvance.com/ceptaris-secures-15m-in-venture-debt-financing/) - Ceptaris Secures $15M in Venture Debt Financing Read more here
- [Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel](https://bioadvance.com/ceptaris-therapeutics-receives-ema-orphan-drug-designation-for-proprietary-mechlorethamine-gel/) - Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel Read more here
- [InfraScan Launches International Sales of a Handheld Brain Hematoma Detector](https://bioadvance.com/infrascan-2/) - InfraScan Launches International Sales of a Handheld Brain Hematoma Detector Read more here
- [InfraScanner: Star Trek Style Scanner Looks for Clots](https://bioadvance.com/infrascan-3/) - InfraScanner: Star Trek Style Scanner Looks for Clots Read more here
- [InfraScan Inc. Announces Issuance of US Patent for Hematoma Detection](https://bioadvance.com/1253-2/) - InfraScan Inc. Announces Issuance of US Patent for Hematoma Detection Read more here
- [FDA Permits Marketing of the First Hand-held Device to Aid in the Detection of Bleeding in the Skull](https://bioadvance.com/1256-2/) - FDA Permits Marketing of the First Hand-held Device to Aid in the Detection of Bleeding in the Skull Read more here
- [Melior Discovery Enters New Pharmaceutical Collaboration](https://bioadvance.com/melior-3/) - Melior Discovery Enters New Pharmaceutical Collaboration Read more here
- [TREVENTIS Corporation Scientific Founder, Named Sobey Chair in Alzheimer’s Disease Research](https://bioadvance.com/treventis-corporation-scientific-founder-donald-weaver-md-named-sobey-chair-in-alzheimers-disease-research-his-third-endowed-chair/) - TREVENTIS Corporation Scientific Founder, Named Sobey Chair in Alzheimer’s Disease Research Read more here
- [TREVENTIS Corporation Founder Wins Prestigious Discovery Award](https://bioadvance.com/treventis-corporation-founder-wins-prestigious-discovery-award/) - TREVENTIS Corporation Founder Wins Prestigious Discovery Award Read more here
- [TREVENTIS Corporation Moves to New Facilities in NRC Incubation Space](https://bioadvance.com/treventis-corporation-moves-to-new-facilities-in-nrc-incubation-space/) - TREVENTIS Corporation Moves to New Facilities in NRC Incubation Space Read more here
- [Ossianix Announces Lundbeck Investment](https://bioadvance.com/ossianix-announces-lundbeck-investment/) - Ossianix Announces Lundbeck Investment Read more here
- [InfrascannerTM Handheld Brain Scanner Gets $2M-Addresses Top Cause of Combat Death](https://bioadvance.com/infrascannertm-handheld-brain-scanner-gets-2m-addresses-top-cause-of-combat-death/) - InfrascannerTM Handheld Brain Scanner Gets $2M-Addresses Top Cause of Combat Death Read more here
- [PETNET Avid Announcement](https://bioadvance.com/petnet-avid-announcement/) - PETNET Avid Announcement Read more here
- [Infrascanner Handheld Brain Scanner Experiences Significant Sales Growth in Romania, Bucharest](https://bioadvance.com/infrascanner-handheld-brain-scanner-experiences-significant-sales-growth-in-romania-emergency-rescue-service-in-south-romania-and-bucharest-use-novel-device-to-facilitate-care-of-head-trauma-victims/) - Infrascanner Handheld Brain Scanner Experiences Significant Sales Growth in Romania, Bucharest Read more here
- [Lilly Snags Avid in $800M Buyout Deal](https://bioadvance.com/lilly-snags-avid-in-800m-buyout-deal/) - Lilly Snags Avid in $800M Buyout Deal Read more here
- [Expert: Avid Could Launch Alzheimer's Agent Ahead of GE, Bayer](https://bioadvance.com/expert-avid-could-launch-alzheimers-agent-ahead-of-ge-bayer/) - Expert: Avid Could Launch Alzheimer's Agent Ahead of GE, Bayer Read more here
- [Promise Seen for Detecting Alzheimer's (Avid Radiopharmaceuticals)](https://bioadvance.com/promise-seen-for-detecting-alzheimers-avid-radiopharmaceuticals/) - Promise Seen for Detecting Alzheimer's (Avid Radiopharmaceuticals) Read more here
- [InfraScan to Present at Medtech Insight's "Investment In Innovation''](https://bioadvance.com/infrascan/) - InfraScan to Present at Medtech Insight's "Investment In Innovation'' Read more here
- [NuPathe Wins U.S. FDA Approval for Migraine Skin Patch](https://bioadvance.com/nupathe-wins-u-s-fda-approval-for-migraine-skin-patch/) - NuPathe Wins U.S. FDA Approval for Migraine Skin Patch Read more here
- [InfraScan Receives FDA Approval of Next Generation, Noninvasive Handheld Brain Hematoma Detector](https://bioadvance.com/infrascan-receives-fda-approval-of-next-generation-noninvasive-handheld-brain-hematoma-detector/) - InfraScan Receives FDA Approval of Next Generation, Noninvasive Handheld Brain Hematoma Detector Read more here
- [FDA is Readying to Rule on NuPathe’s Revised Application for its Patch to Treat Migraines](https://bioadvance.com/fda-is-readying-to-rule-on-nupathes-revised-application-for-its-patch-to-treat-migraines/) - FDA is Readying to Rule on NuPathe’s Revised Application for its Patch to Treat Migraines Read more here
- [Philly Inc: Small Businesses Solving Big Problems](https://bioadvance.com/philly-inc-small-businesses-solving-big-problems/) - Philly Inc: Small Businesses Solving Big Problems Read more here
- [Novira Therapeutics Raises $23M](https://bioadvance.com/novira-therapeutics-raises-23m/) - Novira Therapeutics raises $23M Read more here
- [FDA Accepts NuPathe Inc. (PATH)'s Migraine Patch NDA Resubmission for Filing](https://bioadvance.com/fda-accepts-nupathe-inc-paths-migraine-patch-nda-resubmission-for-filing/) - FDA Accepts NuPathe Inc. (PATH)'s Migraine Patch NDA Resubmission for Filing Read more here
- [FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients](https://bioadvance.com/fda-approves-amyvid-florbetapir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-disease-and-other-causes-of-cognitive-decline/) - FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Read more here
- [Yaupon Changes Name to Ceptaris Therapeutics, Inc.](https://bioadvance.com/yaupon-changes-name-to-ceptaris-therapeutics-inc/) - Yaupon Changes Name to Ceptaris Therapeutics, Inc. Read more here
- [ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab](https://bioadvance.com/http-www-bioadvance-com-media-enb-therapeutics-demonstrated-early-efficacy-in-phase-i-clinical-trial-of-enb-003-in-combination-with-pembrolizumab-pdf/) - ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
- [Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study](https://bioadvance.com/http-www-bioadvance-com-media-annovis-bios-lead-candidate-anvs401-improves-cognitive-and-functional-outcomes-in-stroke-mice-study-pdf/) - Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study See more here
- [Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults](https://bioadvance.com/http-www-bioadvance-com-media-annovis-bio-receives-european-patent-for-method-of-treating-acute-nerve-and-brain-insults-pdf/) - Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults See more here
- [Wellsheet Featured in KLAS Spotlight Targeting Physician Burnout](https://bioadvance.com/http-www-bioadvance-com-media-2-18-21-wellsheet-featured-in-klas-spotlight-targeting-physician-burnout-pdf/) - Wellsheet Featured in KLAS Spotlight Targeting Physician Burnout 100% of Respondents Would Buy Wellsheet Again for Quick Access to Relevant Electronic Health Record Data to Reduce Time in the EHR See more here
- [Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate](https://bioadvance.com/http-www-bioadvance-com-media-3-10-21-venatorx-pharmaceuticals-expands-anti-infective-portfolio-with-hbv-candidate-pdf/) - Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021 See more here
- [Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury](https://bioadvance.com/http-www-bioadvance-com-media-3-10-21-annovis-bio-receives-japanese-patent-for-the-treatment-of-acute-brain-or-nerve-injury-pdf/) - Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury See more here
- [Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies](https://bioadvance.com/http-www-bioadvance-com-media-3-11-21-annovis-bio-signs-gmp-manufacturing-agreement-to-support-planned-late-stage-studies-pdf/) - Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies See more here
- [Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients](https://bioadvance.com/http-www-bioadvance-com-media-3-11-21-annovis-bio-signs-gmp-manufacturing-agreement-to-support-planned-late-stage-studies-pdf-2/) - Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients See more here
- [Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder](https://bioadvance.com/http-www-bioadvance-com-media-2020-12-07_relmada_therapeutics_announces_initiation_of_220-pdf/) - Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder See more here
- [ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline](https://bioadvance.com/http-www-bioadvance-com-media-12-9-20-immunogenesis-acquisition-strengthens-cold-tumor-targeting-pipeline-pdf/) - ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021. Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer. See more here
- [Oncora Medical to power Mass General's Pediatric Proton/Photon Consortium Registry to fight pediatric cancer with data](https://bioadvance.com/http-www-bioadvance-com-media-12-22-20-oncora-medical-to-power-mass-generals-pediatric-proton_photon-consortium-registry-to-fight-pediatric-cancer-with-data-pdf/) - Oncora Medical to power Mass General's Pediatric Proton/Photon Consortium Registry to fight pediatric cancer with data See more here
- [Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita](https://bioadvance.com/http-www-bioadvance-com-media-12-23-20-palvella-therapeutics-reports-top-line-results-from-pivotal-phase-23-valo-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-in-patients-with-pachyonychia-congeni-pdf/) - Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita ~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~ ~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~ ~ Palvella Plans to Share Results with the
- [Ride Health and ACTIV-2 Partner to Provide Transportation for Nationwide COVID-19 Therapeutic Study](https://bioadvance.com/http-www-bioadvance-com-media-1-5-21-ride-health-and-activ-2-partner-to-provide-transportation-for-nationwide-covid-19-therapeutic-study-pdf/) - Ride Health and ACTIV-2 Partner to Provide Transportation for Nationwide COVID-19 Therapeutic Study NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2) study leveraging company's COVID-19 equipped transportation network across dozens of sites nationwide See more here
- [Ride Health and COVID-19 Prevention Trials Network (CoVPN) Partner to Provide Transportation for Vaccine Trial Participants](https://bioadvance.com/http-www-bioadvance-com-media-ride-health-and-covid-19-prevention-trials-network-covpn-partner-to-provide-transportation-for-vaccine-trial-participants-pdf/) - Ride Health and COVID-19 Prevention Trials Network (CoVPN) Partner to Provide Transportation for Vaccine Trial Participants Fred Hutchinson-led 'harmonizer' network for Operation Warp Speed vaccines leverages company's COVID-equipped transportation network for five vaccines in Phase III clinical trials See more here
- [Optimizing Nourishment in the NICU](https://bioadvance.com/1-28-21-keriton-optimizing-nourishment-in-the-nicu/) - Optimizing Nourishment in the NICU The Connecticut Children’s Neonatal Intensive Care Unit at the UConn John Dempsey Hospital is offering a high-tech tool for moms to ensure their infants get the most out of breast milk and formula feeding. See more here
- [Venatorx Pharmaceuticals Names New Head of Regulatory Affairs](https://bioadvance.com/http-www-bioadvance-com-media-1-28-21-venatorx-pharmaceuticals-names-new-head-of-regulatory-affairs-pdf/) - Venatorx Pharmaceuticals Names New Head of Regulatory Affairs Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx's global regulatory strategy for its clinical and pre-clinical anti-infectives programs See more here
- [Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones](https://bioadvance.com/http-www-bioadvance-com-media-2020-10-27_relmada_therapeutics_expands_r_d_team_appoints_218-pdf/) - Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones See more here
- [Mebias Discovery Receives Grant from NIDA to Advance MEB 1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder](https://bioadvance.com/http-www-bioadvance-com-media-10-29-20-mebias-discovery-receives-grant-from-nida-to-advance-meb-1170-as-an-analgesic-drug-candidate-for-the-prevention-and-treatment-of-opioid-use-disorder-pdf/) - Mebias Discovery Receives Grant from NIDA to Advance MEB‑1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder Grant to Fund IND Enabling and Phase 1 Clinical Trials Preclinical Data Demonstrates MEB‑1170 Lacks Dangerous Side Effects Including Respiratory Depression and Opioid Abuse Potential See more here
- [Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease After COVID-Related Delay](https://bioadvance.com/http-www-bioadvance-com-media-10-29-20-annovis-bio-resumes-treatment-of-patients-in-ongoing-phase-2a-study-pdf/) - Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease After COVID-Related Delay See more here
- [Aptar Pharma Acquires the Assets of Cohero Health, a Digital Respiratory Health Company, Further Expanding its Capabilities in Digital Health](https://bioadvance.com/http-www-bioadvance-com-media-11-4-2020-aptar-pharma-cohero-health-press-release-pdf/) - Aptar Pharma Acquires the Assets of Cohero Health, a Digital Respiratory Health Company, Further Expanding its Capabilities in Digital Health See more here
- [Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies](https://bioadvance.com/http-www-bioadvance-com-media-11-09-20-ossianix-press-release-pdf/) - Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies - Over 30-Fold Increase in Hippocampus Observed - - Results Promising for Delivery of Biological Therapeutics for Neurologic Diseases - - Results to be Presented at Protein & Antibody Engineering Summit Europe - See more here
- [Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases](https://bioadvance.com/http-www-bioadvance-com-media-11-12-20-annovis-reports-positive-results-from-nih-funded-chronic-toxicology-study-for-its-lead-compound-pdf/) - Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases See more here
- [Halo Labs Announces New CEO](https://bioadvance.com/http-www-bioadvance-com-media-11-23-2020-halo-labs-announces-new-ceo-pdf/) - Halo Labs Announces New CEO See more here
- [Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC](https://bioadvance.com/http-www-bioadvance-com-media-11-24-20-venatorx-names-robert-waltermire-as-sr-vp-of-cmc-pdf/) - Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC See more here
- [InfraScan Inc. Announces Issuance of US Patents for Brain Diagnosis](https://bioadvance.com/http-www-bioadvance-com-media-8-3-20-infrascan-announces-issuance-of-patent-for-brain-diagnosis-pdf/) - Infrascan Inc. Announces Issuance of US Patents for Brain Diagnosis Latest patents expand near infrared platform capabilities related to trauma and stroke diagnosis See more here
- [Phrase Health Awarded NIH Grant To Align Electronic Health Record Data With Quality Outcomes](https://bioadvance.com/http-www-bioadvance-com-media-8-5-20-phrase-health-awarded-nih-grant-pdf/) - Phrase Health Awarded NIH Grant To Align Electronic Health Record Data With Quality Outcomes The new quality improvement dashboard will facilitate continuous improvement for any healthcare stakeholder interested in pursuing quality or safety initiatives See more here
- [Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial](https://bioadvance.com/http-www-bioadvance-com-media-9-1-20-annovis-bio-begins-treatment-of-first-patients-in-its-phase-2a-alzheimers-and-parkinsons-trial-pdf/) - Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial See more here
- [Wellsheet Deployed by RWJBarnabas Health Improves Clinical Workflow and Improves Patient Care](https://bioadvance.com/http-www-bioadvance-com-media-9-10-20-wellsheet-deployed-by-rwjbarnabas-health-pdf/) - Wellsheet Deployed by RWJBarnabas Health Improves Clinical Workflow and Improves Patient Care Wellsheet Reduces Doctors’ Time in the EHR Chart by 40% See more here
- [Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy](https://bioadvance.com/http-www-bioadvance-com-media-9-17-20-venatorx-names-william-sargent-senior-vice-president-commercial-strategy-pdf/) - Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy See more here
- [Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease](https://bioadvance.com/http-www-bioadvance-com-media-9-29-20-annovis-demonstrates-improved-axonal-transport-in-nerve-cells-and-brain-of-down-syndrome-mice-pdf/) - Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal transport, the information highway of the nerve cell
- [Halo Labs Announces New Products and Leadership Changes](https://bioadvance.com/http-www-bioadvance-com-media-10-16-20-halo-labs-announces-new-products-and-leadership-changes-pdf/) - Halo Labs Announces New Products and Leadership Changes Dr. Joseph Keegan, Executive Chairman, to Assume Interim Leadership See more here
- [Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award](https://bioadvance.com/http-www-bioadvance-com-media-10-22-20-annovis-ceo-receives-smart-business-dealmaker-award-pdf/) - Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award See more here
- [Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19](https://bioadvance.com/http-www-bioadvance-com-media-melior-discovery-june-24-2020-announces-partnership-with-sfa-on-grant-directed-to-covid-19-pdf-2/) - Melior Discovery Announces Partnership with SFA on Grant Directed to Covid-19 - SFA Therapeutics receives award from Ben Franklin Technology Partners - - Melior Discovery selected as partner - See more here
- [Wellsheet Appoints Dr. Frederik Lindberg, MD, PhD, and Healthcare Executive as VP of Product Management](https://bioadvance.com/http-www-bioadvance-com-media-6-26-20-wellsheet-appoints-dr-frederik-lindberg-md-phd-vp-of-product-management-pdf/) - Wellsheet Appoints Dr. Frederik Lindberg, MD, PhD, and Healthcare Executive as VP of Product Management Former Flatiron Health executive Dr. Frederik Lindberg, MD, PhD joins Wellsheet management team to lead product management and transform the EHR experience for physicians. See more here
- [Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients](https://bioadvance.com/http-www-bioadvance-com-media-7-7-20-annovis-bio-receives-irb-approval-to-initiate-15-site-phase-2-study-in-68-parkinson-pdf/) - Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients See more here
- [Bainbridge Health Is Harnessing Medication Utilization Data to Conserve Waste and Manage The Supply of Critical Care Drugs Used to Treat COVID- 19 Patients](https://bioadvance.com/http-www-bioadvance-com-media-7-06-20-bainbridge-health-harnessing-medication-utilization-data-pdf/) - Bainbridge Health Is Harnessing Medication Utilization Data to Conserve Waste and Manage The Supply of Critical Care Drugs Used to Treat COVID-19 Patients Bainbridge Health, a provider of medication safety and stewardship solutions, is utilizing data from its network of over 50 hospitals to help clinicians understand the impact of COVID-19 on critical care medications.
- [Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®](https://bioadvance.com/http-www-bioadvance-com-media-2020-07-13_relmada_therapeutics_announces_uplisting_to_the_217-pdf/) - Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® See more here
- [Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen](https://bioadvance.com/http-www-bioadvance-com-media-7-27-20-venatorx-pharmaceuticals-awarded-a-contract-up-to-44-2m-by-niaid-nih-and-hhs-pdf/) - Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen See more here
- [Healthify Partners with Ride Health to Provide Non-Medical Transportation Services to People in Need](https://bioadvance.com/http-www-bioadvance-com-media-7-21-20-ride-health-and-healthify-partnership-pdf/) - Healthify Partners with Ride Health to Provide Non-Medical Transportation Services to People in Need See more here
- [Ride Health Expands Transportation Services to Support Hospitals and Health Plans Through COVID-19 Challenges](https://bioadvance.com/http-www-bioadvance-com-media-7-7-20-ride-health-announcements-pdf/) - Ride Health Expands Transportation Services to Support Hospitals and Health Plans Through COVID-19 Challenges Harvard Pilgrim Health Care and Novant Health among customers taking advantage of company’s food delivery, safe transportation and contact tracing capabilities amid pandemic Ray West named President and Chief Operating Officer of Ride Health See more here
- [Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations](https://bioadvance.com/http-www-bioadvance-com-media-2020-05-26_relmada_therapeutics_appoints_molly_harper_as_212-pdf/) - Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations See more here
- [Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19](https://bioadvance.com/http-www-bioadvance-com-media-annovis-5-27-20-files-patent-application-pdf/) - Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19 See more here
- [Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder](https://bioadvance.com/http-www-bioadvance-com-media-2020-05-27_relmada_therapeutics_announces_outcome_of_end_of_213-pdf/) - Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder Phase 3 Program Can Advance and the Company Plans to Initiate Registration Studies in the Fourth Quarter of 2020 See more here
- [Palvella Therapeutics Completes $45 Million Series C Financing](https://bioadvance.com/http-www-bioadvance-com-media-5-28-20-palvella-therapeutics-completes-45-million-series-c-financing-pdf/) - Palvella Therapeutics Completes $45 Million Series C Financing Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome Top-Line Data Expected in Q4 2020 from Phase 2/3 Pivotal Study for Fast Track-Designated Lead Program Pachyonychia Congenita See more here
- [Wellsheet Raises Series A Funding for Healthcare Workflow Platform to Reduce Time in the EHR and Physician Burnout](https://bioadvance.com/http-www-bioadvance-com-media-june-112020-wellsheet-series-a-funding-and-new-board-member-announcment-pdf/) - Wellsheet Raises Series A Funding for Healthcare Workflow Platform to Reduce Time in the EHR and Physician Burnout Dr. John Glaser, former CIO of Partners, and Dr. Georgia Papathomas, former SVP of Johnson & Johnson, Join the Wellsheet Board of Director See more here
- [ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab](https://bioadvance.com/http-www-bioadvance-com-media-6-15-20-enb-announces-successful-completion-of-first-dosing-cohort-in-phase-l-trial-pdf/) - ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
- [Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study](https://bioadvance.com/http-www-bioadvance-com-media-annovis-6-16-20-positive-results-from-nih-funded-chronic-toxicology-study-pdf/) - Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study See more here
- [Halo Labs Launches Aura for Particle and Aggregate ID in Biotherapeutic Development](https://bioadvance.com/http-www-bioadvance-com-media-halo-labs-june-25-2020-pr-launches-aura-for-particle-and-aggregate-id-in-biotherapeutic-development-pdf/) - Halo Labs Launches Aura for Particle and Aggregate ID in Biotherapeutic Development Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing See more here
- [Halo Labs Raises $12M in Series B1 Financing Round and Enters into the FDA Market](https://bioadvance.com/http-www-bioadvance-com-media-halo-labs-4-6-20-12m-series-b1-financing-pdf/) - Halo Labs Raises $12M in Series B1 Financing Round and Enters into the FDA Market See more here
- [Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.](https://bioadvance.com/http-www-bioadvance-com-media-ossianix-apr-2-2020-responding-to-the-covid-19-pandemic-pdf/) - Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein. See more here
- [Wellsheet Used by Physicians at Concord Hospital Battling COVID-19 Outbreak](https://bioadvance.com/http-www-bioadvance-com-media-4-7-20-wellsheet-predictive-workflow-platform-pdf/) - Wellsheet Used by Physicians at Concord Hospital Battling COVID-19 Outbreak Predictive Workflow Platform Provides Coronavirus Alerts, Clinical Visibility, and Reduces Time in the EHR and Reduces Physician Burnout See more here
- [Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs](https://bioadvance.com/http-www-bioadvance-com-media-2020-04-28_relmada_therapeutics_enhances_senior_leadership_211-pdf/) - Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs See more here
- [Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections with Limited Treatment Options](https://bioadvance.com/http-www-bioadvance-com-media-4-29-20-venatorx-gardp-partner-pdf/) - Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections with Limited Treatment Options Serious bacterial infections among major causes of disability and death for people in healthcare settings. Collaboration comes at critical time with studies showing bacterial infections present in half of deceased COVID-19 patients. See more here
- [Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients](https://bioadvance.com/http-www-bioadvance-com-media-4-30-20-annovis-bio-announces-plans-for-a-new-phase-ii-clinical-trial-to-treat-68-parkinsons-and-alzheimers-patients-pdf/) - Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson's and Alzheimer's Patients See more here
- [Keriton Kare Selected by Connecticut Children's to Improve Quality and Safety of Feeding Management in Its NICU and PICU](https://bioadvance.com/http-www-bioadvance-com-media-5-12-20-keriton-kare-selected-by-connecticut-childrens-pdf/) - Keriton Kare Selected by Connecticut Children's to Improve Quality and Safety of Feeding Management in Its NICU and PICU While the Keriton Kare Mom app is designed to help mothers produce more breast milk, its chat and photo-sharing functions have proven to be a lifeline during the pandemic -- allowing separated parents to stay engaged
- [Ride Health Launches First Comprehensive COVID-19 Equipped Transportation Network for New York City Metropolitan Area](https://bioadvance.com/http-www-bioadvance-com-media-5-14-20-ride-health-launches-first-comprehensive-covid-19-equipped-transportation-network-for-new-york-city-metropolitan-area-pdf/) - Ride Health Launches First Comprehensive COVID-19 Equipped Transportation Network for New York City Metropolitan Area See more here
- [Pillo Health Launches Pillo Remotely, a Population Health Data and Device Manager to Improve Engagement & Visibility into In-Home Health Habits](https://bioadvance.com/http-www-bioadvance-com-media-pillo-launches-pillo-remotely-2-27-20-pdf/) - Pillo Health Launches Pillo Remotely, a Population Health Data and Device Manager to Improve Engagement & Visibility into In-Home Health Habits Customizable device management interface offers increased control for healthcare professionals to deliver relevant, engaging communication to patients at scale. See more here
- [Curb and Ride Health Give Hospitals and Health Plans a Better Way to Hail Taxis for Patients](https://bioadvance.com/http-www-bioadvance-com-media-2-19-20-ride-health-and-curb-give-better-way-to-hail-taxis-for-patients-pdf/) - Curb and Ride Health Give Hospitals and Health Plans a Better Way to Hail Taxis for Patients See more here
- [Pillo Health Introduces Groundbreaking Automation of Multi-Dose Prescription Packaging](https://bioadvance.com/http-www-bioadvance-com-media-3-3-20-pillo-health-introduces-automation-of-multi-dose-perscription-packaging-pdf/) - Pillo Health Introduces Groundbreaking Automation of Multi-Dose Prescription Packaging All-in-one pill packaging automation software streamlines pharmacies' ability to fill multi-dose prescriptions that integrate into Pillo's home health robot. See more here
- [Ride Health CEO Imran Cronk to Present at South by Southwest Alongside Leaders from American Heart Association and Ascension](https://bioadvance.com/http-www-bioadvance-com-media-ride-health-ceo-imran-cronk-to-present-at-south-by-southwest-alongside-leaders-from-american-heart-association-and-ascension-pdf/) - Ride Health CEO Imran Cronk to Present at South by Southwest Alongside Leaders from American Heart Association and Ascension Company also exhibiting cloud-based transportation coordination platform at RISE Medicare Advantage Summit and AMGA Annual Conference See more here
- [Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita](https://bioadvance.com/http-www-bioadvance-com-media-3-6-20-palvella-completes-enrollment-in-phase-2-3-pivotel-study-pdf/) - Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita Top-Line Data Expected in Q4 2020 for Fast Track-Designated Program See more here
- [Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development](https://bioadvance.com/http-www-bioadvance-com-media-2020-03-09_relmada_therapeutics_appoints_cns_specialist_208-pdf/) - Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development See more here
- [Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development](https://bioadvance.com/http-www-bioadvance-com-media-2020-03-24_relmada_therapeutics_strengthens_scientific_209-pdf/) - Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development See more here
- [Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety](https://bioadvance.com/http-www-bioadvance-com-media-2020-03-31_relmada_therapeutics_solidifies_its_r_d_210-pdf/) - Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety See more here
- [Bainbridge Health Will Provide Children's Mercy Kansas City with Its Med O.S.© Infusion Pump Platform to Ensure the Safe Use of IV Medications](https://bioadvance.com/http-www-bioadvance-com-media-1-28-20-bainbridge-health-provides-childrens-mercy-kc-with-med-o-s-infusion-pump-pdf/) - Bainbridge Health Will Provide Children's Mercy Kansas City with Its Med O.S.© Infusion Pump Platform to Ensure the Safe Use of IV Medications Bainbridge Health is partnering with Children's Mercy Kansas City, a top-ranked pediatric hospital, in an effort to prevent harm associated with IV medication errors. See more here
- [Annovis Bio Announces Pricing of Initial Public Offering](https://bioadvance.com/http-www-bioadvance-com-media-1-28-20-annovis-announces-price-of-initial-public-offering-pdf/) - Annovis Bio Announces Pricing of Initial Public Offering See more here
- [Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](https://bioadvance.com/http-www-bioadvance-com-media-annovis-closes-ipo-final-jan-31-2020-pdf/) - Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares See more here
- [Children's National Hospital Partners with Bainbridge Health to Enhance Visibility on IV Medication Use Data](https://bioadvance.com/http-www-bioadvance-com-media-bainbridge-partners-with-childrens-national-hospital-feb-11-2020-pdf/) - Children's National Hospital Partners with Bainbridge Health to Enhance Visibility on IV Medication Use Data Children's National, a top-ranked pediatric health system based in Washington D.C., has partnered with Bainbridge Health to optimize the use of infusion pump data. See more here
- [Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer's Disease](https://bioadvance.com/http-www-bioadvance-com-media-annovisbio_announces-update-on-phase-ii-trial-2-13-20-pdf/) - Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer's Disease See more here
- [Annovis Issued Patent for Method of Treating Parkinson's Disease and Other Lewy Body Diseases](https://bioadvance.com/http-www-bioadvance-com-media-annovis-issued-patent-2-20-20-pdf/) - Annovis Issued Patent for Method of Treating Parkinson's Disease and Other Lewy Body Diseases See more here
- [Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board](https://bioadvance.com/http-www-bioadvance-com-media-renovacor-board-appt-anne-prener-2-24-2020-pdf/) - Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board Former CEO of Freeline Therapeutics, Ltd. has outstanding international drug development, commercialization expertise, with focus on rare disease, gene therapy See more here
- [Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies](https://bioadvance.com/http-www-bioadvance-com-media-2-27-20-annovis-awarded-1-7m-nih-grant-pdf/) - Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies See more here
- [iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis](https://bioadvance.com/http-www-bioadvance-com-media-12-19-19-iview-announces-first-patient-treated-in-phase-2-clinical-trial-program-pdf/) - iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis See more here
- [Venatorx Pharmaceuticals Joins the Alliance for Biosecurity](https://bioadvance.com/http-www-bioadvance-com-media-12-19-19-venatorx-joins-the-alliance-for-biosecurity-pdf/) - Venatorx Pharmaceuticals Joins the Alliance for Biosecurity See more here
- [Relmada Therapeutics Strengthens Board of Directors with Appointment of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool](https://bioadvance.com/http-www-bioadvance-com-media-2019-12-20_relmada_therapeutics_strengthens_board_of_205-pdf/) - Relmada Therapeutics Strengthens Board of Directors with Appointment of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool See more here
- [Ride Health Raises $6.2 Million to Coordinate the Medical Transportation Ecosystem](https://bioadvance.com/http-www-bioadvance-com-media-ride-health-raises-6-2m-jan-7-2020-pdf/) - Ride Health Raises $6.2 Million to Coordinate the Medical Transportation Ecosystem Company delivers first real-time ride coordination platform to improve access to care and patients' ride experience See more here
- [Wayne biopharmaceutical company sold to North Carolina drug developer](https://bioadvance.com/http-www-bioadvance-com-media-jan-8-2020-pbj-onspira-therapeutics-acquired-article-posted-pbj-article-pdf/) - Wayne biopharmaceutical company sold to North Carolina drug developer See more here
- [Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer](https://bioadvance.com/http-www-bioadvance-com-media-2020-01-10_relmada_therapeutics_strengthens_financial_206-pdf/) - Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer See more here
- [Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares](https://bioadvance.com/http-www-bioadvance-com-media-2019-12-09_relmada_therapeutics_announces_closing_of_115_204-pdf/) - Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares See more here
- [Ride Health And Uber Health Partner To Simplify Patients' Path To Medical Appointments](https://bioadvance.com/http-www-bioadvance-com-media-ride-health-partners-with-uber-health-jan-21-2020-pdf/) - Ride Health And Uber Health Partner To Simplify Patients' Path To Medical Appointments Companies aim to lower healthcare costs by combining multiple transportation options, ensuring all patients get the care they need to ensure good health See more here
- [Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology](https://bioadvance.com/http-www-bioadvance-com-media-varian-and-oncora-partner-sept-13-2019-pdf/) - Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology See more here
- [Pillo Health And BLACK+DECKER Partner To Deliver Smart Home Care Companion](https://bioadvance.com/http-www-bioadvance-com-media-pillo-and-black-and-decker-partner-sept-19-pdf/) - Pillo Health And BLACK+DECKER Partner To Deliver Smart Home Care Companion See more here
- [Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform](https://bioadvance.com/http-www-bioadvance-com-media-mebias-funding-viva-and-sprout-investments-final-pdf/) - Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects See more here
- [Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression](https://bioadvance.com/http-www-bioadvance-com-media-2019-10-15_relmada_therapeutics_announces_top_line_results_200-pdf/) - Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures See more here
- [Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients](https://bioadvance.com/http-www-bioadvance-com-media-tmunity-oncora-medical-partner-11-4-19-pdf/) - Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients - Strategic collaboration may support future trials with CAR T-cell therapy - Tmunity will use Oncora Medical's proprietary analytical tools to access real world data and innovate clinical trial design See more here
- [Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita](https://bioadvance.com/http-www-bioadvance-com-media-11-13-19-palvella-commences-phase-3-portion-of-phase-2-3-pivotel-study-pdf/) - Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita Fast Track-designated program aims to be first targeted therapy addressing root cause of chronically debilitating rare genetic disease See more here
- [CARB-X funds  VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea](https://bioadvance.com/http-www-bioadvance-com-media-carb-x-4-1m-non-diluted-funding-to-venatorx-nov-25-2019-pdf/) - CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea Funding represents 51st CARB-X Award, and 2nd CARB-X Award for VenatoRx See more here
- [Harvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States](https://bioadvance.com/http-www-bioadvance-com-media-12-5-19-ride-health-collaborate-with-harvard-pilgrim-health-care-for-medicare-members-pdf/) - Harvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States See more here
- [HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections](https://bioadvance.com/http-www-bioadvance-com-media-7-22-19-hhs-dod-venatorx-pharmaceuticals-to-co-develop-novel-antibiotic-pdf/) - HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections See more here
- [Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression](https://bioadvance.com/http-www-bioadvance-com-media-2019-07-29_relmada_therapeutics_announces_completion_of_195-pdf/) - Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression REL-1017 is a novel NMDA receptor antagonist in development as a rapidly acting oral agent for the treatment of depression See more here
- [Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease](https://bioadvance.com/http-www-bioadvance-com-media-renovacor-series-a-announcement-8-2019-pdf/) - Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease - Funding supports preclinical development through IND submission for its BAG3 gene therapy, the first gene replacement product for genetic forms of dilated cardiomyopathy - Company announces leadership team and board of directors with leading scientists, physicians and
- [VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio](https://bioadvance.com/http-www-bioadvance-com-media-venatorx-expands-developmental-team-aug-21-2019-pdf/) - VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio Key Hires in Quality Assurance, Medical Sciences and Regulatory Affairs See more here
- [Bainbridge Health Partners with Tabula Rasa HealthCare's subsidiary DoseMe To Expand Medication Management Capabilities to Health Systems(s)](https://bioadvance.com/http-www-bioadvance-com-media-aug-22-2019-bainbridge-partners-with-tabula-rasa-healthcares-subsidiary-doseme-pdf/) - Bainbridge Health Partners with Tabula Rasa HealthCare's subsidiary DoseMe To Expand Medication Management Capabilities to Health Systems(s) See more here
- [VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections](https://bioadvance.com/http-www-bioadvance-com-media-venatorx-aug-29-enrollment-in-phase-3-trial-of-cefepime-pdf/) - VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections - Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa - VNRX-5133 may provide a therapeutic option for these emerging pathogens, which are classified as urgent public health threats by the Centers for Disease Control and Prevention
- [VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development](https://bioadvance.com/http-www-bioadvance-com-media-venatorx-names-joseph-larson-vp-strategic-portfolio-development-sept-4-2019-pdf/) - VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development See more here
- [Berwyn biopharma firm files for IPO](https://bioadvance.com/http-www-bioadvance-com-media-annovis-bio-files-for-ipo-pdf/) - Berwyn biopharma firm files for IPO See more here
- [IView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-4-2-2/) - IView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis See more here
- [IView Therapeutics was awarded SBIR Innovative  grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID)](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-4-3/) - IView Therapeutics was awarded SBIR Innovative grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID) See more here
- [Pillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-5/) - Pillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home See more here
- [VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-3/) - VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia See more here
- [Nemours Children's Health System Expands Partnership with Bainbridge Health to Support Its Continued Commitment to Medication Safety](https://bioadvance.com/http-www-bioadvance-com-media-palvella-therapeutics-announces-10million-in-funding-from-ligand-pharma-12-18-18-pdf-2-2/) - Nemours Children's Health System Expands Partnership with Bainbridge Health to Support Its Continued Commitment to Medication Safety Bainbridge Health is partnering with Nemours Children's Hospital to further support the system's efforts to improve medication and infusion pump safety. See more here
- [QR Pharma Adopts new Corporate Name: Annovis Bio](https://bioadvance.com/annovis-qr-pharma-name-change-f-i-n-a-l-june-24-2019-v2/) - QR Pharma Adopts new Corporate Name: Annovis Bio Change reflects enhanced focus on neurodegenerative diseases See more here
- [Annovis Appoints Jeffrey McGroarty Chief Financial Officer](https://bioadvance.com/http-www-bioadvance-com-media-2019-07-09-annovis-hires-jeff-mcgroarty-as-cfo-pdf/) - Annovis Appoints Jeffrey McGroarty Chief Financial Officer See more here
- [South Shore Health Selects Bainbridge Health to Enhance Medication Safety and  Stewardship](https://bioadvance.com/http-www-bioadvance-com-media-south-shore-selects-bainbridge-health-7-16-19-pdf/) - South Shore Health Selects Bainbridge Health to Enhance Medication Safety and Stewardship Bainbridge Health is partnering with South Shore Health, a leading provider of emergency, acute and outpatient care, to enhance its efforts to improve safety and reduce medication waste. See more here
- [Children's of Alabama Selects Bainbridge Health to Support its Continued Commitment to Medication Safety and Stewardship](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf/) - Children's of Alabama Selects Bainbridge Health to Support its Continued Commitment to Medication Safety and Stewardship Bainbridge Health is partnering with Children's of Alabama, ranked among the best pediatric medical centers in the nation by U.S. News and World report, to further bolster its efforts to improve medication safety and stewardship. See more here
- [VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2/) - VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability Leveraging a Unique Small Molecule Library, VenatoRx seeks to open challenging bottlenecks for antibacterial drug discovery and successfully introduce new antibacterial agents into the clinic See more here
- [VenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2/) - VenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer See more here
- [Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-3/) - Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations Ms. DiGuglielmo consolidates and expands her role from advisor to a full-time position to lead Relmada's clinical operations See more here
- [Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-3-2/) - Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results Research Findings Accepted for Publication in Journal of Clinical Psychopharmacology See more here
- [Palvella Therapeutics raises $3M to advance rare disease drug](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2/) - Palvella Therapeutics raises $3M to advance rare disease drug See more here
- [IView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID)](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-4/) - IView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID) See more here
- [IView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-4-2/) - IView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA See more here
- [Oncora Medical teams up with oncologists at N.Y.'s largest health system](https://bioadvance.com/http-www-bioadvance-com-media-10-26-18-oncora-medical-teams-up-with-oncologists-at-ny-largest-health-system-pdf/) - Oncora Medical teams up with oncologists at N.Y.'s largest health system See more here
- [Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita](https://bioadvance.com/http-www-bioadvance-com-media-palvella-therapeutics-announces-fda-fast-track-designation-for-ptx-november2018-pdf/) - Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita See more here
- [Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans](https://bioadvance.com/http-www-bioadvance-com-media-pillo-health-launches-innovative-home-health-assistant-to-dispense-medication-pdf/) - Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans See more here
- [Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017](https://bioadvance.com/http-www-bioadvance-com-media-2018-12-12_relmada_therapeutics_presents_clinical_data_on_189-pdf/) - Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology See more here
- [Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita](https://bioadvance.com/http-www-bioadvance-com-media-palvella-therapeutics-announces-10million-in-funding-from-ligand-pharma-12-18-18-pdf/) - Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita - Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 - See more here
- [Philadelphia scientific instruments developer raises $5.6M](https://bioadvance.com/http-www-bioadvance-com-media-halo-philadelphia-scientific-instruments-developer-raises-5-6m-12-20-18-pdf/) - Philadelphia scientific instruments developer raises $5.6M See more here
- [VenatoRx Pharmaceuticals Joins Antimicrobials Working Group](https://bioadvance.com/http-www-bioadvance-com-media-venatorx-pharmaceuticals-joins-antimicrobials-working-group-1-3-19-pdf/) - VenatoRx Pharmaceuticals Joins Antimicrobials Working Group See more here
- [ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA(R) (pembrolizumab) for Advanced Solid Tumors](https://bioadvance.com/http-www-bioadvance-com-media-feb-4-2019-enb-announces-clinical-trial-collaboration-pdf/) - ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA(R) (pembrolizumab) for Advanced Solid Tumors See more here
- [Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors](https://bioadvance.com/http-www-bioadvance-com-media-palvella-appoints-rare-diseases-expert-to-board-sept-5-2018-pdf/) - Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors - Dr. Heron Adds Deep Expertise in Orphan Drug Development and Commercialization - See more here
- [Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder](https://bioadvance.com/http-www-bioadvance-com-media-2018-09-18_relmada_therapeutics_provides_enrollment_update_187-pdf/) - Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Trial Enrolling Well, with Approximately 25% of Targeted Subjects Recruited Top-line Data Expected in First Half of 2019 See more here
- [Digital health startup Keriton names new CEO to scale operations](https://bioadvance.com/http-www-bioadvance-com-media-digital-health-startup-keriton-names-new-ceo-to-scale-operations-sept-19-2018-pdf/) - Digital health startup Keriton names new CEO to scale operations See more here
- [ENB Therapeutics Closes Series A Round of Funding](https://bioadvance.com/http-www-bioadvance-com-media-enb-therapeutics-closes-series-a-round-of-funding-9-20-18-pdf/) - ENB Therapeutics Closes Series A Round of Funding Remiges led the Series A round of Financing See more here
- [Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate](https://bioadvance.com/http-www-bioadvance-com-media-mebias-discovery-receives-grant-from-nida-to-advance-its-signaling-9-24-18-pdf/) - Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids See more here
- [VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133](https://bioadvance.com/http-www-bioadvance-com-media-venatorx-pharmaceuticals-and-everest-medicines-limited-sept-2018-pdf/) - VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133 VenatoRx is eligible to receive up to $114 million, including upfront milestone payments, in addition to royalties See more here
- [Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels](https://bioadvance.com/http-www-bioadvance-com-media-2018-10-02_relmada_therapeutics_to_present_clinical_data_on_188-pdf/) - Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology See more here
- [Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK](https://bioadvance.com/http-www-bioadvance-com-media-oct-19-2018-palvella-therapeutics-to-present-update-on-ptx-pdf/) - Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK See more here
- [Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy](https://bioadvance.com/httpwww-bioadvance-commediacombination-of-checkpoint-inhibitors-and-intezyne-4-10-18-pdf/) - Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy See more here
- [Hackensack Meridian Health Funds Key Innovation to Improve Health Care in New Jersey](https://bioadvance.com/httpwww-bioadvance-commediahackensack-meridian-health-funds-key-innovation-to-improve-health-care-in-new-jersey-june-14-2018-pdf/) - Hackensack Meridian Health Funds Key Innovation to Improve Health Care in New Jersey Pillo, a medical hub for home, is the first health care innovation supported by network's $25 million Innovation Center Fund to improve patient experience and care while reducing costs See more here
- [CHOP spinout Bainbridge Health raises $1.6 million to expand mission, team](https://bioadvance.com/httpwww-bioadvance-commediachop-spinout-bainbridge-health-raises-1-6m-june-15-2018-pdf/) - CHOP spinout Bainbridge Health raises $1.6 million to expand mission, team Medical errors remain a significant cause of death in the U.S. This Center City company is looking to combat that through technology. See more here
- [AARP, startups partner to study digital healthcare technology](https://bioadvance.com/httpwww-bioadvance-commediaaarp-partners-with-pillo-startup-to-study-digital-healthcare-technology-pdf/) - AARP, startups partner to study digital healthcare technology Clinicians and groups like AARP view in-home digital technology as the future healthcare and are studying different technologies to assist patients in home. See more here
- [Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder](https://bioadvance.com/httpwww-bioadvance-commedia2018-06-27_relmada_therapeutics_inc_announces_first_patient_185-pdf/) - Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Top-Line Data Expected in First Half of 2019 See more here
- [Robert Wicke Appointed as New CEO of Halo Labs](https://bioadvance.com/http-www-bioadvance-com-media-july-31-2018-halo-labs-new-ceo-appointment-pdf/) - Robert Wicke Appointed as New CEO of Halo Labs See more here
- [Cohero Health Announces Additions to Executive Leadership Team](https://bioadvance.com/http-www-bioadvance-com-media-cohero-new-hires-pr-aug-2018-pdf/) - Cohero Health Announces Additions to Executive Leadership Team Company appoints executives with proven industry experience in connected care, medical device, and pharma to drive growth of the BreathSmart® digital platform for asthma and COPD See more here
- [Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases](https://bioadvance.com/http-www-bioadvance-com-media-ossianix-novo-nordisk-press-release-sept-2018-pdf/) - Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases See more here
- [VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens](https://bioadvance.com/httpwww-bioadvance-commediajan4-2018-venatorx-receives-award-for-up-to-16m-from-dtra-pdf/) - VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens See more here
- [VenatoRx Pharmaceuticals Receives FDA's QIDP and Fast Track Designations for Development of its Lead Antibiotic Program](https://bioadvance.com/httpwww-bioadvance-commediajan3-2018-venatorx-receives-fdas-qidp-and-fast-track-designations-for-lead-antibiotic-program-pdf/) - VenatoRx Pharmaceuticals Receives FDA's QIDP and Fast Track Designations for Development of its Lead Antibiotic Program See more here
- [Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System](https://bioadvance.com/httpwww-bioadvance-commedia2018-01-17_relmada_therapeutics_acquires_global_rights_to_183-pdf/) - Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System See more here
- [Pillo Health and Orbita Partner to Deliver Engaging Voice-first Experiences via a First-of-its-kind Digital Care Management Platform for Home](https://bioadvance.com/httpwww-bioadvance-commediapillo-2-23-18-partnership-with-oribta-pdf/) - Pillo Health and Orbita Partner to Deliver Engaging Voice-first Experiences via a First-of-its-kind Digital Care Management Platform for Home See more here
- [Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic](https://bioadvance.com/httpwww-bioadvance-commediaintezyne-partners-with-exosome-diagnostics-on-it-139-march-2018-pdf/) - Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic See more here
- [Intezyne Taps Veteran Banker E. Russell McAllister  as President and CEO](https://bioadvance.com/httpwww-bioadvance-commediaintezyne-taps-veteran-banker-as-new-ceo-march-2018-pdf/) - Intezyne Taps Veteran Banker E. Russell McAllister as President and CEO See more here
- [VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting](https://bioadvance.com/httpwww-bioadvance-commediavenatorx-pharmaceuticals-to-present-its-lead-clinical-antibacterial-candidate-march-2018-pdf/) - VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting See more here
- [Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer](https://bioadvance.com/httpwww-bioadvance-commedia2018-04-03_dr_ottavio_vitolo_joins_relmada_therapeutics_as_184-pdf/) - Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer See more here
- [VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria](https://bioadvance.com/httpwww-bioadvance-commediavenatorx-receives-9-4m-from-carb-x-7-27-17-pdf/) - VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria See more here
- [Oncora Medical raised $1.3 million to hire more tech staff](https://bioadvance.com/httpwww-bioadvance-commediaoncora-medical-raised-1-3m-for-more-tech-staff-pdf/) - Oncora Medical raised $1.3 million to hire more tech staff See more here
- [Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases](https://bioadvance.com/httpwww-bioadvance-commediaopsidio-closes-bridge-financing-to-develop-monoclonal-antibodies-to-treat-fibrotic-diseases-pdf/) - Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases See more here
- [Relmada Therapeutics Announces $6.9 Million Private Placement](https://bioadvance.com/httpwww-bioadvance-commedia2017-10-05_relmada_therapeutics_announces_6_9_million_180-pdf/) - Relmada Therapeutics Announces $6.9 Million Private Placement See more here
- [Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development](https://bioadvance.com/httpwww-bioadvance-commedia10-16-17-intezyne-closes-series-a-pdf/) - Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development See more here
- [MEBIAS Discovery LLC Presents Pre-Clinical Data on MU Opioid Receptor Pain Compounds at ADDC](https://bioadvance.com/httpwww-bioadvance-commediamebias-oct-16-2017-presents-preclinical-data-on-mu-opioid-receptor-pain-compounds-pdf/) - MEBIAS Discovery LLC Presents Pre-Clinical Data on MU Opioid Receptor Pain Compounds at ADDC See more here
- [Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms](https://bioadvance.com/httpwww-bioadvance-commedia2018-01-09_relmada_therapeutics_announces_notice_of_182-pdf/) - Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms See more here
- [UCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety](https://bioadvance.com/httpwww-bioadvance-commediajan9-2018-bainbridge-health-ucsf-med-ctr-selects-bainbridge-to-support-medication-saftey-pdf/) - UCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety See more here
- [Joe Biden Singles Out The One Health Company at SXSW Connect to End Cancer](https://bioadvance.com/httpwww-bioadvance-commediaonehealth-joebiden-pdf/) - Joe Biden Singles Out The One Health Company at SXSW Connect to End Cancer See more here
- [Bainbridge Health launches InfusionWare™ Intelligence to Address Medication Safety Practices](https://bioadvance.com/httpwww-bioadvance-commediabainbridge-health-launches-infusionware-pdf/) - Bainbridge Health launches InfusionWare™ Intelligence to Address Medication Safety Practices See more here
- [The One Health Company Teams with the Johns Hopkins University School of Medicine to Advance Sarcoma Treatment for Dogs and Humans](https://bioadvance.com/httpwww-bioadvance-commediaonehealth-jh-hemangiosarcoma-release-final-6-12-17-pdf/) - The One Health Company Teams with the Johns Hopkins University School of Medicine to Advance Sarcoma Treatment for Dogs and Humans See more here
- [Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer](https://bioadvance.com/httpwww-bioadvance-commediaintezyne-granted-orphan-drug-designation-for-it-139-6-20-17-pdf/) - Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer See more here
- [Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics](https://bioadvance.com/httpwww-bioadvance-commedia2017-06-21_dr_ottavio_vitolo_appointed_executive_clinical_178-pdf/) - Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics See more here
- [Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors](https://bioadvance.com/httpwww-bioadvance-commedia2017-06-15_charles_j_casamento_appointed_chairman_of_relmada__177-pdf/) - Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors See more here
- [Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program](https://bioadvance.com/httpwww-bioadvance-commedia2017-06-28_relmada_therapeutics_appoints_dr_maurizio_fava_as__179-pdf/) - Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program See more here
- [VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-Leading Antibiotics Developer](https://bioadvance.com/venatorx-raises-42-million-series-b-versant-abingworth-foresite-back-industry-leading-antibiotics-developer/) - VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-Leading Antibiotics Developer See more here
- [CHOP's latest spinout is using data to stop medication errors](https://bioadvance.com/httpwww-bioadvance-commediabainbridge-health-oct-2016-introduction-article-pdf/) - CHOP's latest spinout is using data to stop medication errors See more here
- [Immigrant-founded Keriton raised $1 million to help keep premature babies on breast milk](https://bioadvance.com/httpwww-bioadvance-commediakeriton-ceo-personal-story-2-16-17-pdf/) - Immigrant-founded Keriton raised $1 million to help keep premature babies on breast milk See more here
- [MD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance](https://bioadvance.com/httpwww-bioadvance-commediaoncora-mdanderson-pressrelease-003-pdf/) - MD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance See more here
- [Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder](https://bioadvance.com/httpwww-bioadvance-commedia2017-04-13_relmada_announces_fda_fast_track_designation_for_175-pdf/) - Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder See more here
- [Cohero Health Names Joe Condurso As Chief Executive Officer](https://bioadvance.com/httpwww-bioadvance-commediacohero-health_press-release_cohero-health-names-joe-condurso-as-chief-executive-officer_4-20-17-pdf/) - Cohero Health Names Joe Condurso As Chief Executive Officer See more here
- [Optofluidics Announces Name Change to Halo Labs](https://bioadvance.com/httpwww-bioadvance-commediaoptofluidics-name-change-pdf/) - Optofluidics Announces Name Change to Halo Labs See more here
- [Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium](https://bioadvance.com/httpwww-bioadvance-commediaintezyne-3-31-17-initiates-first-in-human-trials-for-it-141-pdf/) - Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium See more here
- [Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone](https://bioadvance.com/httpwww-bioadvance-commedia2017-01-25_relmada_announces_fda_acceptance_of_ind_and_172-pdf/) - Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone See more here
- [Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated](https://bioadvance.com/httpwww-bioadvance-commedia2016-03-01_relmada_therapeutics_announces_publication_of_146-pdf/) - Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated See more here
- [Managing Health Care Compliance in the Cloud](https://bioadvance.com/httpwww-bioadvance-commediawelltrackone-managing-health-care-compliance-in-the-cloud-by-samuel-greengard-pdf/) - Managing Health Care Compliance in the Cloud See more here
- [Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression](https://bioadvance.com/httpwww-bioadvance-commedia2016-06-27_relmada_therapeutics_announces_notice_of_157-pdf/) - Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression See more here
- [ImagineCare and Cohero Health Merge Digital Technologies for COPD Management](https://bioadvance.com/httpwww-bioadvance-commediacohero-health-and-imaginecare-oct-4-2016-pdf/) - ImagineCare and Cohero Health Merge Digital Technologies for COPD Management See more here
- [Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms](https://bioadvance.com/httpwww-bioadvance-commedia2016-10-19_relmada_therapeutics_announces_issuance_of_key_u_167-pdf/) - Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms See more here
- [Cohero Health Closes Series A Funding to Accelerate Commercial Expansion](https://bioadvance.com/httpwww-bioadvance-commediacohero-health-a-round-press-release_11-2-16_final-pdf/) - Cohero Health Closes Series A Funding to Accelerate Commercial Expansion See more here
- [H&T Presspart and Cohero Health Launch First Market-Ready, Fully-Connected Metered Dose Inhaler to Optimize care of Asthma and COPD](https://bioadvance.com/httpwww-bioadvance-commediacohero-and-ht-presspart-mdi-press-release_email-pdf/) - H&T Presspart and Cohero Health Launch First Market-Ready, Fully-Connected Metered Dose Inhaler to Optimize care of Asthma and COPD See more here
- [Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology](https://bioadvance.com/httpwww-bioadvance-commedialundbeck-press-release-final-version-jan-2017-1-pdf/) - Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology See more here
- [MD Revolution and WellTrackONE Partner to Prepare Renaissance Health Network for Value Based Care](https://bioadvance.com/md-revolution-and-welltrackone-partner-to-prepare-renaissance-health-network-for-value-based-care/) - MD Revolution and WellTrackONE Partner to Prepare Renaissance Health Network for Value Based Care Read more here
- [Novira Therapeutics Announces Acquisition Agreement with Johnson & Johnson](https://bioadvance.com/novira-therapeutics-announces-acquisition-agreement-with-johnson-johnson/) - Novira Therapeutics Announces Acquisition Agreement with Johnson & Johnson See more here
- [Melior Discovery Announces Spinout of Melior Pharmaceuticals II, LLC](https://bioadvance.com/httpwww-bioadvance-commedia2016-05-08-melior-pharma-ii-spinout-pr-v3-pdf/) - Melior Discovery Announces Spinout of Melior Pharmaceuticals II, LLC See more here
- [McKesson and HealthQX Announce Alliance to Accelerate Value-Based Payment](https://bioadvance.com/httpwww-bioadvance-commediahealthqx-announce-alliance-to-accelerate-value-based-payment-_-pdf/) - McKesson and HealthQX Announce Alliance to Accelerate Value-Based Payment See more here
- [HealthQX First To Achieve Certification With HCI3's Latest Version](https://bioadvance.com/httpwww-bioadvance-commediahealthqx-first-to-achieve-certification-with-hci3s-latest-version-_-healthq-pdf/) - HealthQX First To Achieve Certification With HCI3's Latest Version See more here
- [Cohero Health and Presspart Group Announce Completion of Connected Metered Dose Inhaler](https://bioadvance.com/httpwww-bioadvance-commediacoherohealthpressrelease040416-pdf/) - Cohero Health and Presspart Group Announce Completion of Connected Metered Dose Inhaler See more here
- [The One Health Company Wins Prestigious Robert Woods Award](https://bioadvance.com/httpwww-bioadvance-commediathe-one-health-company-wins-the-prestigious-robert-woods-award-the-one-hea-pdf/) - The One Health Company Wins Prestigious Robert Woods Award See more here
- [Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects](https://bioadvance.com/httpwww-bioadvance-commedia2016-05-04_relmada_therapeutics_announces_results_of_in_vivo__152-pdf/) - Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects See more here
- [Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone](https://bioadvance.com/relmada-therapeutics-receives-health-canada-clearance-to-commence-first-clinical-study-of-d-methadone-2/) - Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone Read more here
- [Melior Discovery Awarded SBIR Grant for Studying MLR-1023 Mechanism of Action](https://bioadvance.com/melior-discovery-awarded-sbir-grant-for-studying-mlr-1023-mechanism-of-action/) - Melior Discovery Awarded SBIR Grant for Studying MLR-1023 Mechanism of Action Read more here
- [Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics](https://bioadvance.com/ossianix-expands-and-extends-its-research-collaboration-with-lundbeck-on-cns-therapeutics/) - Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics Read More Here
- [Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone](https://bioadvance.com/relmada-therapeutics-doses-first-cohort-of-subjects-in-human-clinical-trial-of-d-methadone/) - Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone Read more here
- [Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone](https://bioadvance.com/relmada-therapeutics-reaches-midway-point-in-dose-escalation-for-phase-one-study-of-novel-nmda-receptor-antagonist-d-methadone/) - Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone Read more here
- [Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine](https://bioadvance.com/relmada-therapeutics-receives-health-canada-clearance-to-commence-first-clinical-study-for-novel-oral-formulations-of-buprenorphine/) - Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine Read more here
- [HealthQx First to Receive New Certification by HCI3](https://bioadvance.com/healthqx-first-to-receive-new-certification-by-hci3/) - HealthQx First to Receive New Certification by HCI3 Read more here
- [Melior Discovery Receives Patent Approval from U.S. Patent And Trademark Office for New Parkinson’s Disease Drug Candidate](https://bioadvance.com/melior-discovery-receives-patent-approval-from-u-s-patent-and-trademark-office-for-new-parkinsons-disease-drug-candidate/) - Melior Discovery Receives Patent Approval from U.S. Patent and Trademark Office for New Parkinson’s Disease Drug Candidate Read more here
- [Relmada Therapeutics Gears Up to Become a Publicly Traded Company](https://bioadvance.com/relmada-therapeutics-gears-up-to-become-a-publicly-traded-company/) - Relmada Therapeutics Gears Up to Become a Publicly Traded Company Read more here
- [Relmada Therapeutics Announces Levocap ER Development Progress](https://bioadvance.com/relmada-therapeutics-announces-levocap-er-development-progress/) - Relmada Therapeutics Announces Levocap ER Development Progress Read more here
- [Relmada Therapeutics Reinforces Balance Sheet with $15.2 Million from Exercise of Warrants](https://bioadvance.com/relmada-therapeutics-reinforces-balance-sheet-with-15-2-million-from-exercise-of-warrants/) - Relmada Therapeutics Reinforces Balance Sheet with $15.2 Million from Exercise of Warrants Read more here
- [Venatorx Completes Series A Financing](https://bioadvance.com/venatorx-completes-series-a-financing/) - Venatorx Completes Series A Financing Read more here
- [Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride](https://bioadvance.com/ceptaris-resubmits-new-drug-application-nda-to-fda-for-proprietary-gel-formulation-of-mechlorethamine-hydrochloride-2/) - Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride Read more here
- [Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics](https://bioadvance.com/actelion-enters-into-an-agreement-to-acquire-privately-held-ceptaris-therapeutics/) - Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics Read more here
- [Relmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development](https://bioadvance.com/relmada-therapeutics-appoints-michael-becker-as-senior-vice-president-of-finance-and-corporate-development/) - Relmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development Read more here
- [Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778](https://bioadvance.com/novira-therapeutics-announces-presentation-of-phase-1a-safety-and-pharmacokinetic-data-for-nvr-3-778/) - Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778 Read more here
- [Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER](https://bioadvance.com/relmada-therapeutics-enters-into-agreement-with-memorial-sloan-kettering-to-better-clarify-unique-mechanism-of-action-for-levocap-er/) - Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER Read more here
- [Relmada Announces the Filing of Clinical Trial Application in Canada for D-Methadone](https://bioadvance.com/relmada-announces-the-filing-of-clinical-trial-application-in-canada-for-d-methadone/) - Relmada Announces the Filing of Clinical Trial Application in Canada for D-Methadone Read more here
- [Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker](https://bioadvance.com/relmada-therapeutics-inc-completes-name-change-and-announces-new-ticker-2/) - Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker Read more here
- [Relmada Therapeutics Files Shares Registration Statement](https://bioadvance.com/relmada-therapeutics-files-shares-registration-statement-2/) - Relmada Therapeutics Files Shares Registration Statement Read more here
- [Relmada Therapeutics Successfully Completes Offerings Totaling $28 Million in Connection with Going Public Transaction](https://bioadvance.com/relmada-therapeutics-successfully-completes-offerings-totaling-28-million-in-connection-with-going-public-transaction/) - Relmada Therapeutics Successfully Completes Offerings Totaling $28 Million in Connection with Going Public Transaction Read more here
- [Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise in Series A Financing](https://bioadvance.com/relmada-therapeutics-inc-completes-8-0-million-capital-raise-in-series-a-financing-2/) - Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise in Series A Financing Read more here
- [Relmada Therapeutics Inc. Announces Collaboration with the Malvern Consulting Group](https://bioadvance.com/relmada-therapeutics-inc-announces-collaboration-with-the-malvern-consulting-group/) - Relmada Therapeutics Inc. Announces Collaboration with the Malvern Consulting Group Read more here
- [Relmada Therapeutics Announces Positive Results of LevoCap ER Pivotal Pharmacokinetic Study](https://bioadvance.com/relmada-therapeutics-announces-positive-results-of-levocap-er-pivotal-pharmacokinetic-study/) - Relmada Therapeutics Announces Positive Results of LevoCap ER Pivotal Pharmacokinetic Study Read more here
- [HealthQx Partners with Leader in Value-based Payment Reform](https://bioadvance.com/1170-2/) - HealthQx Partners with Leader in Value-based Payment Reform Read more here
- [Infrascanner™ Brain Scanner Gets $3.7M-Expands head trauma detection capabilities](https://bioadvance.com/infrascanner-brain-scanner-gets-3-7m-expands-head-trauma-detection-capabilities/) - Infrascanner™ Brain Scanner Gets $3.7M-Expands head trauma detection capabilities Read more here
- [HealthQx Expands, Fueled by a New Round of Funding](https://bioadvance.com/healthqx-expands-fueled-by-a-new-round-of-funding/) - HealthQx Expands, Fueled by a New Round of Funding Read more here
- [HealthQx Partners with HCI3, Leader in Value-based Payment Reform](https://bioadvance.com/healthqx-partners-with-hci3-leader-in-value-based-payment-reform/) - HealthQx Partners with HCI3, Leader in Value-based Payment Reform Read more here
- [Sean Cunliffe Joins TREVENTIS Corporation as CEO](https://bioadvance.com/1336-2/) - Sean Cunliffe Joins TREVENTIS Corporation as CEO Read more here
- [TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust](https://bioadvance.com/treventis-corporation-closes-4-4-million-financing-with-wellcome-trust/) - TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust Read more here
- [Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments](https://bioadvance.com/intezyne-technologies-expands-executive-leadership-team-with-two-key-appointments/) - Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments Read more here
- [Venatorx Awarded NIH RO1 Grant](https://bioadvance.com/venatorx-awarded-nih-ro1-grant/) - Venatorx Awarded NIH RO1 Grant Read more here
- [Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma](https://bioadvance.com/intezyne-technologies-expands-its-oncology-pipeline-through-strategic-acquisition-of-niiki-pharma/) - Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma Read more here
- [Novira Therapeutics Expands Management Team](https://bioadvance.com/novira-therapeutics-expands-management-team-with-appointment-of-klaus-klumpp-ph-d-the-former-global-head-of-roches-virology-discovery-initiatives-as-vice-president-discovery-research/) - Novira Therapeutics Expands Management Team Read more here
- [The U.S. Military's Miracle Scanner](https://bioadvance.com/the-u-s-militarys-miracle-scanner/) - The U.S. Military's Miracle Scanner Read more here
- [Novira Therapeutics Completes $25 Million Series A Financing](https://bioadvance.com/novira-therapeutics-completes-25-million-series-a-financing/) - Novira Therapeutics Completes $25 Million Series A Financing Read more here
- [Teva buys NuPathe to Expand Central Nervous System Business](https://bioadvance.com/teva-buys-nupathe-to-expand-central-nervous-system-business/) - Teva buys NuPathe to Expand Central Nervous System Business Read more here
- [Novira Therapeutics Begins Phase 1a Clinical Study of NVR–1221 for the Treatment of Chronic Hepatitis B (HBV) Infection](https://bioadvance.com/novira-therapeutics-begins-phase-1a-clinical-study-of-nvr-1221-for-the-treatment-of-chronic-hepatitis-b-hbv-infection/) - Novira Therapeutics Begins Phase 1a Clinical Study of NVR–1221 for the Treatment of Chronic Hepatitis B (HBV) Infection Read more here
- [Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board](https://bioadvance.com/985-2/) - Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board Read more here
- [Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies](https://bioadvance.com/996-2/) - Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies Read more here
- [Ossianix Announces Research Collaboration with Lundbeck](https://bioadvance.com/ossianix/) - Ossianix Announces Research Collaboration with Lundbeck Read more here
- [Teva Completes $144 Million NuPathe Deal](https://bioadvance.com/teva-completes-144-million-nupathe-deal/) - Teva Completes $144 Million NuPathe Deal Read more here
- [Novira Names Christian Schade as Chief Executive Officer](https://bioadvance.com/novira-names-christian-schade-as-chief-executive-officer/) - Novira Names Christian Schade as Chief Executive Officer Read more here
- [Healthcare Startup WellTrackONE Finds Traction with Automated Tools for Wellness Exams for Medicare](https://bioadvance.com/healthcare-startup-finds-traction-with-automated-tools-for-wellness-exams-for-medicare/) - Healthcare Startup WellTrackONE Finds Traction with Automated Tools for Wellness Exams for Medicare Read more here
- [The Marine Corps Awards Contract for the Infrascanner™ Model 2000](https://bioadvance.com/the-marine-corps-award-a-contract-for-the-infrascanner-model-2000/) - The Marine Corps Awards Contract for the Infrascanner™ Model 2000 Read more here
- [The Future of Drug Discovery: Two Required Supplements to Current Practices](https://bioadvance.com/the-future-of-drug-discovery-two-required-supplements-to/) - The Future of Drug Discovery: Two Required Supplements to Current Practices Read more here
- [Actelion Closes Acquisition of Privately-held Ceptaris Therapeutics](https://bioadvance.com/actelion-closes-acquisition-of-privately-held-ceptaris-therapeutics-adding-valchlor-to-actelions-product-portfolio/) - Actelion Closes Acquisition of Privately-held Ceptaris Therapeutics Adding Valchlor to Actelion's Product Portfolio Read more here
- [Galderma Receives FDA Approval of Mirvaso®](https://bioadvance.com/galderma-receives-fda-approval-of-mirvaso-2/) - Galderma Receives FDA Approval of Mirvaso® Read more here
- [Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics](https://bioadvance.com/https-www-bioadvance-com-media-12-14-21-annovis-bio-announces-publication-of-anvs401-mechanism-of-action-in-peer-reviewed-pharmaceutics-pdf/) - Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases See more here
- [Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option](https://bioadvance.com/https-www-bioadvance-com-media-2021-12-14_relmada_therapeutics_announces_closing_of_public_250-pdf/) - Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option See more here
- [Bridge Bank Issues $4 Million Line of Credit to Ride Health](https://bioadvance.com/https-www-bioadvance-com-media-11-9-21-bridge-bank-issues-4-million-line-of-credit-to-ride-health-pdf/) - Bridge Bank Issues $4 Million Line of Credit to Ride Health See more here
- [Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-2021-11-11_relmada_therapeutics_provides_corporate_update_246-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results See more here
- [Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference](https://bioadvance.com/https-www-bioadvance-com-media-11-15-21-immunogenesis-sitc-poster-presentations-pdf/) - Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference See more here
- [Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-11-15-21-renovacor-announces-third-quarter-2021-financial-results-and-provides-corporate-update-pdf/) - Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via
- [Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs](https://bioadvance.com/https-www-bioadvance-com-media-12-2-21-venatorx-pharmaceuticals-names-scott-mcconnell-pharm-d-as-vice-president-medical-affairs-pdf/) - Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs See more here
- [AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR](https://bioadvance.com/https-www-bioadvance-com-media-12-7-21-alliancechicago-to-offer-wellsheets-predictive-clinical-workflow-platform-pdf/) - AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR Wellsheet Integration with athenaOne to Empower Primary Care Clinicians in Community Health Centers See more here
- [Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock](https://bioadvance.com/https-www-bioadvance-com-media-2021-12-08_relmada_therapeutics_announces_pricing_of_upsized__249-pdf/) - Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock See more here
- [ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers](https://bioadvance.com/https-www-bioadvance-com-media-12-14-21-immunogenesis-svp-clinical-development-pdf/) - ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers Clinical trials for ImmunoGenesis drug candidates to initiate in 2022 See more here
- [Relmada Therapeutics Announces Top- Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential](https://bioadvance.com/https-www-bioadvance-com-media-2021-07-27_relmada_therapeutics_announces_top_line_results_237-pdf/) - Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential - All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs. oxycodone with p-values
- [Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science](https://bioadvance.com/https-www-bioadvance-com-media-renovacor-announces-the-appointment-of-jordan-shin-m-d-ph-d-as-senior-vice-president-of-clinical-development-and-translational-science-pdf/) - Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice See more here
- [Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality](https://bioadvance.com/https-www-bioadvance-com-media-10-4-21-halo-labs-launches-the-aura-gt-for-gene-therapy-product-quality-pdf/) - Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality Aura GT is the first system specifically designed to quantify capsid aggregates and identify the mechanism of aggregation See more here
- [Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations](https://bioadvance.com/https-www-bioadvance-com-media-10-4-21-renovacor-announces-the-appointment-of-kumar-dhanasekharan-ph-d-as-svp-of-technical-operations-pdf/) - Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies See more here
- [Annovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-10-5-21-annovis-bio-annonces-positive-phase-2-efficacy-data-for-treatment-of-parkinsons-disease-pdf/) - Annovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson's Disease Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET See more
- [Phrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance](https://bioadvance.com/https-www-bioadvance-com-media-10-28-21-phrase-health-announces-3m-investment-from-health-it-leaders-pdf/) - Phrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance The new investment will enhance growth initiatives, accelerate development, and support additional research to enhance platform capabilities. See more here
- [Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen](https://bioadvance.com/https-www-bioadvance-com-media-11-1-21-venatorx-pharmaceuticals-announces-collaboration-with-roche-to-develop-new-class-of-antibiotics-targeting-who-critical-priority-pathogen-pdf/) - Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen Development of novel antibiotics to circumvent antimicrobial resistance and address increasing threat of superbugs See more here
- [Wellsheet Collaborates with Horizon to Provide Clinicians with a Single View of Key Data and Insights within their EHR Workflow](https://bioadvance.com/https-www-bioadvance-com-media-11-3-21-wellsheet-collaborates-with-horizon-to-provide-clinicians-with-a-single-view-of-key-data-and-insights-within-their-ehr-workflow-pdf/) - Wellsheet Collaborates with Horizon to Provide Clinicians with a Single View of Key Data and Insights within their EHR Workflow New Jersey Health Providers Can Access a Near Real-Time Comprehensive View of Patients’ Medical History See more here
- [Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145](https://bioadvance.com/https-www-bioadvance-com-media-7-28-21-venatorx-pharmaceuticals-announces-positive-phase-1-results-for-vnrx-7145-pdf/) - Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145 Investigational oral beta-lactamase inhibitor VNRX-7145 was well-tolerated with no safety signals up to the highest dose as a single agent Ceftibuten/VNRX-7145 Combination Phase 1 Study Initiated with Top Line Results Expected Fourth Quarter 2021 Company Plans to Initiate Phase 3 Clinical Trial for Ceftibuten/VNRX-7145 in Second
- [Wellsheet Granted Patent to Make Electronic Health Records User-Friendly](https://bioadvance.com/https-www-bioadvance-com-media-8-4-21-wellsheet-granted-patent-to-make-electronic-health-records-user-friendly-pdf/) - Wellsheet Granted Patent to Make Electronic Health Records User-Friendly Intuitive and Predictive Workflow App for EHR: • Reduces time spent in the EHR, which reduces physician burnout • Reduces training time and improves productivity • Increases clinician satisfaction by an order of magnitude See more here
- [Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam](https://bioadvance.com/https-www-bioadvance-com-media-8-17-21-venatorx-pharmaceuticals-provides-update-on-cefepime-taniborbactam-pdf/) - Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to support the development of cefepime-taniborbactam in patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia (HABP/VABP) Phase 3 clinical trial of cefepime-taniborbactam
- [Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer](https://bioadvance.com/https-www-bioadvance-com-media-8-25-21-renovacor-announces-the-appointment-of-matt-killeen-ph-d-as-chief-scientific-officer-pdf/) - Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases See more here
- [ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals](https://bioadvance.com/https-www-bioadvance-com-media-8-31-21-immunogenesis-announces-positive-preclinical-glioblastoma-and-pancreatic-cancer-data-for-stimulator-of-interferon-genes-sting-agonist-published-in-two-scien-pd/) - ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future
- [Phrase Health Awarded Phase 2 NIH Grant To Scale Quality Improvement Platform](https://bioadvance.com/https-www-bioadvance-com-media-8-31-21-phrase-health-awarded-phase-2-nih-grant-to-scale-quality-improvement-pdf/) - Phrase Health Awarded Phase 2 NIH Grant To Scale Quality Improvement Platform The $1.7 million Phase 2 STTR grant expands upon the quality improvement and informatics cloud-based software developed by the company See more here
- [Renovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange](https://bioadvance.com/https-www-bioadvance-com-media-9-2-21-renovacor-inc-closes-its-business-combination-with-chardan-healthcare-acquisition-2-corp-and-will-begin-trading-on-the-new-york-stock-exchange-1-pdf/) - Renovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively. Gross proceeds from the transaction
- [Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention](https://bioadvance.com/https-www-bioadvance-com-media-syneos-health-and-ride-health-partner-pdf/) - Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research See more here
- [Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO](https://bioadvance.com/https-www-bioadvance-com-media-7-1-21-annovis-bio-ceo-wins-2021-pact-enterprise-award-for-life-sciences-and-healthcare-ceo-pdf/) - Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO See more here
- [CrossBridge Health acquires Geisinger-developed PACER software](https://bioadvance.com/https-www-bioadvance-com-media-7-13-21-crossbridge-health-acquires-geisinger-developed-pacer-software-pdf/) - CrossBridge Health acquires Geisinger-developed PACER software CrossBridge to integrate PACER intelligence to improve outcomes for patients with chronic inflammatory diseases See more here
- [Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance](https://bioadvance.com/https-www-bioadvance-com-media-7-12-21-renovacor-announces-the-appointment-of-jiwen-zhang-phd-as-senior-vice-president-regulatory-affairs-and-quality-assurance-pdf/) - Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy See more here
- [Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study](https://bioadvance.com/https-www-bioadvance-com-media-7-20-21-annovis-bio-reports-positive-safety-data-from-its-phase-2-alzheimers-study-pdf/) - Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort See more here
- [InfraScan Inc. Announces DoD/DHA Product Development Partnership](https://bioadvance.com/https-www-bioadvance-com-media-6-17-21-infrascan-inc-announces-dod-dha-product-development-partnership-pdf/) - InfraScan Inc. Announces DoD/DHA Product Development Partnership InfraScan announces product development partnership with DoD See more here
- [Ride Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers](https://bioadvance.com/https-www-bioadvance-com-media-7-20-21-ride-health-and-the-american-heart-association-partner-to-improve-health-equity-for-patients-facing-transportation-barriers-pdf/) - Ride Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers American Heart Association's Social Impact Fund and Bernard J. Tyson Impact Fund invest $500,000 to support comprehensive patient transportation programs at renowned hospitals See more here
- [Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC](https://bioadvance.com/https-www-bioadvance-com-media-7-20-21-relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc-pdf/) - Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC See more here
- [ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory](https://bioadvance.com/https-www-bioadvance-com-media-7-28-21-immunogenesis-expands-rd-clinical-and-business-development-teams-and-opens-research-laboratory-pdf/) - ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory Clinical and CMC hires to ready initiation of multiple immuno-oncology clinical programs in 2022 Proven business development expertise key to executing global clinical development strategy R&D hires and lab opening to facilitate critical translational research See more here
- [Annovis Bio, Inc. Announces Pricing of Public Offering](https://bioadvance.com/https-www-bioadvance-com-media-5-23-21-annovis-bio-announces-pricing-of-public-offering-pdf/) - Annovis Bio, Inc. Announces Pricing of Public Offering See more here
- [Annovis Bio, Inc. Announces Closing of $50 Million Public Offering](https://bioadvance.com/https-www-bioadvance-com-media-5-27-21-annovis-bio-announces-closing-of-50-million-public-offering-pdf/) - Annovis Bio, Inc. Announces Closing of $50 Million Public Offering See more here
- [Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer](https://bioadvance.com/https-www-bioadvance-com-media-6-2-21-renovacor-announces-the-appointment-of-marc-semigran-m-d-as-chief-medical-officer-pdf/) - Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer Former chief medical officer of MyoKardia to lead clinical development at Renovacor See more here
- [Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies](https://bioadvance.com/https-www-bioadvance-com-media-ossianix-press-release-_061021-pdf/) - Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies A highly potent panel of VNARs against the SARS-CoV-2 spike protein has been isolated Neutralization of SARS-CoV-2 was demonstrated in in vitro infectivity assays In vitro blocking activities were also found against the N501Y and
- [Ride Health Raises $10 Million to Scale National Medical Transportation Platform](https://bioadvance.com/https-www-bioadvance-com-media-6-21-21-ride-health-raises-10-million-to-scale-national-medical-transportation-platform-pdf/) - Ride Health Raises $10 Million to Scale National Medical Transportation Platform Company brings real-time visibility to the non-emergency medical transportation industry, improving access to care and social resources for underserved populations See more here
- [Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection](https://bioadvance.com/https-www-bioadvance-com-media-6-28-21-venatorx-pharmaceuticals-announces-first-patient-dosed-in-phase-1-study-of-vnrx-9945-for-the-treatment-of-chronic-hepatitis-b-virus-infection-pdf/) - Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection See more here
- [Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science](https://bioadvance.com/https-www-bioadvance-com-media-6-29-21-venatorx-pharmaceuticals-names-mary-beth-dorr-ph-d-vice-president-clinical-science-pdf/) - Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science See more here
- [Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors](https://bioadvance.com/https-www-bioadvance-com-media-6-29-21-renovacor-announces-the-appointments-to-its-board-of-directors-pdf/) - Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. See more here
- [Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY](https://bioadvance.com/https-www-bioadvance-com-media-3-29-21-ride-health-to-provide-non-emergency-transportation-for-complex-patient-populations-across-new-york-state-through-partnership-with-imsny-pdf/) - Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY See more here
- [Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-2021-04-01_relmada_therapeutics_announces_initiation_of_225-pdf/) - Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder See more here
- [Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality](https://bioadvance.com/https-www-bioadvance-com-media-4-20-21-halo-labs-launches-the-aura-cl-for-cell-therapy-product-quality-pdf/) - Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants See more here
- [Wellsheet Appoints Healthcare Veteran Ryan Sadlo to Help Health Systems Modernize EHR Systems to Address Physician Burnout](https://bioadvance.com/https-www-bioadvance-com-media-5-5-21-wellsheet-appoints-healthcare-veteran-ryan-sadlo-pdf/) - Wellsheet Appoints Healthcare Veteran Ryan Sadlo to Help Health Systems Modernize EHR Systems to Address Physician Burnout New Vice President of Growth to Accelerate Commercial Operations in the Public and Private Sector See more here
- [3D Systems Announces Two Strategic Growth Acquisitions](https://bioadvance.com/https-www-bioadvance-com-media-05-06-2021-3d-systems-announces-two-strategic-growth-acquisitions-pdf/) - 3D Systems Announces Two Strategic Growth Acquisitions - Acquisition of Allevi, Inc. to expand regenerative medicine initiative by accelerating growth in medical and pharmaceutical research laboratories - Acquisition of German software firm, Additive Works GmbH to expand simulation capabilities for rapid optimization of industrial-scale 3D printing processes See more here
- [Venatorx Pharmaceuticals’ Novel Antibiotic Pipeline Addresses the Next Pandemic: Superbugs](https://bioadvance.com/https-www-bioadvance-com-media-5-11-21-venatorx-pharmaceuticals-novel-antibiotic-pipeline-addresses-the-next-pandemic-superbugs-pdf/) - Venatorx Pharmaceuticals’ Novel Antibiotic Pipeline Addresses the Next Pandemic: Superbugs Company to Watch – Venatorx Pharmaceuticals See more here
- [Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research](https://bioadvance.com/https-www-bioadvance-com-media-5-18-21-annovis-bio-appoints-accomplished-neuroscientist-dr-cheng-fang-as-vp-of-research-pdf/) - Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research See more here
- [Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome](https://bioadvance.com/https-www-bioadvance-com-media-5-13-21-annovis-bio-files-for-fda-orphan-drug-designation-for-anvs401-for-the-treatment-of-alzheimers-disease-in-persons-with-down-syndrome-pdf/) - Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome See more here
- [Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-110822-annovis-bio-announces-third-quarter-2022-results-and-provides-corporate-update-pdf/) - Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update See more here
- [Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-2022-11-10_relmada_therapeutics_provides_corporate_update_271-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results See more here
- [Immunome Reports Third Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-111422-immunome-reports-third-quarter-2022-financial-results-pdf/) - Immunome Reports Third Quarter 2022 Financial Results See more here
- [Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-101322-relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder-pdf/) - Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder See more here
- [Philadelphia medtech company Bainbridge Health raises $3.35M](https://bioadvance.com/https-www-bioadvance-com-media-10142022-chop-spinout-bainbridge-health-raises-3-35m-pdf/) - Philadelphia medtech company Bainbridge Health raises $3.35M See more here
- [Wellsheet Introduces EHR Workflow Relief to Increase Efficiency During Critical Nursing Shortage](https://bioadvance.com/https-www-bioadvance-com-media-101722-wellsheet-introduces-ehr-workflow-relief-pdf/) - Wellsheet Introduces EHR Workflow Relief to Increase Efficiency During Critical Nursing Shortage Virtual Nursing Station with Real-Time Notifications Increases Care Team Collaboration and Patient Care Quality See more here
- [Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022](https://bioadvance.com/https-www-bioadvance-com-media-102022-venatorx-presents-data-at-idweek-2022-pdf/) - Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022 Superior to Meropenem for the Primary Efficacy Endpoint Safety Profile Consistent with Meropenem See more here
- [Senzo Receives Funding from the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test](https://bioadvance.com/https-www-bioadvance-com-media-102722-barda-press-release-senzo-pdf/) - Senzo Receives Funding from the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test See more here
- [ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference](https://bioadvance.com/https-www-bioadvance-com-media-110322-immunogenesis-to-present-pre-clinical-data-from-lead-program-at-society-for-immunotherapy-of-cancer-conference-pdf/) - ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference See more here
- [ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy](https://bioadvance.com/https-www-bioadvance-com-media-110422-enb-therapeutics-announces-poster-presentation-at-the-2022-summit-for-cancer-immunotherapy-pdf/) - ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint See more here
- [Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting](https://bioadvance.com/https-www-bioadvance-com-media-110722-immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting-pdf/) - Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting - IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing - EPN1 appears to play an important role in cancer
- [Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer](https://bioadvance.com/https-www-bioadvance-com-media-8-29-22-annovis-bio-appoints-henry-hagopian-iii-as-chief-financial-officer-pdf/) - Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer See more here
- [Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders](https://bioadvance.com/https-www-bioadvance-com-media-090822-innervace-secures-up-to-40-million-to-advance-novel-regenerative-medicine-platform-for-neurological-disorders-pdf/) - Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders Series A financing round, led by Deerfield Management, to accelerate a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease See more here
- [Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases](https://bioadvance.com/https-www-bioadvance-com-media-1-070722-annovis-bio-announces-positive-fda-notice-for-buntanetap-phase-3-clinical-trial-in-parkinsons-disease-pdf/) - Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases See more here
- [Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-relmada-therapeutics-announces-completion-of-treatment-in-companys-registrational-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-major-depre-pdf/) - Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder See more here
- [Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy](https://bioadvance.com/https-www-bioadvance-com-media-rocket-pharmaceuticals-to-acquire-renovacor-extending-leadership-in-aav-based-cardiac-gene-therapy-pdf/) - Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy - Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions - Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease - Creates strong synergies
- [Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract](https://bioadvance.com/https-www-bioadvance-com-media-100322-venatorx-venatorx-pharmaceuticals-awarded-barda-project-bioshield-contract-pdf/) - Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract Total award of up to $318M for development and procurement of novel antibiotic cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections See more here
- [Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease](https://bioadvance.com/https-www-bioadvance-com-media-100622-annovis-bio-announces-fda-authorization-to-proceed-with-phase-2_3-trial-for-buntanetap-in-alzheimers-disease-pdf/) - Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease See more here
- [Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease](https://bioadvance.com/https-www-bioadvance-com-media-101122-annovis-bio-announces-publication-of-phase-2a-clinical-data-in-the-journal-of-prevention-of-alzheimers-disease-pdf/) - Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease See more here
- [Wellsheet Partners with athenahealth’s Marketplace Program to Improve EHR Productivity and Reduce Clinician Burnout](https://bioadvance.com/https-www-bioadvance-com-media-072722-wellsheet-partners-with-athenahealths-marketplace-program-to-improve-ehr-productivity-and-reduce-clinician-burnout-pdf/) - Wellsheet Partners with athenahealth’s Marketplace Program to Improve EHR Productivity and Reduce Clinician Burnout See more here
- [Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-8-8-22-renovacor-reports-second-quarter-2022-financial-results-and-provides-corporate-update-pdf/) - Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science See more here
- [Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-8-8-22-annovis-bio-announces-second-quarter-2022-results-and-provides-corporate-update-pdf/) - Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update See more here
- [Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-8-9-22-relmada-therapeutics-receives-fda-fast-track-designation-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder-pdf/) - Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder See more here
- [InfraScan Inc. Announces Publication of the Largest Study to date for TBI Diagnosis Utilizing NIRD](https://bioadvance.com/https-www-bioadvance-com-media-8-11-22-infrascan-announces-publication-of-the-largest-study-to-date-for-tbi-diagnosis-utilizing-nird-pdf/) - InfraScan Inc. Announces Publication of the Largest Study to date for TBI Diagnosis Utilizing NIRD Duke Global Neurosurgery and Neurology publishes its independent results from the largest U.S.-based study using a near-infrared device (NIRD) to detect hemorrhage due to Traumatic Brain Injuries (TBI). See more here
- [Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-8-11-22-relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-results-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results See more here
- [Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer](https://bioadvance.com/https-www-bioadvance-com-media-8-23-22-immunome-announces-publication-in-clinical-translational-immunology-highlighting-b-cell-repertoires-in-patients-with-breast-cancer-pdf/) - Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer - The study demonstrates the importance of tumor and lymph node-derived B cells for the discovery of antibodies directed at potentially novel targets - The study results provide a framework for understanding the evolution of B cell families in cancer
- [Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-8-24-22-annovis-bio-announces-first-patient-dosed-in-phase-3-trial-in-patients-with-early-parkinsons-disease-pdf/) - Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease See more here
- [Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy](https://bioadvance.com/https-www-bioadvance-com-media-071222-renovacor-announces-pipeline-expansion-with-new-research-program-for-multiple-genetic-segments-of-arrhythmogenic-cardiomyopathy-_-business-wire-pdf/) - Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathy See more here
- [Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology](https://bioadvance.com/https-www-bioadvance-com-media-071922-eliksa-therapeutics-launched-with-university-of-utahs-commercial-and-clinical-stage-regenerative-medicine-technology-pdf/) - Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology Founding investors include Militia Hill Ventures and University of Utah See more here
- [KaloCyte Closes Investment from New York Blood Center](https://bioadvance.com/https-www-bioadvance-com-media-072022-kalocyte-closes-investment-from-new-york-blood-center-pdf/) - KaloCyte Closes Investment from New York Blood Center This funding will be used to support KaloCyte as it scales up in advance of human trials See more here
- [Senzo lands $2M investment to advance at-home tests for infectious diseases](https://bioadvance.com/https-www-bioadvance-com-media-072122-senzo-gets-to-2m-investment-led-by-bioadvance-philadelphia-business-journal-pdf/) - Senzo lands $2M investment to advance at-home tests for infectious diseases See more here
- [Wellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report](https://bioadvance.com/https-www-bioadvance-com-media-072022-wellsheet-recognized-as-a-sample-vendor-in-smart-ehr-ui-in-a-gartner-report-pdf/) - Wellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report Smart EHR UI Critical as Healthcare Burnout and Turnover Reach Record Levels, Jeopardizing Patient Care and the Bottom Line of Health Systems See more here
- [Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial](https://bioadvance.com/https-www-bioadvance-com-media-2022-07-21_relmada_therapeutics_appoints_biopharmaceutical_264-pdf/) - Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 See more here
- [New Zealand Endovascular Thought Leader Joins the VESTECK Scientific Advisory Board](https://bioadvance.com/https-www-bioadvance-com-media-072622-new-zealand-endovascular-thought-leader-joins-the-vesteck-scientific-advisory-board-pdf/) - New Zealand Endovascular Thought Leader Joins the VESTECK Scientific Advisory Board See more here
- [Concarlo Therapeutics Hires Vadim Shepel as Chief Business & Operating Officer, Completing Build-out of Company's Core Executive Team](https://bioadvance.com/https-www-bioadvance-com-media-072722-concarlo-therapeutics-hires-vadim-shepel-as-chief-business-pdf/) - Concarlo Therapeutics Hires Vadim Shepel as Chief Business & Operating Officer, Completing Build-out of Company's Core Executive Team Senior Leader Brings Deep Biotech and Pharmaceutical Industry Experience See more here
- [Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging](https://bioadvance.com/https-www-bioadvance-com-media-4-28-22-annovis-bio-announces-cooperative-research-and-development-agreement-crada-with-the-national-institute-on-aging-pdf/) - Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap See more here
- [Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research](https://bioadvance.com/https-www-bioadvance-com-media-6-1-22-renovacor-announces-data-from-pilot-pig-study-pdf/) - Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart See more here
- [Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer](https://bioadvance.com/https-www-bioadvance-com-media-6-2-22-concarlo-expands-executive-leadership-team-with-the-appointment-of-dr-krishna-allamneni-as-chief-development-officer-pdf/) - Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer Industry veteran will help accelerate Company's drive to create transformative therapies for drug resistant cancers by controlling the p27 target See more here
- [Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections](https://bioadvance.com/https-www-bioadvance-com-media-6-9-22-annovis-submits-international-patent-application-pdf/) - Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries See more here
- [Bainbridge Health and Purdue University Collaborate to Advance the Infusion Pump Industry](https://bioadvance.com/https-www-bioadvance-com-media-062822-bainbridge-health-and-purdue-university-collaborate-to-advance-the-infusion-pump-industry-3-pdf/) - Bainbridge Health and Purdue University Collaborate to Advance the Infusion Pump Industry Collaboration will form the leading infusion pump management platform and community in the United States See more here
- [VESTECK, Inc. Continues to Expand Scientific Advisory Board](https://bioadvance.com/https-www-bioadvance-com-media-070522-vesteck-inc-continues-to-expand-scientific-advisory-board-pdf/) - VESTECK, Inc. Continues to Expand Scientific Advisory Board See more here
- [Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-070722-annovis-bio-announces-positive-fda-notice-for-buntanetap-phase-3-clinical-trial-in-parkinsons-disease-pdf/) - Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease See more here
- [Halo Labs Completes $6M Series C Growth Financing](https://bioadvance.com/https-www-bioadvance-com-media-071122-halo-labs-completes-6m-series-c-growth-financing-pdf/) - Halo Labs Completes $6M Series C Growth Financing See more here
- [Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund](https://bioadvance.com/https-www-bioadvance-com-media-4-4-22-venatorx-pharmaceuticals-raises-series-c-financing-pdf/) - Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund See more here
- [Scripps Health and UT Health San Antonio purchase Oncora's software to improve physician documentation and enhance personalized cancer care](https://bioadvance.com/https-www-bioadvance-com-media-4-13-22-scripps-health-and-ut-health-san-antonio-purchase-oncoras-software-to-improve-physician-documentation-and-enhance-personalized-cancer-care-pdf/) - Scripps Health and UT Health San Antonio purchase Oncora's software to improve physician documentation and enhance personalized cancer care See more here
- [Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology](https://bioadvance.com/https-www-bioadvance-com-media-2022-04-29_relmada_therapeutics_announces_publication_of_rel__259-pdf/) - Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology See more here
- [Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-5-4-22-annovis-bio-announces-first-quarter-2022-results-and-provides-corporate-update-pdf/) - Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update See more here
- [Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-2022-05-05_relmada_therapeutics_provides_corporate_update_260-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results See more here
- [VESTECK, Inc. Expands Scientific Advisory Board](https://bioadvance.com/https-www-bioadvance-com-media-5-6-22-vesteck-inc-expands-scientific-advisory-board-pdf/) - VESTECK, Inc. Expands Scientific Advisory Board See more here
- [Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-5-12-22-renovacor-reports-first-quarter-2022-financial-results-and-provides-corporate-update-pdf/) - Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO See more here
- [ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer](https://bioadvance.com/https-www-bioadvance-com-media-1-7-5-24-22-enb-therapeutics-announces-orphan-drug-designation-granted-by-fda-for-enb-003-for-the-treatment-of-pancreatic-cancer-pdf/) - ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
- [InfraScan announces FDA clearance of the first hand-held diagnostic device for Traumatic Brain Hemorrhage in children](https://bioadvance.com/https-www-bioadvance-com-media-2-17-22-infrascan-announces-fda-clearance-of-the-first-hand-held-diagnostic-device-for-traumatic-brain-hemorrhage-in-children-pdf/) - InfraScan announces FDA clearance of the first hand-held diagnostic device for Traumatic Brain Hemorrhage in children InfraScanner is now the only hand-held device cleared by the FDA to detect Traumatic Brain Hemorrhage in children See more here
- [Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential](https://bioadvance.com/https-www-bioadvance-com-media-2022-02-23_relmada_therapeutics_announces_top_line_results_253-pdf/) - Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values
- [Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders](https://bioadvance.com/https-www-bioadvance-com-media-2-28-22-renovacor-announces-partnerships-pdf/) - Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders See more here
- [Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI](https://bioadvance.com/https-www-bioadvance-com-media-3-10-22-venatorx-pharmaceuticals-announces-positive-results-for-phase-3-clinical-trial-certain-1-of-cefepime-taniborbactam-for-treatment-of-cuti-pdf/) - Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI Cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem Cefepime-taniborbactam was well-tolerated with similar safety profile to meropenem NDA on track to be submitted in the fourth quarter 2022 See more here
- [KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics](https://bioadvance.com/https-www-bioadvance-com-media-3-16-22-kayothera-inc-raises-8-million-in-series-a-financing-led-by-accelerator-life-science-partners-to-develop-novel-cancer-immunotherapeutics-pdf/) - KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics Novel Approach to Treat Late-Stage and Metastatic Cancers See more here
- [Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-3-24-22-renovacor-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-update-pdf/) - Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen,
- [Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-2022-03-23_relmada_therapeutics_provides_corporate_update_256-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results See more here
- [WellTrackONE Corporation releases Targeted Risk Adjustment Coding system (TRAC)](https://bioadvance.com/https-www-bioadvance-com-media-4-5-22-welltrackone-corporation-releases-targeted-risk-adjustment-coding-system-trac-1-pdf/) - WellTrackONE Corporation releases Targeted Risk Adjustment Coding system (TRAC) TRAC will help with HCC RAF scores, lost revenue opportunities and avoidance of RAC/RADV audit penalties See more here
- [VESTECK, Inc. Closes $5.95 M Series A Preferred equity round](https://bioadvance.com/https-www-bioadvance-com-media-1-4-22-vesteck-inc-closes-5-95-m-series-a-preferred-equity-round-pdf/) - VESTECK, Inc. Closes $5.95 M Series A Preferred equity round See more here
- [Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry](https://bioadvance.com/https-www-bioadvance-com-media-2021-12-22_relmada_therapeutics_announces_publication_of_rel__251-pdf/) - Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD - Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo - Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of
- [Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401](https://bioadvance.com/https-www-bioadvance-com-media-1-5-22-annovis-bio-announces-official-unique-name-buntanetap-for-lead-candidate-anvs401-pdf/) - Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 See more here
- [Annovis Bio Enhances Leadership Team with Two Senior Appointments](https://bioadvance.com/https-www-bioadvance-com-media-1-10-22-annovis-bio-enhances-leadership-team-with-two-senior-appointments-pdf/) - Annovis Bio Enhances Leadership Team with Two Senior Appointments Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations Company Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & Development See more here
- [VESTECK named "Top 10 Cardiovascular Device Company for 2021" by MedTech Outlook Magazine](https://bioadvance.com/https-www-bioadvance-com-media-vesteck-inc-top-10-cv-companies-7-pd_-pdf/) - VESTECK named "Top 10 Cardiovascular Device Company for 2021" by MedTech Outlook Magazine See more here
- [ASHP Innovation Center and Bainbridge Health Collaborate to Improve Patient Safety, Increase Use of Standardized Medication Concentrations in Health Systems](https://bioadvance.com/https-www-bioadvance-com-media-american-society-of-health-systems-pharmacists-and-bainbridge-health-announce-collaboration-pdf/) - ASHP Innovation Center and Bainbridge Health Collaborate to Improve Patient Safety, Increase Use of Standardized Medication Concentrations in Health Systems See more here
- [Halo Labs Launches New Instruments for Protein, Cell, and Gene Therapy Developers](https://bioadvance.com/https-www-bioadvance-com-media-halo-labs-launches-new-instruments-for-protein-cell-and-gene-therapy-developers-pdf/) - Halo Labs Launches New Instruments for Protein, Cell, and Gene Therapy Developers Aura PTx analyzes degraded excipients in protein therapeutics, and Aura+ is an all-in-one drug product quality tool for mAb, cell, and gene therapy See more here
- [Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-1-25-22-annovis-bio-announces-positive-fda-feedback-for-buntanetap-phase-3-clinical-development-in-parkinsons-disease-pdf/) - Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease See more here
- [Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-2023-09-20_relmada_therapeutics_announces_efficacy_and_285-pdf/) - Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events
- [Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze](https://bioadvance.com/https-www-bioadvance-com-media-092623-strados-labs-announces-pediatric-asthma-study-pdf/) - Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze Strados Labs’ RESP™ Biosensor is currently being used in a clinical trial at Lurie Children’s to determine if the technology can accurately detect wheezing and other symptoms of asthma exacerbation in children. See more here
- [SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting](https://bioadvance.com/https-www-bioadvance-com-media-092723-sirpant-immunotherapeutics-to-present-trial-in-progress-poster-pdf/) - SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting See more here
- [Venatorx Pharmaceuticals to Present at IDWeek 2023](https://bioadvance.com/https-www-bioadvance-com-media-092723-venatorx-pharmaceuticals-to-present-at-idweek-2023-pdf/) - Venatorx Pharmaceuticals to Present at IDWeek 2023 - New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam - MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer See more here
- [ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors](https://bioadvance.com/https-www-bioadvance-com-media-092823-immunogenesis-doses-first-patient-pdf/) - ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies See more here
- [Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies](https://bioadvance.com/https-www-bioadvance-com-media-100323-immunome-and-morphimmune-announce-successful-completion-of-merger-pdf/) - Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1
- [Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome](https://bioadvance.com/https-www-bioadvance-com-media-072023-palvella-therapeutics-announces-planned-pivotal-phase-3-study-design-of-qtorin-pdf/) - Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant
- [Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-2023-08-08_relmada_therapeutics_provides_corporate_update_283-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results See more here
- [Immunome Reports Second Quarter 2023 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-080923-immunome-reports-second-quarter-2023-financial-results-pdf/) - Immunome Reports Second Quarter 2023 Financial Results See more here
- [Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US](https://bioadvance.com/https-www-bioadvance-com-media-081423-venatorx-pharmaceuticals-highlights-two-recent-publications-indicating-rising-metallo-beta-lactamases-for-carbapenem-resistant-enterobacterales-in-us-pdf/) - Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US Growing Global Incidence of Carbapenem-Resistant Enterobacterales Metallo-beta-lactamases were the most frequently identified carbapenem resistance mechanism among Enterobacterales isolates in IHMA global surveillance See more here
- [Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults](https://bioadvance.com/https-www-bioadvance-com-media-081523-venatorx-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-cefepime-taniborbactam-pdf/) - Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults Cefepime-taniborbactam has also demonstrated in vitro activity against CDC Urgent and Serious Threat Pathogens carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa and Extended Spectrum Beta-lactamase-producing Enterobacterales In the CERTAIN-1 cUTI Phase 3 study,
- [VESTECK Scientific Advisory Board members address significant global unmet need](https://bioadvance.com/https-www-bioadvance-com-media-082823-vesteck-scientific-advisory-board-members-address-significant-global-unmet-need-pdf/) - VESTECK Scientific Advisory Board members address significant global unmet need See more here
- [KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate](https://bioadvance.com/https-www-bioadvance-com-media-091823-kayothera-inc-nominates-first-in-class-oral-inhibitor-of-the-retinoid-pathway-in-genetically-defined-oncology-indications-as-a-development-candidate-pdf/) - KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of
- [Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-2023-08-23_relmada_therapeutics_announces_dosing_of_first_284-pdf/) - Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder See more here
- [VESTECK , Inc. is excited to announce that the U.S. Patent Application No. 17/841,373 Title: REMOTE SURGICAL SUTURE SYSTEM, has been allowed by the U.S. Patent and Trademark Office (USPTO)](https://bioadvance.com/https-www-bioadvance-com-media-061523-vesteck-pdf/) - VESTECK , Inc. is excited to announce that the U.S. Patent Application No. 17/841,373 Title: REMOTE SURGICAL SUTURE SYSTEM, has been allowed by the U.S. Patent and Trademark Office (USPTO) See more here
- [ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors](https://bioadvance.com/https-www-bioadvance-com-media-062723-immunogenesis-and-cancer-focus-fund-announce-4-5-million-investment-pdf/) - ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors First dual-specific PD-L1/PD-L2 antibody with killing function designed to treat the many immune-excluded cancers that are resistant to existing immunotherapies Phase 1b will focus on tumors that are resistant to existing immunotherapy, which
- [Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies](https://bioadvance.com/https-www-bioadvance-com-media-062923-immunome-and-morphimmune-announce-definitive-merger-agreement-pdf/) - Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies - The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities - Clay B. Siegall, Ph.D., current Morphimmune President
- [SIRPant Immunotherapeutics Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer](https://bioadvance.com/https-www-bioadvance-com-media-071123-sirpant-immunotherapeutics-appoints-jelle-kijlstra-md-mba-as-chief-medical-officer-pdf/) - SIRPant Immunotherapeutics Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer Accomplished healthcare executive brings extensive drug development and regulatory experience from global CRO and multiple pharmaceutical companies to SIRPant Immunotherapeutics Inc See more here
- [ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023](https://bioadvance.com/https-www-bioadvance-com-media-071823-enb-therapeutics-presents-top-line-results-from-phase-1b-enbolden-101-study-pdf/) - ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023 ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint - The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated - Promising
- [KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million](https://bioadvance.com/https-www-bioadvance-com-media-071923-kayothera-extension-grant-financing-pr-final-pdf/) - KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in
- [Halo Labs Unveils Aura+ Subscription Program for Convenient and Affordable Particle Analysis](https://bioadvance.com/https-www-bioadvance-com-media-071823-halo-labs-unveils-aura-subscription-program-for-convenient-and-affordable-particle-analysis-pdf/) - Halo Labs Unveils Aura+ Subscription Program for Convenient and Affordable Particle Analysis See more here
- [Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita](https://bioadvance.com/https-www-bioadvance-com-media-072023-palvella-therapeutics-reports-topline-results-from-pivotal-phase-3-vapaus-study-of-qtorin-pdf/) - Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita See more here
- [Senzo and Abingdon Health Enter Into Strategic Partnership](https://bioadvance.com/https-www-bioadvance-com-media-032023-senzo-and-abingdon-health-enter-into-strategic-partnership-pdf/) - Senzo and Abingdon Health Enter Into Strategic Partnership Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities. See more here
- [Services for the UnderServed (S:US) Partners with Ride Health to Improve Transportation for Clients with Intellectual and Developmental Disabilities (I/DD)](https://bioadvance.com/https-www-bioadvance-com-media-020724-services-for-the-underserved-partners-with-ride-health-pdf/) - Services for the UnderServed (S:US) Partners with Ride Health to Improve Transportation for Clients with Intellectual and Developmental Disabilities (I/DD) See more here
- [SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy](https://bioadvance.com/https-www-bioadvance-com-media-050123-sirpant-_fda-clearance-pr-pdf/) - SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy See more here
- [VESTECK SAB Member Accepts International Leadership Appointment](https://bioadvance.com/https-www-bioadvance-com-media-050123-vesteck-sab-member-accepts-international-leadership-appointment-pdf/) - VESTECK SAB Member Accepts International Leadership Appointment See more here
- [Immunome Reports First Quarter 2023 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-050523-immunome-reports-first-quarter-2023-financial-results-pdf/) - Immunome Reports First Quarter 2023 Financial Results See more here
- [Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-051123-relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-results-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results See more here
- [Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity](https://bioadvance.com/https-www-bioadvance-com-media-052323-immunome-publishes-preclinical-research-pdf/) - Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity See more here
- [VESTECK Continues to Help Patients Around the World](https://bioadvance.com/https-www-bioadvance-com-media-053123-vesteck-continues-to-help-patients-around-the-world-pdf/) - VESTECK Continues to Help Patients Around the World See more here
- [InfraScan receives 2022 Life Sciences PA Patient Impact Award](https://bioadvance.com/https-www-bioadvance-com-media-032223-infrascan-receives-2022-life-sciences-pa-patient-impact-award-pdf/) - InfraScan receives 2022 Life Sciences PA Patient Impact Award InfraScan receives the Life Sciences PA Patient Impact Award for the second time. See more here
- [Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-032323-relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-results-pdf/) - Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results See more here
- [iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease](https://bioadvance.com/https-www-bioadvance-com-media-013023-iview-announces-a-successful-pre-ind-meeting-with-fda-pdf/) - iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease See more here
- [Clario and Strados Labs partner to bring new pulmonary endpoints to respiratory clinical trials](https://bioadvance.com/https-www-bioadvance-com-media-032123-clario-and-strados-labs-partner-to-bring-new-pulmonary-endpoints-to-respiratory-clinical-trials-pdf/) - Clario and Strados Labs partner to bring new pulmonary endpoints to respiratory clinical trials Clario has partnered with Strados Labs to offer its customers the RESP™ Biosensor System, an advanced technological innovation for the at-home capture of lung sounds. The revolutionary device enables Clario to support the capture of additional clinical respiratory endpoints such as
- [Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-040323-annovis-bio-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update-pdf/) - Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update See more here
- ["Vesteck, Inc. Successfully Completes Five Clinical Cases"](https://bioadvance.com/https-www-bioadvance-com-media-040623-vesteck-inc-successfully-completes-five-clinical-cases-pdf/) - "Vesteck, Inc. Successfully Completes Five Clinical Cases" See more here
- [Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board](https://bioadvance.com/https-www-bioadvance-com-media-020823-immunome-announces-formation-of-antibody-drug-conjugate-and-t-cell-redirection-advisory-board-pdf/) - Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board Advisory board to help guide selection of novel antibody-target pairs for ADC and T cell redirection modalities See more here
- [Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies](https://bioadvance.com/https-www-bioadvance-com-media-022123-palvella-therapeutics-announces-pipeline-update-on-qtorin-pdf/) - Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies - Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b data for the
- [Hanimune Therapeutics raises $3.3M, sets sights on first food allergy treatment product](https://bioadvance.com/https-www-bioadvance-com-media-022323-hanimune-therapeutics-raises-3-3m-sets-sights-on-first-food-allergy-treatment-product-pdf/) - Hanimune Therapeutics raises $3.3M, sets sights on first food allergy treatment product See more here
- [Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman](https://bioadvance.com/https-www-bioadvance-com-media-03072023-venatorx-pharmaceuticals-appoints-tomas-j-heyman-as-non-executive-chairman-pdf/) - Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman Dr. Michael Diem Steps Down from Board of Directors See more here
- [Immunome to Present at 13th Annual World ADC London Conference](https://bioadvance.com/https-www-bioadvance-com-media-030923-immunome-to-present-at-13th-annual-world-adc-london-conference-pdf/) - Immunome to Present at 13th Annual World ADC London Conference See more here
- [VESTECK, Inc. is pleased to announce the first in human use of several SUTURE-TIGHT devices](https://bioadvance.com/https-www-bioadvance-com-media-030923-vesteck-inc-is-pleased-to-announce-the-first-in-human-use-of-several-suture-tight-devices-pdf/) - VESTECK, Inc. is pleased to announce the first in human use of several SUTURE-TIGHT devices See more here
- [Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies](https://bioadvance.com/https-www-bioadvance-com-media-030923-palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-pdf/) - Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies - QTORIN™ rapamycin generally well-tolerated; no drug related severe adverse events and no observed rapamycin in systemic circulation - 100%
- [Immunome Reports Fourth Quarter and Full Year 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-031623-immunome-reports-fourth-quarter-and-full-year-2022-financial-results-pdf/) - Immunome Reports Fourth Quarter and Full Year 2022 Financial Results See more here
- [Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer](https://bioadvance.com/https-www-bioadvance-com-media-010923-relmada-therapeutics-appoints-cns-therapeutic-expert-cedric-ogorman-md-as-cmo-pdf/) - Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer See more here
- [Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors](https://bioadvance.com/https-www-bioadvance-com-media-2023-01-12_relmada_therapeutics_appoints_fabiana_fedeli_-pdf/) - Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors See more here
- [Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time](https://bioadvance.com/https-www-bioadvance-com-media-011023-scipher-medicine-acquires-crossbridge-and-its-saas-platform-pdf/) - Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. See more here
- [Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder](https://bioadvance.com/https-www-bioadvance-com-media-2022-12-07_relmada_therapeutics_announces_top_line_results_272-pdf/) - Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder See more here
- [Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-012523-annovis-bio-announces-patient-enrollment-update-for-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease-pdf/) - Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Strong enrollment in Phase 3 trial demonstrates continued execution Interim analysis expected in 2Q 2023 See more here
- [Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study](https://bioadvance.com/https-www-bioadvance-com-media-012623-strados-labs-forms-collaboration-with-boehringer-ingelheim-for-its-idiopathic-pulmonary-fibrosis-pilot-study-pdf/) - Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study Starting in early 2023 the biopharmaceutical company will use the Strados RESP™ Biosensor to remotely monitor cough and crackles in patients at home. See more here
- [Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses](https://bioadvance.com/https-www-bioadvance-com-media-20123-annovis-bio-announces-filing-of-patent-covering-the-administration-of-buntanetap-and-its-analogues-for-the-treatment-of-mental-illnesses-pdf/) - Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses See more here
- [Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease](https://bioadvance.com/https-www-bioadvance-com-media-020823-annovis-bio-announces-approval-for-european-union-clinical-trial-sites-for-the-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease-pdf/) - Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries Annovis Currently has 50 Clinical Trial Sites Open in the United States See more here
- [Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders](https://bioadvance.com/https-www-bioadvance-com-media-111722-attralus-and-ossianix-announce-an-option-and-license-agreement-using-the-txp1-brain-shuttle-for-targeted-delivery-of-at-pdf/) - Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders See more here
- [Dr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board](https://bioadvance.com/https-www-bioadvance-com-media-112822-dr-sean-lyden-agrees-to-assume-the-role-of-chief-medical-consultant-and-join-the-vesteck-scientific-advisory-board-pdf/) - Dr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board See more here
- [Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder](https://bioadvance.com/https-www-bioadvance-com-media-112922-mebias-discovery-initiates-a-phase-i-clinical-trial-of-meb-1170-a-novel-analgesic-drug-candidate-for-the-treatment-of-pain-and-prevention-of-opioid-use-disorder/) - Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder Preclinical Data Demonstrates MEB–1170 Lacks Adverse Effects of Opioids Including Respiratory Depression and Opioid Abuse Potential See more here
- [Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test](https://bioadvance.com/https-www-bioadvance-com-media-121222-senzo-secures-additional-1-9mm-equity-funding-for-its-pcr-accurate-lateral-flow-test-pdf/) - Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo's Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples See more
- [Venatorx Pharmaceuticals Announces Organizational Changes](https://bioadvance.com/https-www-bioadvance-com-media-122022-venatorx-pharmaceuticals-announces-organizational-changes-pdf/) - Venatorx Pharmaceuticals Announces Organizational Changes Chief Medical Officer Timothy Henkel, M.D., Ph.D., Retires Vincent Milano Steps Down from Board of Directors See more here
- [Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases](https://bioadvance.com/https-www-bioadvance-com-media-010523-palvella-therapeutics-announces-series-d-financing-of-up-to-37-7-million-pdf/) - Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no
- [AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets](https://bioadvance.com/https-www-bioadvance-com-media-010623-abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets-pdf/) - AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets - Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine - Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties See
- [Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team](https://bioadvance.com/https-www-bioadvance-com-media-010623-annovis-bio-announces-new-appointments-to-strengthen-its-senior-leadership-team-pdf-pdf/) - Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team See more here
- [Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook](https://bioadvance.com/https-www-bioadvance-com-media-062223-melior-is-selected-as-a-top-20-cro-by-pharma-tech-outlook-pdf/) - Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook - Melior has cover appearance on this industry-leading magazine - Melior is recognized for the combination of its attention to quality, culture and, innovative offering See more here
- [Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda](https://bioadvance.com/https-www-bioadvance-com-media-041123-treventis-partners-its-preclinical-program-in-alzheimers-disease-with-takeda-pdf/) - Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda See more here
- [iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis](https://bioadvance.com/https-www-bioadvance-com-media-011823-iview-announces-completion-of-first-patient-treatment-in-phase-ii-clinical-study-of-iview-pdf/) - iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis See more here
- [BioAdvance Breaks Life Sciences Investing Record Year in 2022](https://bioadvance.com/https-www-bioadvance-com-media-final-bioadvance-invests-record-amount-11-09-22-pdf/) - BioAdvance Breaks Life Sciences Investing Record Year in 2022 Nearly $5 million invested in eight new promising Mid-Atlantic life sciences companies See more here
- [Treventis Awarded $2.97M Grant from the U.S. Department of Defense](https://bioadvance.com/https-www-bioadvance-com-media-101822-treventis-awarded-2-97m-grant-from-the-u-s-department-of-defense-pdf/) - Treventis Awarded $2.97M Grant from the U.S. Department of Defense Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases See more here
- [Immunome Reports Second Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-8-5-22-immunome-reports-second-quarter-2022-financial-results-pdf/) - Immunome Reports Second Quarter 2022 Financial Results See more here
- [Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1](https://bioadvance.com/https-www-bioadvance-com-media-070622-immunomes-covid-19-cocktail-retains-neutralizing-activity-against-the-most-prevalent-omicron-subvariants_-in-the-us-ba-4_5-and-ba-2-12-1-pdf/) - Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 - IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing - IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022 See more here
- [Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19](https://bioadvance.com/https-www-bioadvance-com-media-immunome-announces-initiation-of-phase-1b-study-of-imm-bcp-01-for-the-treatment-of-covid-19-_-business-wire-pdf/) - Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 - First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients - - Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments - See more here
- [Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38](https://bioadvance.com/https-www-bioadvance-com-media-5-23-22-immunome-provides-research-development-update-on-lead-oncology-candidate-targeting-il-38-pdf/) - Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 - Profiling of IL-38 mRNA in over 60 cancer types revealed notably high frequency (60-80%) of IL-38 expression in select solid tumor sub-types of high unmet clinical need - - Collaboration with Fox Chase Cancer Center to directly confirm IL-38 protein expression in
- [Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant](https://bioadvance.com/https-www-bioadvance-com-media-5-19-22-immunome-announces-data-demonstrating-covid-19-antibody-cocktail-potently-clears-omicron-ba-1-variant-in-hamster-model-and-retains-activity-against-ba-2-subvar/) - Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant - Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters - - IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional
- [Immunome Reports First Quarter 2022 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-5-12-22-immunome-reports-first-quarter-2022-financial-results-pdf/) - Immunome Reports First Quarter 2022 Financial Results See more here
- [Melior Announces Substantial Additions to Its Management and Scientific Team](https://bioadvance.com/https-www-bioadvance-com-media-4-12-22-melior-announces-substantial-additions-to-its-management-and-scientific-team-pdf/) - Melior Announces Substantial Additions to Its Management and Scientific Team • Dr. Ken Kilgore joins Melior as VP of Scientific Operations • Dr. Hongyan Li joins Melior as Director of Oncology • Dr. Vivian Cong rises to VP of Research & Development See more here
- [Immunome Reports Fourth Quarter and Full Year 2021 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-3-28-22-immunome-reports-fourth-quarter-and-full-year-2021-financial-results-pdf/) - Immunome Reports Fourth Quarter and Full Year 2021 Financial Results - Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application - - Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial - - Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint - See more here
- [FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19](https://bioadvance.com/https-www-bioadvance-com-media-3-11-22-fda-lifts-clinical-hold-on-immunomes-imm-bcp-01-ind-application-for-the-treatment-of-covid-19-pdf/) - FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19 See more here
- [Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing](https://bioadvance.com/https-www-bioadvance-com-media-2-8-22-immunomes-antibody-cocktail-effective-against-sars-cov-2-omicron-variant-in-in-vitro-live-virus-testing-pdf/) - Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing - Antibody Cocktail Demonstrates Comparable Head-to-Head Potency to GSK/Vir’s Sotrovimab in Live Virus Neutralization Assay Against Omicron (B.1.1.529) - - IMM20253 Antibody Exhibits a Novel Mechanism of Action - See more here
- [Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19](https://bioadvance.com/https-www-bioadvance-com-media-1-10-22-immunome-provides-update-on-investigational-new-drug-application-for-imm-bcp-01-for-the-treatment-of-covid-19-_-business-wire-pdf/) - Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 • Immunome has received a clinical hold letter from the FDA requesting further information related to the preparation and administration of the IMM-BCP-01 cocktail at clinical sites • Immunome expects to provide the requested information soon and remains on track
- [Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19](https://bioadvance.com/https-www-bioadvance-com-media-11-29-21-immunome-announces-submission-of-an-investigational-new-drug-ind-application-for-imm-bcp-01-for-the-treatment-of-covid-19-pdf/) - Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 - IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern - IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well
- [Immunome Reports Third Quarter 2021 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-11-15-21-immunome-reports-third-quarter-2021-financial-results-pdf/) - Immunome Reports Third Quarter 2021 Financial Results - IMM-BCP-01 Progressing Towards IND Filing - See more here
- [Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics](https://bioadvance.com/https-www-bioadvance-com-media-immunome-presents-compelling-preclinical-data-on-anti-il-38-antibody-program-at-the-american-association-for-cancer-research-nci-eortc-international-conference-pdf/) - Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics See more here
- [BioAdvance Announces ~$7M in Recent Investments  and Leadership Transition](https://bioadvance.com/https-www-bioadvance-com-media-bioadvance-investments-leadership-transition-092921-final-pdf/) - BioAdvance Announces ~$7M in Recent Investments and Leadership Transition Barbara Schilberg retiring as Managing Director and CEO; Shahram Hejazi, Ph.D., appointed as Managing Director and CEO See more here
- [Melior Pharmaceuticals Announces Execution of a License Agreement for Armesocarb by Adhera Therapeutics](https://bioadvance.com/https-www-bioadvance-com-media-7-29-21-adhera-melior-license-pr-pdf/) - Melior Pharmaceuticals Announces Execution of a License Agreement for Armesocarb by Adhera Therapeutics Under the terms of the license: Adhera will underwrite development of MLR-1019 Adhera has option to acquire MLR-1019 See more here
- [Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing](https://bioadvance.com/https-www-bioadvance-com-media-9-7-21-immunome-antibody-cocktail-imm-bcp-01-neutralizes-sars-cov-2-lambda-and-delta-plus-variants-in-pre-clinical-testing-pdf/) - Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing - IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing See more here
- [Centers for Medicare & Medicaid Services Issues New Code for Encala®](https://bioadvance.com/https-www-bioadvance-com-media-8-25-21-centers-for-medicare-medicaid-services-issues-new-code-for-encala-pdf/) - Centers for Medicare & Medicaid Services Issues New Code for Encala® Code S9432 Will Provide Improved Access for Individuals with Malabsorption and Take Effect October 1, 2021 See more here
- [Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing](https://bioadvance.com/https-www-bioadvance-com-media-7-20-21-immunome-antibody-cocktail-imm-bcp-01-neutralizes-the-sars-cov-2-delta-variant-in-pre-clinical-testing-pdf/) - Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing - IMM-BCP-01 already shown to neutralize all other CDC variants of concern in pre-clinical testing - IND submission planned for this quarter See more here
- [Envara Health Named Winner of 2021 PACT Enterprise Awards](https://bioadvance.com/https-www-bioadvance-com-media-7-9-21-envara-health-named-winner-of-2021-pact-enterprise-awards-pdf/) - Envara Health Named Winner of 2021 PACT Enterprise Awards Nutrition Company Redefining 'Food as Medicine' Recognized for Commitment to Science-Backed Technology in the Life Sciences Industry See more here
- [Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors](https://bioadvance.com/https-www-bioadvance-com-media-6-17-21-immunome-appoints-franklyn-g-prendergast-m-d-ph-d-to-board-of-directors-pdf/) - Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors - Dr. Prendergast is a renowned scientific researcher with over 45 years of association with the Mayo Foundation and over 20 years' experience as a non-executive director of Eli Lilly See more here
- [Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics](https://bioadvance.com/https-www-bioadvance-com-media-6-7-21-melior-pharmaceuticals-announces-entry-into-letter-of-intent-for-the-acquisition-of-armesocarb-by-adhera-therapeutics-pdf/) - Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics Under the terms of the intended acquisition: Adhera will continue clinical development of MLR-1019 Melior Pharmaceuticals will receive Adhera stock plus royalties See more here
- [Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern](https://bioadvance.com/https-www-bioadvance-com-media-5-20-21-immunome-announces-additional-4-3-million-award-by-dod-following-positive-preclinical-testing-results-on-covid-19-variants-of-concern-pdf/) - Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern - Additional $4.3 million in funding brings total DOD funding to $17.6 million. - Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein. - Neutralizes South
- [Immunome Reports First Quarter 2021 Financial Results](https://bioadvance.com/https-www-bioadvance-com-media-5-12-21-immunome-reports-first-quarter-2021-financial-results-pdf/) - Immunome Reports First Quarter 2021 Financial Results - IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing - - IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies - - Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed
- [Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing](https://bioadvance.com/https-www-bioadvance-com-media-4-26-21-immunome-sars-cov-2-antibody-cocktail-neutralizes-uk-south-africa-brazil-and-california-variants-in-preclinical-testing-progressing-towards-ind-filing-pdf/) - Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing - Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein. - Efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules.
- [Immunome Announces $27 Million Private Placement](https://bioadvance.com/https-www-bioadvance-com-media-4-26-21-immunome-announces-27-million-private-placement-pdf/) - Immunome Announces $27 Million Private Placement See more here
- [Immunome Appoints Dr. Dennis Giesing as Chief Development Officer](https://bioadvance.com/https-www-bioadvance-com-media-3-30-21-immunome-appoints-dr-dennis-giesing-as-chief-development-officer-pdf/) - Immunome Appoints Dr. Dennis Giesing as Chief Development Officer - Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies - See more here
- [Immunome Appoints Corleen Roche as Chief Financial Officer](https://bioadvance.com/https-www-bioadvance-com-media-4-20-21-immunome-appoints-corleen-roche-as-chief-financial-officer-pdf/) - Immunome Appoints Corleen Roche as Chief Financial Officer - Seasoned biopharmaceutical executive with more than 30 years of corporate finance and business strategy experience - See more here
- [Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.](https://bioadvance.com/https-www-bioadvance-com-media-3-23-21-renovacor-inc-to-merge-with-chardan-healthcare-acquisition-2-corp_-pdf/) - Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. - Renovacor, Inc. has entered into a de nitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) - - Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under
- [Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update](https://bioadvance.com/https-www-bioadvance-com-media-3-25-21-immunome-reports-fourth-quarter-and-full-year-2020-financial-results-provides-corporate-update-pdf/) - Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update - IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing - - IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies - - Raised $44.9 million in gross proceeds in NASDAQ IPO - - Program updates
- [ArchCare Delivers PACE Participants Seamless, Free Transportation](https://bioadvance.com/https-www-bioadvance-com-media-3-17-21-archcare-delivers-pace-participants-seamless-free-transportation-pdf/) - ArchCare Delivers PACE Participants Seamless, Free Transportation Technology-Based Ride System Will Serve 702 Home-Based Elderly See more here
- [Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies](https://bioadvance.com/https-www-bioadvance-com-media-3-23-21-immunome-advances-its-proprietary-antibody-against-il-38-a-novel-innate-immune-checkpoint-into-ind-enabling-studies-pdf/) - Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies First oncology product candidate identified using the company’s human memory B-cell platform, and intended for potential treatment of solid tumors See more here
- [Renowned Nutrition Expert Puts Rare Disease Day on the Radar](https://bioadvance.com/http-www-bioadvance-com-media-2-24-21-renowned-nutrition-expert-puts-rare-disease-day-on-the-radar-pdf/) - Renowned Nutrition Expert Puts Rare Disease Day on the Radar Dr. Virginia A. Stallings Discusses Individualized Nutrition Therapy for People with Cystic Fibrosis See more here
- [Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic](https://bioadvance.com/http-www-bioadvance-com-media-3-9-21-melior-receives-ind-clearance-for-covid-19-therapeutic-pdf/) - Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic Melior's therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies See more here
- [Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing](https://bioadvance.com/http-www-bioadvance-com-media-2-18-21-immunome-discovers-antibodies-capable-of-neutralizing-multiple-sars-cov-2-variants-pdf/) - Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing See more here
- [Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment](https://bioadvance.com/http-www-bioadvance-com-media-abzena-selected-by-immunome-to-develop-and-manufacture-antibody-cocktail-for-immunomes-covid-19-antibody-based-treatment-pdf/) - Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment See more here
- [Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus](https://bioadvance.com/http-www-bioadvance-com-media-immunomes-research-reveals-a-broad-super-responder-memory-b-cell-response-to-the-sars-cov-2-virus-_-business-wire-pdf/) - Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus Findings support the potential of Immunome’s approach to developing IMM-BCP-01 as an optimized antibody cocktail for the treatment and prophylaxis of COVID-19 See more here
- [Envara Health Named Winner of Rabobank's FoodBytes! Pitch 2020 Competition](https://bioadvance.com/http-www-bioadvance-com-media-12-7-20-envara-health-named-winner-of-rabobanks-foodbytes-pitch-2020-competition-pdf/) - Envara Health Named Winner of Rabobank's FoodBytes! Pitch 2020 Competition Advanced Nutrition Company Recognized in Food Tech Category with Award for Innovation in Clinical Nutrition See more here
- [TiE Boston recognizes Purnanand Sarma, Ph.D. President & CEO of Immunome, as 2020 Lifetime Achievement Awardee](https://bioadvance.com/http-www-bioadvance-com-media-12-9-2020-tie-boston-recognizes-purnanand-sarma-ph-d-president-ceo-of-immunome-as-recipient-of-its-2020-lifetime-achievement-award-pdf/) - TiE Boston recognizes Purnanand Sarma, Ph.D. President & CEO of Immunome, as 2020 Lifetime Achievement Awardee Dr. Sarma to be honored at the 2020 TiE Boston Gala, Keynote Fireside Chat with Kiran Mazumdar-Shaw, CMD of Biocon See more here
- [Immunome Reports Third Quarter 2020 Financial Results and Significant Progress](https://bioadvance.com/http-www-bioadvance-com-media-11-17-20-immunome-reports-3rd-quarter-2020-financial-results-and-significant-progress-pdf/) - Immunome Reports Third Quarter 2020 Financial Results and Significant Progress - Completed $44.9M IPO in October - - Identified COVID 19 Neutralizing antibodies - - Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense - See more here
- [Envara Health Launches Encala® to Enhance Fat Absorption and Provide Healthy Calories for Patients with Cystic Fibrosis](https://bioadvance.com/http-www-bioadvance-com-media-10-20-20-envara-health-launches-encala-to-enhance-fat-absorption-and-provide-healthy-calories-for-patients-with-cystic-fibrosis-pdf/) - Envara Health Launches Encala® to Enhance Fat Absorption and Provide Healthy Calories for Patients with Cystic Fibrosis New, innovative therapy brings breakthrough science and clinical evidence to nutrition Helps patients with malabsorption meet their weight and nutritional needs See more here
- [Immunome Announces Pricing of Upsized Initial Public Offering](https://bioadvance.com/http-www-bioadvance-com-media-immunome-announces-ipo-pricing-10-1-20-pdf/) - Immunome Announces Pricing of Upsized Initial Public Offering See more here
- [Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering](https://bioadvance.com/http-www-bioadvance-com-media-10-13-20-immunome-announces-exercise-in-full-and-closing-of-over-allotment-option-in-initial-public-offering-pdf/) - Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering See more here
- [IVIEW Collaboration With Dr. Amin Javer at St. Paul's Hospital and Sinus Centre, Canada to Study Povidone Iodine Formulations Including IVIEW-1503, a Long-Lasting Povidone Iodine Nasal Spray for the Treatment of COVID-19](https://bioadvance.com/http-www-bioadvance-com-media-9-17-20-iview-collaboration-with-dr-amin-javer-pdf/) - IVIEW Collaboration With Dr. Amin Javer at St. Paul's Hospital and Sinus Centre, Canada to Study Povidone Iodine Formulations Including IVIEW-1503, a Long-Lasting Povidone Iodine Nasal Spray for the Treatment of COVID-19 See more here
- [Immunome Announces Creation of COVID-19 Advisory Board](https://bioadvance.com/http-www-bioadvance-com-media-9-16-20-immunome-announces-creation-of-covid-19-advisory-board-pdf/) - Immunome Announces Creation of COVID-19 Advisory Board Advisory Board to help guide development and clinical testing of biosynthetic convalescent plasma as a potential COVID-19 treatment and prevention of disease See more here
- [Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial](https://bioadvance.com/http-www-bioadvance-com-media-9-15-20-melior-awarded-grant-for-advancing-pulmonary-therapeutic-pdf/) - Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial Melior's therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies See more here
- [Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China](https://bioadvance.com/http-www-bioadvance-com-media-9-14-20-everest-medicines-announces-top-line-results-from-phase-1-clinical-trial-pdf/) - Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China See more here
- [Preclinical oncology biotech Immunome files for a $30 million IPO](https://bioadvance.com/http-www-bioadvance-com-media-9-9-20-immunome-files-for-a-30-million-ipo-pdf/) - Preclinical oncology biotech Immunome files for a $30 million IPO See more here
- [The marketplace for new antibiotics is fundamentally broken | Opinion](https://bioadvance.com/http-www-bioadvance-com-media-8-14-20-the-marketplace-for-new-antibiotics-is-fundamentally-broken-opinion-pdf/) - The marketplace for new antibiotics is fundamentally broken | Opinion See more here
- [Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19](https://bioadvance.com/http-www-bioadvance-com-media-7-28-2020-immunome-awarded-dept-of-defense-contract-pdf/) - Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19 Up to $13.3M funding to accelerate development and early clinical testing of antibodies derived from large-scale B cell interrogation of COVID-19 “Super-Responders” See more here
- [Genome Profiling, Fox Chase Cancer Center to Collaborate on Immune System Blood Test to Predict Checkpoint Inhibitor Response in Non-Small Cell Lung Cancer](https://bioadvance.com/http-www-bioadvance-com-media-7-21-20-genome-profiling-and-fox-chase-canncer-center-to-collaborate-pdf/) - Genome Profiling, Fox Chase Cancer Center to Collaborate on Immune System Blood Test to Predict Checkpoint Inhibitor Response in Non-Small Cell Lung Cancer See more here
- [This isn't a 'biotech bubble,' it's 'Philadelphia's moment' to become a center for gene therapy, says Penn-based CEO](https://bioadvance.com/http-www-bioadvance-com-media-steve-nichtberger-phila-inquirer-article-2-24-20-pdf/) - This isn't a 'biotech bubble,' it's 'Philadelphia's moment' to become a center for gene therapy, says Penn-based CEO See more here
- [pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology](https://bioadvance.com/http-www-bioadvance-com-media-immunome-and-ph-pharma-enter-into-collaboration-10-21-19-pdf/) - pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology See more here
- [Philadelphia biotech firm teams up with CDC to battle Zika](https://bioadvance.com/http-www-bioadvance-com-media-3-26-19-groupk-teams-up-with-cdc-to-battle-zika-pdf/) - Philadelphia biotech firm teams up with CDC to battle Zika See more here
- [Group K Diagnostics and Health Network Laboratories Announce the Commencement of a Clinical Trial](https://bioadvance.com/http-www-bioadvance-com-media-groupk-announces-commencement-of-clinical-trial-august-20-2019-pdf/) - Group K Diagnostics and Health Network Laboratories Announce the Commencement of a Clinical Trial See more here
- [Immunome Appoints Purnanand Sarma, PhD, as President and Chief Executive Officer](https://bioadvance.com/http-www-bioadvance-com-media-palvella-therapeutics-announces-10million-in-funding-from-ligand-pharma-12-18-18-pdf-2-2-2/) - Immunome Appoints Purnanand Sarma, PhD, as President and Chief Executive Officer Industry Veteran to Take the Helm of Next-Generation Oncology Company Focused on Harnessing Human Immune Response See more here
- [Group K Diagnostics Expands Research Team, Updates Lab and Manufacturing Facilities](https://bioadvance.com/http-www-bioadvance-com-media-palvella-therapeutics-announces-10million-in-funding-from-ligand-pharma-12-18-18-pdf-2/) - Group K Diagnostics Expands Research Team, Updates Lab and Manufacturing Facilities Enhancements will triple manufacturing output capacity, improve production speed six-fold See more here
- [Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-3-2-2/) - Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes • Tolimidone treatment significantly reduced HbA1c compared to placebo • Company makes strategic decision to move tolimidone into NASH development See more here
- [Group K Diagnostics Has Begun Part II of its Liver Function Clinical Trial](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-3/) - Group K Diagnostics Has Begun Part II of its Liver Function Clinical Trial See more here
- [Life Sciences PA. reveals awards for its top CEO, top products and deal of the year](https://bioadvance.com/http-www-bioadvance-com-media-feb-5-2019-bainbridge-health-selected-by-childrens-of-alabama-pdf-2-2-2-2/) - Life Sciences PA. reveals awards for its top CEO, top products and deal of the year See more here
- [Group K Diagnostics Relocates to New Laboratory, Manufacturing and Office Space in Philadelphia](https://bioadvance.com/http-www-bioadvance-com-media-group-k-diagnostics-relocates-to-new-laboratory-jan-7-2019-pdf/) - Group K Diagnostics Relocates to New Laboratory, Manufacturing and Office Space in Philadelphia See more here
- [Smart pillbox developer introduces first commercial product](https://bioadvance.com/http-www-bioadvance-com-media-smart-pillbox-developer-introduces-first-commercial-product-nov-2018-pdf/) - Smart pillbox developer introduces first commercial product See more here
- [CEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board](https://bioadvance.com/ceo-of-group-k-diagnostics-nominated-to-the-philadelphia-startup-leaders-board-news-provided-by-group-k-diagnostics-dec-07-2018-0848-et-share-this-article-philadelphia-dec-7-2018-prn/) - CEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board See more here
- [Group K Diagnostics Raises $2 Million in Series A Funding](https://bioadvance.com/http-www-bioadvance-com-media-group-k-diagnostics-raises-series-a-pdf/) - Group K Diagnostics Raises $2 Million in Series A Funding See more here
- [Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes](https://bioadvance.com/http-www-bioadvance-com-media-melior-pharmaceuticals-enrolls-last-subject-in-phase-2b-study-with-tolimidone-for-type-2-diabetes-pdf/) - Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes - Last subject randomized in Phase 2b study- - Study randomized 433 subjects across 61 sites in 2 countries- See more here
- [Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study](https://bioadvance.com/http-www-bioadvance-com-media-corbus-and-jenrin-sept-20-2018-pdf/) - Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study See more here
- [Group K Diagnostics is the Technology Category Winner in the 2018 Stellar Startup Awards](https://bioadvance.com/http-www-bioadvance-com-media-group-k-diagnostics-is-the-technology-category-winner-in-the-2018-stellar-startup-awards-sept-17-2018-pdf/) - Group K Diagnostics is the Technology Category Winner in the 2018 Stellar Startup Awards See more here
- [Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting](https://bioadvance.com/httpwww-bioadvance-commediadata-on-cancer-resistance-pathway-inhibitor-it-presenting-at-aacr-pdf/) - Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting See more here
- [BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018](https://bioadvance.com/bioadvance-commits-3-2m-to-life-sciences-companies-in-first-six-months-of-fy-2018/) - BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018 Investment Capabilities Expanded as Frederick ("Rick") Jones, M.D., M.B.A., Joins Team See more here
- [Servier and Treventis begin strategic research partnership in neurodegenerative diseases](https://bioadvance.com/httpwww-bioadvance-commediapr-partnership-treventis_final-2018-01-03-pdf/) - Servier and Treventis begin strategic research partnership in neurodegenerative diseases See more here
- [New painkillers could thwart opioids' fatal flaw](https://bioadvance.com/httpwww-bioadvance-commediamebias-pr-new-painkillers-could-thwart-opioids-fatal-flaw-11-16-17-w-color-diagram-pdf/) - New painkillers could thwart opioids' fatal flaw See more here
- [Jenrin Discovery's IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials](https://bioadvance.com/httpwww-bioadvance-commediajenrin-ind-application-cleared-12-14-17-pdf/) - Jenrin Discovery's IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials See more here
- [BioBots adopts new name, launches new software](https://bioadvance.com/httpwww-bioadvance-commediabiobots-adopts-new-name-11-7-17-pdf/) - BioBots adopts new name, launches new software See more here
- [Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes](https://bioadvance.com/melior-pharmaceuticals-initiates-phase-2b-study-with-mlr-1023-for-type-2-diabetes/) - Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes See more here
- [BioAdvance investments topped $3M in fiscal 2017](https://bioadvance.com/httpwww-bioadvance-commediapbj-fy2017-article-on-bioadvance-pdf/) - BioAdvance investments topped $3M in fiscal 2017 See more here
- [BioAdvance Commits $4M to 14 Life Sciences Companies](https://bioadvance.com/httpwww-bioadvance-commediafinal-bioadvance-july-2017-pr-8-14-17-pdf/) - BioAdvance Commits $4M to 14 Life Sciences Companies See more here
- [GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017](https://bioadvance.com/httpwww-bioadvance-commediagenpro-poster-at-naacr-w-intro-summary-april-2017-pdf/) - GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017 See more here
- [QR Pharma, Inc. Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference](https://bioadvance.com/httpwww-bioadvance-commedia2017-02-10-qr-newsrelease-adpd-presentation-pdf/) - QR Pharma, Inc. Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference See more here
- [BioBots unveils 3D biology toolset](https://bioadvance.com/httpwww-bioadvance-commediabiobots-unveils-3d-biology-toolset-4-27-2017-pdf/) - BioBots unveils 3D biology toolset See more here
- [QR Pharma Raises $800,000 of Series A Preferred Stock](https://bioadvance.com/httpwww-bioadvance-commediaqr-pharma-raises-800k-oct-2016-pdf/) - QR Pharma Raises $800,000 of Series A Preferred Stock See more here
- [BioBots to Bring Revolutionary 3D Bioprinter to the Masses with $5,000 Beta Program & Eventually Print Whole Organs](https://bioadvance.com/httpwww-bioadvance-commediabiobots-brings-revolutionary-printer-to-the-masses-november-16-pdf/) - BioBots to Bring Revolutionary 3D Bioprinter to the Masses with $5,000 Beta Program & Eventually Print Whole Organs See more here
- [GenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson's Disease in blood](https://bioadvance.com/genpro-publishes-epimarker-feasibility-study-revealing-distinct-epigenetic-signature-of-parkinsons-disease-in-blood/) - GenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson's Disease in blood See more here
- [GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients](https://bioadvance.com/httpwww-bioadvance-commediagenpro-moffitt_cancer_center_ash_2016_presents-poster_novel_epimarker_for_aml-mds_pre-treatment_azacitidin_responder_v_non_responder_stratification_dec_2016-pdf/) - GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients See more here
- [Optofluidics announces Hexpoint, a new particle analysis system for early stage formulation](https://bioadvance.com/httpwww-bioadvance-commediaoptofluidics-announces-hexpoint-1-7-17-pdf/) - Optofluidics announces Hexpoint, a new particle analysis system for early stage formulation See more here
- [How to enrol your dog in a cancer-drug trial](https://bioadvance.com/httpwww-bioadvance-commediaone-health-in-the-economist-11-12-16-pdf/) - How to enrol your dog in a cancer-drug trial See more here
- [Immunome Raises $12.2 Million in Additional Series A Financing](https://bioadvance.com/httpwww-bioadvance-commediapress-release-immunome-financing-10-2016final-pdf/) - Immunome Raises $12.2 Million in Additional Series A Financing See more here
- [Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study](https://bioadvance.com/httpwww-bioadvance-commediamlr-1023-phase-2-results-june-16-v4-1-pdf/) - Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study See more here
- [PA Biotech Center Companies Showcased to Potential Investors at Second Annual 'Entrepreneur Spotlight'](https://bioadvance.com/pa-biotech-center-companies-showcased-to-potential-investors-at-second-annual-entrepreneur-spotlight/) - PA Biotech Center Companies Showcased to Potential Investors at Second Annual 'Entrepreneur Spotlight' See more here
- [New Data on Posiphen in Traumatic Brain Injury](https://bioadvance.com/httpwww-bioadvance-commediaqr-pharma-new-data-on-posiphen-in-traumatic-brain-injury-8-17-16-pdf/) - New Data on Posiphen in Traumatic Brain Injury See more here
- [GenPro Selected to Lead Epigenetic Profiling on Multi-Company Multi-Institution Team Formed to Discover New Precision Medicine Hypotheses for Undiagnosed Diseases](https://bioadvance.com/httpwww-bioadvance-commediagenpro-selected-to-lead-epigenetic-profiling-on-multi-8-15-16-pdf/) - GenPro Selected to Lead Epigenetic Profiling on Multi-Company Multi-Institution Team Formed to Discover New Precision Medicine Hypotheses for Undiagnosed Diseases See more here
- [Biotech firm obtains patent for experimental iron overload therapy](https://bioadvance.com/httpwww-bioadvance-commediamerganser-biotech-inc-initiates-first-clinical-trial-merganser-biotech-pdf/) - Biotech firm obtains patent for experimental iron overload therapy See more here
- [Melior Pharmaceuticals Achieves Partnership Milestone with Bukwang Pharmaceutical Co.](https://bioadvance.com/httpwww-bioadvance-commediamelior-pharmaceutical-partners-mlr-1023-positive-phase-2-prv3-2final-pdf/) - Melior Pharmaceuticals Achieves Partnership Milestone with Bukwang Pharmaceutical Co. See more here
- [Immunome Raises $5 Million Series A Financing to Advance Novel Cancer Immunotherapies](https://bioadvance.com/httpwww-bioadvance-commediaimmunome-series-a-financing-042016-final-pdf/) - Immunome Raises $5 Million Series A Financing to Advance Novel Cancer Immunotherapies See more here
- [First Ever Life Sciences Ecosystem Interactive Map Launched in Pennsylvania](https://bioadvance.com/httpwww-bioadvance-commediapa-life-science-map-pr-10-28-15-pdf/) - First Ever Life Sciences Ecosystem Interactive Map Launched in Pennsylvania See more here
- [Main Line health care technology firm raises $1.45M for 2 new products](https://bioadvance.com/httpwww-bioadvance-commedia160517-pbj-article-noble-letterhead-1-pdf/) - Main Line health care technology firm raises $1.45M for 2 new products See more here
- [McKesson Health Solutions Extends VBR Portfolio with ClarityQx Value-Based Payment Technology](https://bioadvance.com/mckesson-health-solutions-extends-vbr-portfolio-with-clarityqx-value-based-payment-technology/) - McKesson Health Solutions Extends VBR Portfolio with ClarityQx Value-Based Payment Technology See more here
- [BioAdvance Commits $2.9M to 15 Life Sciences Companies](https://bioadvance.com/httpwww-bioadvance-commediabioadvance_commits-2-9m-7-26-16-pr-pdf/) - BioAdvance Commits $2.9M to 15 Life Sciences Companies See more here
- [BioAdvance Portfolio Companies Attract $85 Million of Capital in 12 Months](https://bioadvance.com/bioadvance-portfolio-companies-attract-85-million-of-capital-in-12-months/) - BioAdvance Portfolio Companies Attract $85 Million of Capital in 12 Months Read more here
- [Galleon Pharmaceuticals Names Joseph Oliveto as Chief Executive Officer](https://bioadvance.com/galleon-pharmaceuticals-names-joseph-oliveto-as-chief-executive-officer/) - Galleon Pharmaceuticals Names Joseph Oliveto as Chief Executive Officer Read more here
- [Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides](https://bioadvance.com/merganser-biotech-inc-raises-28-million-in-a-series-a-financing-to-develop-hepcidin-mimetic-peptides/) - Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides Read more here
- [Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes](https://bioadvance.com/melior-pharmaceuticals-initiates-phase-2-study-with-mlr-1023-for-type-2-diabetes/) - Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes Read more here
- [QR Pharma Announces the Appointment of New Chairman and New Board Member](https://bioadvance.com/qr-pharma-announces-the-appointment-of-new-chairman-and-new-board-member-2/) - QR Pharma Announces the Appointment of New Chairman and New Board Member Read more here
- [BioAdvance Wins Local Venture Impact Award](https://bioadvance.com/bioadvance-wins-local-venture-impact-award/) - BioAdvance Wins Local Venture Impact Award Read more here
- [BioAdvance Newsletter Winter 2007](https://bioadvance.com/bioadvance-newsletter-winter-2007/) - BioAdvance Newsletter Winter 2007 Read more here
- [Tips for Funding a Biotech Start-up](https://bioadvance.com/tips-for-funding-a-biotech-start-up/) - Tips for Funding a Biotech Start-up Read more here
- [Jenrin Discovery’s Non-Brain Penetrant Cb1 Antagonists Show Beneficial Effects in Treating Diabetes and Obesity](https://bioadvance.com/jenrin-discoverys-non-brain-penetrant-cb1-antagonists-show-beneficial-effects-in-treating-diabetes-and-obesity/) - Jenrin Discovery’s Non-Brain Penetrant Cb1 Antagonists Show Beneficial Effects in Treating Diabetes and Obesity Read more here
- [Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso® Gel for Treatment of Persistent Erythema of Rosacea](https://bioadvance.com/galderma-announces-the-publication-of-positive-results-of-the-long-term-study-of-mirvaso-gel-for-treatment-of-persistent-erythema-of-rosacea/) - Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso® Read more here
- [Galderma's Mirvaso® Approved by the European Commission](https://bioadvance.com/mirvaso-brimonidine-the-first-and-only-treatment-targeting-the-facial-redness-of-rosacea-approved-by-the-european-commission/) - Galderma's Mirvaso® Approved by the European Commission Read more here
- [New Funding Model for Start-Ups](https://bioadvance.com/new-funding-model-for-start-ups/) - New Funding Model for Start-Ups Read more here
- [Galleon Pharmaceuticals Named SR One Biotech Company Of The Year](https://bioadvance.com/galleon-pharmaceuticals-named-sr-one-biotech-company-of-the-year/) - Galleon Pharmaceuticals Named SR One Biotech Company Of The Year Read more here
- [Picking the Brains of Venture Capitalists](https://bioadvance.com/picking-the-brains-of-venture-capitalists/) - Picking the Brains of Venture Capitalists Read more here
- [BioAdvance: Cultivating Life Sciences Innovation](https://bioadvance.com/bioadvance-cultivating-life-sciences-innovation/) - BioAdvance: Cultivating Life Sciences Innovation Read more here
- [Cira Discovery Sciences and The Wistar Institute Announce Collaboration](https://bioadvance.com/cira-discovery-sciences-and-the-wistar-institute-announce-collaboration/) - Cira Discovery Sciences and The Wistar Institute Announce Collaboration Read more here
- [Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer](https://bioadvance.com/yaupon-therapeutics-names-steve-tullman-chairman-and-chief-executive-officer/) - Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer Read more here
- [Yaupon Announces Results from Pivotal Study](https://bioadvance.com/yaupon-announces-results-from-pivotal-study/) - Yaupon Announces Results from Pivotal Study Read more here
- [Tips for Emerging Firms on Obtaining Funding](https://bioadvance.com/tips-for-emerging-firms-on-obtaining-funding/) - Tips for Emerging Firms on Obtaining Funding Read more here
- [Yaupon Therapeutics, Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride](https://bioadvance.com/yaupon-therapeutics-inc-submits-new-drug-application-for-proprietary-gel-formulation-of-mechlorethamine-hydrochloride/) - Yaupon Therapeutics, Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride Read more here
- [Yaupon Therapeutics, Inc. Appoints New Management Team](https://bioadvance.com/yaupon-therapeutics-inc-appoints-new-management-team/) - Yaupon Therapeutics, Inc. Appoints New Management Team Read more here
- [FDA Accepts Filing of New Drug Application (NDA) for Yaupon's Proprietary Gel Formulation of Mechlorethamine Hydrochloride](https://bioadvance.com/fda-accepts-filing-of-new-drug-application-nda-for-yaupons-proprietary-gel-formulation-of-mechlorethamine-hydrochloride/) - FDA Accepts Filing of New Drug Application (NDA) for Yaupon's Proprietary Gel Formulation of Mechlorethamine Hydrochloride Read more here
- [Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing](https://bioadvance.com/yaupon-therapeutics-inc-secures-14-4-million-in-series-d-financing/) - Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing Read more here
- [Entities Invest in TheraQuest’s Development of Pain Management Drugs](https://bioadvance.com/entities-invest-in-theraquests-development-of-pain-management-drugs/) - Entities Invest in TheraQuest’s Development of Pain Management Drugs Read more here
- [BioAdvance Portfolio Company Yaupon Therapeutics Named Best Life Sciences Start-Up at 2005 Enterprise Awards](https://bioadvance.com/bioadvance-portfolio-company-yaupon-therapeutics-named-best-life-sciences-start-up-at-2005-enterprise-awards/) - BioAdvance Portfolio Company Yaupon Therapeutics Named Best Life Sciences Start-Up at 2005 Enterprise Awards Read more here
- [BioAdvance’s ROI Tops $11 Million](https://bioadvance.com/bioadvances-roi-tops-11-million/) - BioAdvance’s ROI Tops $11 Million Read more here
- [Cira Discovery Sciences Looks for Seed Capital After BioAdvance](https://bioadvance.com/cira-discovery-sciences-looks-for-seed-capital-after-bioadvance/) - Cira Discovery Sciences Looks for Seed Capital After BioAdvance Investment Read more here
- [BioAdvance Announces 8 Recipients of Funding](https://bioadvance.com/bioadvance-announces-8-recipients-of-funding/) - BioAdvance Announces 8 Recipients of Funding Read more here
- [A Fund to Build Life-Sciences Companies and Create Jobs in the Phila. Area Will Invest $3.3 Million](https://bioadvance.com/a-fund-to-build-life-sciences-companies-and-create-jobs-in-the-phila-area-will-invest-3-3-million/) - A Fund to Build Life-Sciences Companies and Create Jobs in the Phila. Area Will Invest $3.3 Million Read more here
- [Life-Sciences Fund Makes First 7 Loans](https://bioadvance.com/life-sciences-fund-makes-first-7-loans/) - Life-Sciences Fund Makes First 7 Loans Read more here
- [Varied Group of Researchers Gets BioAdvance Funds](https://bioadvance.com/varied-group-of-researchers-gets-bioadvance-funds/) - Varied Group of Researchers Gets BioAdvance Funds Read more here
- [BioAdvance Invests More Than $3 Million In Regional Life Sciences Enterprises](https://bioadvance.com/bioadvance-invests-more-than-3-million-in-regional-life-sciences-enterprises/) - BioAdvance Invests More Than $3 Million In Regional Life Sciences Enterprises Read more here
- [CarePartners Plus® Launches Wellby® -- A New Innovative Patient Engagement and Feedback Technology Tool](https://bioadvance.com/carepartners-plus-launches-wellby-a-new-innovative-patient-engagement-and-feedback-technology-tool/) - CarePartners Plus® Launches Wellby® -- A New Innovative Patient Engagement and Feedback Technology Tool Read more here
- [Firm Logs Instant Feedback on Doctor Visits](https://bioadvance.com/firm-logs-instant-feedback-on-doctor-visits/) - Firm Logs Instant Feedback on Doctor Visits Read more here
- [Niiki Pharma to Present Final Phase I Clinical Data on Anti-Cancer Agent at ASCO](https://bioadvance.com/niiki-pharma-to-present-final-phase-i-clinical-data-on-anti-cancer-agent-at-asco/) - Niiki Pharma to Present Final Phase I Clinical Data on Anti-Cancer Agent at ASCO Read more here
- [Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339](https://bioadvance.com/niiki-pharma-announces-positive-interim-data-from-ongoing-clinical-trial-of-novel-anti-cancer-agent-nkp-1339/) - Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339 Read more here
- [Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents](https://bioadvance.com/niiki-pharma-reports-on-synergistic-activity-of-novel-anti-cancer-agent-nkp-1339-with-other-anti-cancer-agents-2/) - Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents Read more here
- [Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339](https://bioadvance.com/niiki-pharma-announces-the-completion-of-phase-i-dose-escalation-for-first-in-man-anti-cancer-agent-nkp-1339/) - Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339 Read more here
- [Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists](https://bioadvance.com/niiki-pharma-forms-scientific-advisory-board-with-leading-u-s-oncologists/) - Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists Read more here
- [Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent](https://bioadvance.com/niiki-pharma-presents-data-on-nkp-2235-the-first-highly-orally-bioavailable-gallium-based-anti-cancer-agent/) - Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent Read more here
- [QR Pharma to Present at Massachusetts General Hospital](https://bioadvance.com/qr-pharma-to-present-at-massachusetts-general-hospital/) - QR Pharma to Present at Massachusetts General Hospital Read more here
- [QR Taps Region's Proven Experts](https://bioadvance.com/qr-taps-regions-proven-experts/) - QR Taps Region's Proven Experts Read more here
- [Niiki Pharma to Present Preclinical Results, Start Testing Cancer Drug](https://bioadvance.com/niiki-pharma-to-present-preclinical-results-start-testing-cancer-drug/) - Niiki Pharma to Present Preclinical Results, Start Testing Cancer Drug Read more here
- [First-In-Class Novel Anti-Cancer Agent In Development By Niiki Pharma Shows Promising Phase I Results](https://bioadvance.com/first-in-class-novel-anti-cancer-agent-in-development-by-niiki-pharma-shows-promising-phase-i-results/) - First-In-Class Novel Anti-Cancer Agent In Development By Niiki Pharma Shows Promising Phase I Results Read more here
- [QR Pharma Announces Publication on Posiphen Clincial Trials Showing Promise](https://bioadvance.com/qr-pharma-announces-publication-on-posiphen-clincial-trials-showing-promise/) - QR Pharma Announces Publication on Posiphen Clincial Trials Showing Promise Read more here
- [QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine](https://bioadvance.com/qr-pharma-announces-the-start-of-a-phase-i-clinical-study-for-bisnorcymserine/) - QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine Read more here
- [QR's Posiphen® Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice](https://bioadvance.com/posiphen-restores-brain-function-cognition-and-memory-in-transgenic-alzheimer-mice/) - Posiphen® Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice Read more here
- [QR Pharma and UCLA Awarded $3 Million USARMY Grant to Test Posiphen® in Rat Models of Concussion and Blunt Head Trauma](https://bioadvance.com/qr-pharma-and-ucla-awarded-3-million-usarmy-grant-to-test-posiphen-in-rat-models-of-concussion-and-blunt-head-trauma/) - QR Pharma and UCLA Awarded $3 Million USARMY Grant to Test Posiphen® in Rat Models of Concussion and Blunt Head Trauma Read more here
- [QR Pharma Reports Results from SBIR Grant by NIA/NIH to Study Posiphen® and Metabolites in Various Models](https://bioadvance.com/qr-pharma-reports-results-from-sbir-grant-by-nianih-to-study-posiphen-and-metabolites-in-various-models/) - QR Pharma Reports Results from SBIR Grant by NIA/NIH to Study Posiphen® and Metabolites in Various Models Read more here
- [QR Pharma Awarded Funding by Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson's Disease](https://bioadvance.com/qr-pharma-awarded-funding-by-michael-j-fox-foundation-to-test-posiphen-as-a-treatment-for-parkinsons-disease/) - QR Pharma Awarded Funding by Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson's Disease Read more here
- [QR Pharma Has a Gut Feeling about Parkinson's](https://bioadvance.com/qr-pharma-has-a-gut-feeling-about-parkinsons/) - QR Pharma Has a Gut Feeling about Parkinson's Read more here
- [QR Pharma Receives FDA Clearance to Conduct Clinical Trials with its Second Novel Alzheimer Compound, Bisnorcymserine](https://bioadvance.com/qr-pharma-receives-fda-clearance-to-conduct-clinical-trials-with-its-second-novel-alzheimer-compound-bisnorcymserine/) - QR Pharma Receives FDA Clearance to Conduct Clinical Trials with its Second Novel Alzheimer Compound, Bisnorcymserine Read more here
- [Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma's Medical Advisory Board](https://bioadvance.com/jeffrey-cummings-rachelle-doody-martin-farlow-and-mary-sano-to-form-qr-pharmas-medical-advisory-board/) - Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma's Medical Advisory Board Read more here
- [QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients](https://bioadvance.com/qr-pharma-initiates-clinical-trial-for-cognitively-impaired-patients/) - QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients Read more here
- [QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome](https://bioadvance.com/qr-pharma-receives-us-patent-7625942-to-treat-down-syndrome/) - QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome Read more here
- [Massachusetts General Hospital and QR Pharma Start a Collaboration on Posiphen® and Parkinson's Disease](https://bioadvance.com/massachusetts-general-hospital-and-qr-pharma-start-a-collaboration-on-posiphen-and-parkinsons-disease/) - Massachusetts General Hospital and QR Pharma Start a Collaboration on Posiphen® and Parkinson's Disease Read more here
- [QR Pharma Awarded SBIR Grant by NIA/NIH to Test Posiphen® and Metabolites in Various Models](https://bioadvance.com/qr-pharma-awarded-sbir-grant-by-nianih-to-test-posiphen-and-metabolites-in-various-models/) - QR Pharma Awarded SBIR Grant by NIA/NIH to Test Posiphen® and Metabolites in Various Models Read more here
- [Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression](https://bioadvance.com/galleon-pharmaceuticals-reports-positive-results-from-phase-i-study-of-gal-021-for-treatment-of-respiratory-depression/) - Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression Read more here
- [Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer](https://bioadvance.com/galleon-pharmaceuticals-names-lynne-brookes-senior-vice-president-and-chief-business-officer/) - Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer Read more here
- [TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma](https://bioadvance.com/torreypines-therapeutics-licenses-posiphen-bisnorcymcerine-and-phenserine-to-qr-pharma/) - TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma Read more here
- [QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease](https://bioadvance.com/qr-pharma-inc-exclusively-licenses-clinical-stage-compounds-posiphen-bisnorcymserine-and-phenserine-to-treat-alzheimers-disease/) - QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease Read more here
- [No Snooze Button: Galleon Advances Drug Therapy for Sleep Apnea](https://bioadvance.com/1365-2/) - No Snooze Button: Galleon Advances Drug Therapy for Sleep Apnea Read more here
- [Galleon Scientists Win Prestigious Research Awards for First-in-Class Treatment of Emerging Perioperative Sleep Apnea Epidemic](https://bioadvance.com/galleon-scientists-win-prestigious-research-awards-for-first-in-class-treatment-of-emerging-perioperative-sleep-apnea-epidemic/) - Galleon Scientists Win Prestigious Research Awards for First-in-Class Treatment of Emerging Perioperative Sleep Apnea Epidemic Read more here
- [Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform](https://bioadvance.com/galleon-pharmaceuticals-demonstrates-successful-clinical-proof-of-concept-for-lead-product-from-sleep-apnea-drug-discovery-platform-2/) - Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform Read more here
- [Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression](https://bioadvance.com/galleon-pharmaceuticals-reports-positive-results-from-second-phase-i-study-of-gal-021-for-treatment-of-respiratory-depression/) - Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression Read more here
- [Treventis Scientific Founder Named 2009 Recipient of Prix Galien Canada Award for Alzheimer’s Disease](https://bioadvance.com/treventis-scientific-founder-donald-weaver-md-named-2009-recipient-of-prix-galien-canada-award-for-outstanding-achievement-in-development-of-new-medicines-for-alzheimers-disease/) - Treventis Scientific Founder Named 2009 Recipient of Prix Galien Canada Award for Alzheimer’s Disease Read more here
- [Galleon's Sleep Apnea Pill Nears Human Tests](https://bioadvance.com/galleons-sleep-apnea-pill-nears-human-tests/) - Galleon's Sleep Apnea Pill Nears Human Tests Read more here
- [Optofluidics Awarded NSF Phase IIB SBIR](https://bioadvance.com/optofluidics-awarded-nsf-phase-iib-sbir/) - Optofluidics Awarded NSF Phase IIB SBIR Read more here
- [Optofluidics Awarded NIH Phase II SBIR](https://bioadvance.com/optofluidics-awarded-nih-phase-ii-sbir/) - Optofluidics Awarded NIH Phase II SBIR Read more here
- [Immunome Appoints New Management](https://bioadvance.com/immunome-appoints-new-management/) - Immunome Appoints New Management Read more here
- [BioAdvance News 2006](https://bioadvance.com/bioadvance-news-2006/) - BioAdvance News 2006 Read more here
- [Melior: Recycling Existing Drugs](https://bioadvance.com/melior/) - Melior: Recycling Existing Drugs Read more here
- [Melior Enters Research Collaboration with Pfizer](https://bioadvance.com/melior-2/) - Melior Enters Research Collaboration with Pfizer Read more here
- [Melior Pharmaceuticals Receives First Performance Milestone Payment from Bukwang Pharmaceutical](https://bioadvance.com/melior-pharmaceuticals-receives-first-performance-milestone-payment-from-bukwang-pharmaceutical/) - Melior Pharmaceuticals Receives First Performance Milestone Payment from Bukwang Pharmaceutical Read more here
- [Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic](https://bioadvance.com/990-2/) - Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic Read more here
- [Galleon Pharmaceuticals Inc. Is Working On a More Simple Treatment for Sleep Apnea: A Pill](https://bioadvance.com/galleon-pharmaceuticals-inc-is-working-on-a-more-simple-treatment-for-sleep-apnea-a-pill/) - Galleon Pharmaceuticals Inc. Is Working On a More Simple Treatment for Sleep Apnea: A Pill Read more here
- [BioAdvance Portfolio Generated $450M in Fiscal 2014](https://bioadvance.com/bioadvance-portfolio-generated-450m-in-fiscal-2014/) - BioAdvance Portfolio Generated $450M in Fiscal 2014 Read more here
- [QR Pharma Receives Funding](https://bioadvance.com/qr-pharma-receives-funding/) - QR Pharma Receives Funding Read more here
- [Entrepreneur OnRamp Helps Dozens of New Life Science Focused Startups](https://bioadvance.com/entrepreneur-onramp-helps-dozens-of-new-life-science-focused-startups/) - Entrepreneur OnRamp Helps Dozens of New Life Science Focused Startups Read more here
- [15 BioAdvance Firms Get Fed Funds](https://bioadvance.com/15-bioadvance-firms-get-fed-funds-five-outlined-here/) - 15 BioAdvance Firms Get Fed Funds Read more here
- [Jenrin Adds Twist in Quest for Drug to Battle Obesity](https://bioadvance.com/jenrin-adds-twist-in-quest-for-drug-to-battle-obesity/) - Jenrin Adds Twist in Quest for Drug to Battle Obesity Read more here
- [BioAdvance Wins Venture Impact Award (Philadelphia Business Journal)](https://bioadvance.com/bioadvance-wins-venture-impact-award-philadelphia-business-journal/) - BioAdvance Wins Venture Impact Award (Philadelphia Business Journal) Read more here
- [NIH Proposes New Center to Accelerate Drug Development](https://bioadvance.com/nih-proposes-new-center-to-accelerate-drug-development/) - NIH Proposes New Center to Accelerate Drug Development Read more here
- [Yaupon Announces Positive from Pivotal Study](https://bioadvance.com/yaupon-announces-positive-results-from-pivotal-study-of-its-proprietary-topical-mechlorethamine-gel-a-potential-treatment-for-early-stage-cutaneous-t-cell-lymphoma/) - Yaupon Announces Positive from Pivotal Study Read more here
- [BioAdvance Funds Treventis to Advance Alzheimer's Drug Discovery](https://bioadvance.com/bioadvance-funds-treventis-to-advance-alzheimers-drug-discovery/) - BioAdvance Funds Treventis to Advance Alzheimer's Drug Discovery Read more here
- [BioAdvance Names Dr. Philip P. Gerbino Chair and Elects Dr. John M. Daly to Board of Directors](https://bioadvance.com/bioadvance-names-dr-philip-p-gerbino-chair-and-elects-dr-john-m-daly-to-board-of-directors/) - BioAdvance Names Dr. Philip P. Gerbino Chair and Elects Dr. John M. Daly to Board of Directors Read more here
- [QR Pharma, Inc. CEO Awarded Iris Newman Women Entrepreneur of the Year](https://bioadvance.com/dr-maria-maccecchini-ceo-of-qr-pharma-inc-qr-has-been-awarded-the-prestigious-iris-newman-women-entrepreneur-of-the-year-award/) - QR Pharma, Inc. CEO Awarded Iris Newman Women Entrepreneur of the Year Read more here
- [BioAdvance Names Sam Katz as Chair and Elects J. Larry Jameson, M.D., Ph.D., and Lauren Lenfest as Directors](https://bioadvance.com/bioadvance-names-sam-katz-as-chair-and-elects-j-larry-jameson-m-d-ph-d-and-lauren-lenfest-as-directors/) - BioAdvance Names Sam Katz as Chair and Elects J. Larry Jameson, M.D., Ph.D., and Lauren Lenfest as Directors Read more here
- [BioAdvance Expands Team to Support Portfolio and Future Investments](https://bioadvance.com/bioadvance-expands-team-to-support-portfolio-and-future-investments/) - BioAdvance Expands Team to Support Portfolio and Future Investments Read more here
- [Niiki Pharma Developing New Weapons to Battle Cancer](https://bioadvance.com/niiki-pharma-developing-new-weapons-to-battle-cancer/) - Niiki Pharma Developing New Weapons to Battle Cancer Read more here
- [Amyvid™ (Florbetapir F 18 Injection) Recommended for Approval in Europe as a Diagnostic Tool for PET Imaging of Beta-Amyloid Plaque Density](https://bioadvance.com/amyvid-florbetapir-f-18-injection-recommended-for-approval-in-europe-as-a-diagnostic-tool-for-pet-imaging-of-beta-amyloid-plaque-density/) - Amyvid™ (Florbetapir F 18 Injection) Recommended for Approval in Europe as a Diagnostic Tool for PET Imaging of Beta-Amyloid Plaque Density Read more here
- [BioAdvance Expands Team to Support Portfolio Companies and New Investments](https://bioadvance.com/bioadvance-expands-team-to-support-portfolio-companies-and-new-investments/) - BioAdvance Expands Team to Support Portfolio Companies and New Investments Read more here
- [University City Science Center Deciding Factor in Tech Firm's Move to Philadelphia](https://bioadvance.com/university-city-science-center-deciding-factor-in-tech-firms-move-to-philadelphia/) - University City Science Center Deciding Factor in Tech Firm's Move to Philadelphia Read more here
- [Merganser: Hip to Hep](https://bioadvance.com/merganser-hip-to-hep/) - Merganser: Hip to Hep Read more here
- [Pennsylvania Has Enormous Untapped Potential for Investment, Says Venture Capitalist Kush Parmar](https://bioadvance.com/pennsylvania-has-enormous-untapped-potential-for-investment-says-venture-capitalist-kush-parmar/) - Pennsylvania Has Enormous Untapped Potential for Investment, Says Venture Capitalist Kush Parmar Read more here
- [Optofluidics Announces Pre-release of Molecular NanoTweezer System](https://bioadvance.com/optofluidics-announces-pre-release-of-molecular-nanotweezer-system/) - Optofluidics Announces Pre-release of Molecular NanoTweezer System Read more here
- [Pittcon 2013 Editors' Silver Award – Optofluidics](https://bioadvance.com/pittcon-2013-editors-silver-award-optofluidics/) - Pittcon 2013 Editors' Silver Award – Optofluidics Read more here
- [Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel](https://bioadvance.com/ceptaris-receives-fda-approval-for-valchlortm-mechlorethamine-gel-for-the-treatment-of-stage-ia-and-ib-mycosis-fungoides-type-cutaneous-t-cell-lymphoma-in-patients-who-have-received-prior-skin-dir/) - Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel Read more here
- [NanoTweezer Company Graduates to Larger Space](https://bioadvance.com/nanotweezer-company-graduates-to-larger-space/) - NanoTweezer Company Graduates to Larger Space Read more here
- [Jenrin Discovery Announces Recent Advances in Understanding of the Endocannabinoid System Using JD-5037](https://bioadvance.com/jenrin-discovery-announces-recent-advances-in-understanding-of-the-endocannabinoid-system-using-jd-5037/) - Jenrin Discovery Announces Recent Advances in Understanding of the Endocannabinoid System Using JD-5037 Read more here
- [A Tag-Team Effort to Foster the Next Generation of Startups](https://bioadvance.com/a-tag-team-effort-to-foster-the-next-generation-of-startups/) - A Tag-Team Effort to Foster the Next Generation of Startups Read more now
- [USciences Gets into the Biotech Biz](https://bioadvance.com/usciences-gets-into-the-biotech-biz/) - USciences Gets into the Biotech Biz Read more here
- [Alzheimer’s Research Gets Boost](https://bioadvance.com/alzheimers-research-gets-boost/) - Alzheimer’s Research Gets Boost Read more here
- [Optofluidics Announces Launch of NanoTweezer System](https://bioadvance.com/optofluidics-announces-launch-of-nanotweezer-system-a-high-throughput-tractor-beam-for-nanoparticle-measurement-and-manipulation/) - Optofluidics Announces Launch of NanoTweezer System Read more here
- [Melior Licenses Novel Diabetes Drug to Bukwang Pharmaceutical Co.](https://bioadvance.com/melior-licenses-novel-diabetes-drug-to-bukwang-pharmaceutical-co/) - Melior Licenses Novel Diabetes Drug to Bukwang Pharmaceutical Co. Read more here

## Pages

- [Home](https://bioadvance.com/) - Improving Human Health We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life. ABOUT USLET'S TALK Continuing to Grow & Invest We are an evergreen fund that has a long-term investment perspective. OUR APPROACHLET'S TALK Focusing on the Mid-Atlantic Region We invest in life-science companies in the Mid-Atlantic
- [About](https://bioadvance.com/about/) - We work closely and partner with entrepreneurs to build transformational companies in the Mid-Atlantic region focused on improving human health. BioAdvance is an evergreen fund established to address the critical needs of emerging human life science focused companies. Committed to fueling innovation, BioAdvance supports companies dedicated to developing technologies that can meaningfully impact human health.
- [Team](https://bioadvance.com/team/) - The BioAdvance team is dedicated to driving innovation and supporting the growth of life science companies. We bring together a dynamic mix of successful investors, seasoned entrepreneurs, skilled medical professionals, and leading life science experts. Our team is uniquely positioned to identify high-potential ventures, provide strategic guidance, and help companies navigate the complex path from
- [Shahram Hejazi, Ph.D.](https://bioadvance.com/team/shahram-hejazi/) - Shahram Hejazi, Ph.D. Managing Director & CEO Dr. Shahram Hejazi is a life science investor and entrepreneur with general management experience in both early-stage ventures and large global companies. As Managing Director and CEO, Dr. Hejazi is responsible for the overall leadership and strategic direction of BioAdvance. His areas of investment focus are research tools,
- [Marie Lindner, M.D.](https://bioadvance.com/team/marie-lindner/) - Marie Lindner, M.D. Entrepreneur-in-Residence Marie Lindner, MD worked in executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies with experience across therapeutic areas and modalities and between business and clinical development over 30 years. She was recruited to start a team at Novartis Pharmaceuticals, focused on finding new trends in science and medicine.
- [Deneen Vojta, M.D.](https://bioadvance.com/team/deneen-vojta/) - Deneen Vojta, M.D. Entrepreneur-in-Residence Deneen is a visionary physician executive grounded in clinical medicine, scientific research, and new business development. She thrives on finding opportunities and modernizing how we access, pay for, and experience the healthcare system. Deneen is persistent in pursuing good ideas, passionate about engaging with teams in discovery and execution. She is
- [Michael Lark, Ph.D.](https://bioadvance.com/team/michael-lark/) - Michael Lark, Ph.D. Entrepreneur-in-Residence Mike has over 35 years of experience at leading and managing drug discovery and development teams at both large pharmaceutical and small biotech companies. He is an Entrepreneur in Residence at BioAdvance where he sits on the investment committee and does outreach to local research institutions to help bring interesting investable
- [Jeff Edelson, M.D., FRCPC, MHSc](https://bioadvance.com/team/jeff-edelson/) - Jeff Edelson, M.D., FRCPC, MHSc Entrepreneur-in-Residence Dr. Jeff Edelson is a pulmonologist with over 30 years of clinical practice, research, and management experience. Throughout his career, Jeff has demonstrated a strong track record of collaborative strategic and operational achievement and is recognized as a strong creative problem solver, analyst, seasoned technical product expert, leader of
- [Marnie McCoy, M.A.](https://bioadvance.com/team/marnie-mccoy/) - Marnie McCoy, M.A. Program Director As program director at BioAdvance, Ms. McCoy plays a pivotal role in ensuring smooth execution across multiple aspects of BioAdvance’s portfolio and investment activities. With nearly twenty-five years of experience managing the intricacies of the investment process, Ms. McCoy is instrumental in managing due diligence and investment closings, ensuring that
- [Robert Driscoll, M.S.](https://bioadvance.com/team/robert-driscoll/) - Robert Driscoll, M.S. Director of Finance Mr. Driscoll brings twenty years of finance expertise in both multi-national corporations and venture-backed life sciences firms to BioAdvance. His career has focused on financial management reporting and consolidation, budgeting and forecasting, treasury management, and internal financial controls. Prior to joining BioAdvance Mr. Driscoll was controller with BioRexis Pharmaceutical
- [Rick Jones, M.D., MBA](https://bioadvance.com/team/rick-jones/) - Rick Jones, M.D., MBA Advisory Partner Frederick “Rick” Jones, M.D., MBA., is an Advisory Partner. Dr. Jones has over 30 years of experience in the life sciences industry, serving in various roles, including physician, executive, consultant, director, and investor. At BioAdvance, he is responsible for investments in therapeutics and medical devices and serves on the
- [Gregory Harriman, M.D.](https://bioadvance.com/team/gregory-harriman/) - Gregory Harriman, M.D. Partner Dr. Gregory Harriman is an accomplished physician, scientist and biomedical executive having over 25 years of experience with increasing responsibilities in academic medicine and the biopharmaceutical industry. He has held leadership positions in both small and large biopharmaceutical companies, having global responsibilities in research and development of pharmaceuticals, biologics, medical devices
- [David Shin, M.D.](https://bioadvance.com/team/david-shin/) - David Shin, M.D. Partner David Shin, M.D., is a trained physician and engineer who brings over 20 years of investment management and executive operating experience to BioAdvance. His career includes deep focus in both therapeutics and software development for the life sciences, which enables him to support a diverse group of companies in the BioAdvance
- [Gayle Mineo](https://bioadvance.com/team/gayle-mineo/) - Gayle Mineo Office Management Ms. Mineo has more than 15 years of experience in management and business development in the life sciences sector. She has worked in various roles in medical device and pharmaceutical industries. At BioAdvance Ms. Mineo is responsible for providing operational support and high-level administration services for C-Suite management. She holds a
- [Barbara Schilberg](https://bioadvance.com/team/barbara-schilberg/) - Barbara Schilberg Advisor & Former CEO Ms. Schilberg has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO from 2002-2021, BioAdvance committed over $50 million to almost 100 seed-stage companies and technologies focusing in areas including Alzheimer’s disease, cancer, diabetes, obesity
- [News](https://bioadvance.com/news/) - Dec 17 Love0 Insmed Provides Clinical and Business Update By Gayle Mineo Portfolio News, Opsidio Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications
- [Portfolio](https://bioadvance.com/portfolio/) - AllActiveExited
- [test](https://bioadvance.com/test/) - We work closely and partner with entrepreneurs to build transformational companies in the Mid-Atlantic region focused on improving human health. BioAdvance is an evergreen fund established to address the critical needs of emerging human life science focused companies. Committed to fueling innovation, BioAdvance supports companies dedicated to developing technologies that can meaningfully impact human health.
- [Privacy Policy](https://bioadvance.com/privacy-policy/) - Privacy Policy This Privacy Policy sets out how BioAdvance (“BioAdvance” or “we”) will collect and use your personal information. Information we collect when you interact with us If you contact us: You may use our contact us form regarding your personal information on file. When you contact us, we will collect information you provide us
- [Contact](https://bioadvance.com/contact/) - Welcome Are you interested in becoming one of our portfolio companies? Read more about our approach and the types of companies we support at the link below and then complete our contact form to take the next step. Our Approach & Criteria Office Headquarters 101 West Elm Street, Suite 330 Conshohocken, PA, 19428 (610) 230-0544

## Viba Portfolios

- [Venatorx Pharmaceuticals, Inc.](https://bioadvance.com/?viba_portfolio=venatorx-pharmaceuticals-inc) - Dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance.
- [Keriton, LLC.](https://bioadvance.com/?viba_portfolio=keriton) - Developing a pumped breast milk management system for Neonatal ICUs, to improve staff productivity and outcomes for infants.
- [Opsidio](https://bioadvance.com/?viba_portfolio=opsidio) - A biotechnology company seeking to develop monoclonal antibodies to treat fibrotic diseases.
- [WellTrackONE](https://bioadvance.com/?viba_portfolio=welltrackone) - WellTrackONE provides quality wellness programs to healthcare providers and organizations a Medicare-approved patient assessment that provides physicians and organizations with a comprehensive baseline report detailing modifiable risk factors, preventative goals and measurable data. This information allows accountable care agencies to target patient care while reducing total healthcare costs. WellTrackONE is a complete program of scheduling, staffing and documentation powered
- [Ajaya Bio](https://bioadvance.com/?viba_portfolio=ajaya-bio) - Ajaya Bio develops bispecific antibodies that selectively eliminate disease-driving cells in autoimmune disorders and cancer, aiming to move from chronic management to durable, potentially curative outcomes.
- [MasterSwitch Bio](https://bioadvance.com/?viba_portfolio=masterswitch-bio) - MasterSwitch Bio leverages master transcription therapy to rescue end stage organs. For End Stage Liver Disease with cirrhosis from MASH/metALD/ALD, our technology is a modified mRNA of HNF4α (hepatocyte nuclear factor-4 alpha), the master regulator of core functional health of hepatocytes.
- [Atalan](https://bioadvance.com/?viba_portfolio=atalan) - Atalan is the first Clinician Retention Intelligence (CRI) platform, helping health systems predict and prevent surprise clinician resignations up to 12 months in advance. Using real-time, objective data that health systems already have, Atalan’s machine learning models pinpoint at-risk clinicians, uncover the causes, tailor proactive interventions, and evaluate program impact. The outcome: financial loss prevention,
- [Phrase Health](https://bioadvance.com/?viba_portfolio=phrase-health) - Provides tools to health systems to analyze and govern their clinical decision support.
- [Vesteck Inc.](https://bioadvance.com/?viba_portfolio=vesteck) - Novel aortic endograft anchors that improve outcomes and are easier to deploy.
- [Overwatch Health](https://bioadvance.com/?viba_portfolio=__trashed) - Overwatch Health offers an AI-assisted virtual alternative to rehabilitative care for patients with cardiac and pulmonary-related diagnoses.
- [Halo Labs](https://bioadvance.com/?viba_portfolio=halo-labs) - Halo Labs is commercializing the Horizon - a high throughput biopharmaceutical quality control tool.
- [Spirovant Sciences](https://bioadvance.com/?viba_portfolio=spirovant-sciences) - Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases.
- [Palvella Therapeutics](https://bioadvance.com/?viba_portfolio=palvella-therapeutics) - Palvella is developing new therapeutic agents for rare and ultra-rare diseases suffered by patients that lack any treatment choices.
- [Kayothera](https://bioadvance.com/?viba_portfolio=kayothera) - Pioneering first-in-class antagonists of the retinoid nuclear receptor pathway for cardiometabolic diseases and cancer.
- [Tolerance Bio](https://bioadvance.com/?viba_portfolio=tolerance-bio) - Tolerance Bio is dedicated to increasing healthspan by restoring and preserving the function of the thymus.
- [Hula Therapeutics](https://bioadvance.com/?viba_portfolio=hula-therapeutics) - Hula Therapeutics is an immunotherapy company spinout from the lab of Dr, John Maris at Children’s Hospital of Philadelphia (CHOP). Hula is leveraging deep expertise to identify unique, functionally relevant, and essential tumor specific targets and make them accessible to precision therapeutics (e.g. cell therapy, T-cell engagers, bi-specifics, antibody drug conjugates) for the treatment of
- [HueDx](https://bioadvance.com/?viba_portfolio=huedx) - HueDx is a Rapid, Quantitative, Assay-based (RQA) test development and launch platform that eliminates the need to develop physical devices and software to launch an RQA product. In doing so, HueDx makes the accessibility of launching flagship or complimentary diagnostics accessible to companies that would not normally consider the undertaking.
- [Annovis Bio, Inc.](https://bioadvance.com/?viba_portfolio=http-annovisbio-com) - Formerly QR Pharma, is a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
- [IO Biosciences](https://bioadvance.com/?viba_portfolio=io-biosciences) - IO Biosciences is a company focused on developing allogeneic, gene modified cell therapies treating cancers. The company leverages a proprietary gene editing system and cell source, creating a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies.
- [Cohero Health](https://bioadvance.com/?viba_portfolio=2001) - Develops and commercializes sensor-based technologies and platform to improve medication adherence and care coordination between patients and their providers in respiratory care.
- [Avid](https://bioadvance.com/?viba_portfolio=avid) - Novel imaging agent to detect amyloid plaque in patients with Alzheimer’s disease. Acquired in December 2010 by Eli Lilly and Company and approved by the FDA in 2012.
- [Aspicio Therapeutics](https://bioadvance.com/?viba_portfolio=aspicio-therapeutics) - Developing a biologic therapy to promote synaptogenesis and directly affect the vision loss experienced by patients with dryAMD.
- [Senzo](https://bioadvance.com/?viba_portfolio=senzo) - Senzo is an in vitro diagnostics company bringing innovative point-of-care testing products to market. These products utilize novel technology to provide speed, accuracy, cost-effectiveness, and ease-of-use.
- [KaloCyte](https://bioadvance.com/?viba_portfolio=kalocyte) - Developing ErythroMer, a bio-inspired artificial RBC substitute for use when stored blood is not available.
- [Hanimune Therapeutics](https://bioadvance.com/?viba_portfolio=hanimune-therapeutics) - Hanimune Therapeutics is developing novel treatments and prevention methods for food allergy utilizing the tolerogenic immune system.
- [HealthQx](https://bioadvance.com/?viba_portfolio=healthqx) - HealthQx Delivers SaaS data-driven care quality and cost-efficiency solutions to payers, providers and partners. The initial product rates specialty care physicians and hospitals compared to peers market-by-market.
- [Ceptaris](https://bioadvance.com/?viba_portfolio=ceptaris) - Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The product was approved by the FDA in 2013 and the company was acquired by Actelion in September 2013.
- [Accelerated Biosciences](https://bioadvance.com/?viba_portfolio=accelerated-biosciences) - Providing the allogeneic human Trophoblast Stem Cell (TSC) platform as the ideal starting cell source for cell and gene therapy.
- [ChyloMetis](https://bioadvance.com/?viba_portfolio=chylometis) - ChyloMetis is a bio-pharmaceutical company that is developing novel, first-in-class, non-immunosuppressive therapies to treat chronic gastrointestinal conditions, such as Crohn’s Disease and Irritable Bowel Disease.
- [Latus](https://bioadvance.com/?viba_portfolio=latus) - Developing novel therapeutics for CNS disorders with their revolutionary AAV capsids.
- [Ordaos](https://bioadvance.com/?viba_portfolio=ordaos) - De novo designed mini-proteins to help drug hunters deliver life-saving treatments.
- [ImTol](https://bioadvance.com/?viba_portfolio=imtol) - Creating specific pan-antigen therapies for autoimmune diseases.
- [Vittoria Biotherapeutics](https://bioadvance.com/?viba_portfolio=vittoria-biotherapeutics) - Vittoria Biotherapeutics’ mission is to unlock the promise of cell therapies while addressing their inherent challenges; we are dedicated to innovating solutions that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
- [Trace Orthopedics](https://bioadvance.com/?viba_portfolio=trace-orthopedics) - Trace Orthopedics is commercializing novel solutions for tendon attachment with an early focus on repairing partial tears in an outpatient setting.
- [Strados Labs](https://bioadvance.com/?viba_portfolio=strados-labs) - Strados Labs is innovating respiratory care management with machine learning and a first-of-its-kind wearable device for measuring lung health remotely.
- [Hysplex](https://bioadvance.com/?viba_portfolio=hysplex) - Hysplex is focused upon the development of novel PARP inhibitors that could provide breakthrough treatments to cancer patients with defective DNA damage repair pathways, as well as patients afflicted with certain neuroinflammatory conditions, such as Parkinson’s disease.
- [CrossBridge](https://bioadvance.com/?viba_portfolio=https-www-crossbridge-com) - CrossBridge is developing a specialty decision-making Software as a Service (SaaS) solution for improving outcomes and lowering the cost of treating chronic inflammatory disease.
- [SIRPant Immunotherapeutics](https://bioadvance.com/?viba_portfolio=https-sirpantimmunotx-com) - SIRPant technology employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells. The approach results in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.
- [ImmunoGenesis](https://bioadvance.com/?viba_portfolio=immunogenesis) - ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically “cold” cancers such as prostate, colorectal, and pancreatic cancer. These tumor types represent more than half of all cancers, and current immunotherapies have shown limited to no efficacy here. As a result, there is a high unmet need for efficacious
- [RightAir](https://bioadvance.com/?viba_portfolio=rightair) - RightAir LLC is a Medical Device Company focusing on non-invasive negative-pressure ventilators for Chronic Obstructive Pulmonary Disease (COPD). RightAir’s AIR-AD device is the world’s smallest negative pressure ventilator.
- [Concarlo](https://bioadvance.com/?viba_portfolio=concarlo) - Concarlo is a women-founded and run company that is working to revolutionize the metastatic breast cancer field. The company is developing a new approach to inhibition of CDK4 that limits the development of resistance, which is common with current therapies.
- [Eliksa Therapeutics](https://bioadvance.com/?viba_portfolio=eliksa-therapeutics) - Eliksa Therapeutics was founded to deliver on the mission of harnessing the regenerative properties of amniotic fluid and amniotic membrane to heal human disease.
- [WellSheet](https://bioadvance.com/?viba_portfolio=wellsheet) - Developing a Saas product that customizes EHR content based on the patient/practice environment, and provides the physician with a one-sheet view of the patient.
- [Pillo Health](https://bioadvance.com/?viba_portfolio=pillo-health) - Developing an interactive medication dispensing machine to serve as a home healthcare hub
- [IVIEW Therapeutics, Inc.](https://bioadvance.com/?viba_portfolio=iview-therapeutics) - Committed to becoming a leader in topical drug delivery including a propriety sustained release formulation of Povidone Iodine for the treatment of viral conjunctivitis.
- [ENB Therapeutics](https://bioadvance.com/?viba_portfolio=enb-therapeutics) - Developing small molecule inhibitors of a novel pathway to treat melanoma and other cancers.
- [Onspira Therapeutics, Inc.](https://bioadvance.com/?viba_portfolio=https-www-onspiratx-com) - Is a clinical-stage biopharmaceutical company dedicated to developing therapies to treat rare, life threatening pulmonary diseases.
- [Renovacor](https://bioadvance.com/?viba_portfolio=https-www-renovacorinc-com) - Is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease.
- [RiboNova](https://bioadvance.com/?viba_portfolio=ribonova) - Developing small molecule drugs against a new family of targets, defective transfer RNAs. Its focus is on therapies that will be used in the treatment of cancer.
- [Mebias Discovery](https://bioadvance.com/?viba_portfolio=2004) - Holds a game-changing platform exploiting protein-conformation dynamics to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
- [One Health Company](https://bioadvance.com/?viba_portfolio=one-health-company) - To launch a new contract research organization that de-risks new drugs and treatments through efficacy testing in pets suffering the natural counterpart of a human disease.
- [Oncora Medical](https://bioadvance.com/?viba_portfolio=oncora-medical) - To develop a SaaS-based product that integrates all patient EMR/genetic/imaging information to create a personalized radiation treatment plan.
- [Allevi](https://bioadvance.com/?viba_portfolio=biobots-inc) - Creates 3D printers and bioinks for biologics/tissue regeneration for academic research and drug discovery applications.
- [Bainbridge Health](https://bioadvance.com/?viba_portfolio=httpwww-bioadvance-commediabainbridge-new-jpg-jpg) - Provides hospitals and health systems with solutions for optimizing medication administration practices.
- [Ride Health](https://bioadvance.com/?viba_portfolio=ridehealth) - Developing a Saas product platform to enable healthcare providers to schedule, request and pay for rides - to and from medical appointments - on behalf of patients
- [TalexMedical](https://bioadvance.com/?viba_portfolio=talexmedical) - To support the development and commercialization of a device (based on a CHOP technology) for pediatricians to use for correcting deformities of infant’s ears.
- [Phoenix S&T, Inc.](https://bioadvance.com/?viba_portfolio=phoenix-st-inc) - Commercializing proprietary, high performance, nanospray systems and consumables for mass spectrometry applications.
- [Relmada Therapeutics, Inc.](https://bioadvance.com/?viba_portfolio=relmada-therapeutics-inc) - Developing new products for the treatment of acute and chronic pain.
- [TREVENTIS Corporation](https://bioadvance.com/?viba_portfolio=treventis-corporation) - Developing disease-modifying small molecule compounds that prevent the protein misfolding and aggregation seen in Alzheimer’s and other neurodegenerative diseases.
- [Innovative Supply Solutions](https://bioadvance.com/?viba_portfolio=innovative-supply-solutions) - Providing turnkey, a la carte or complete clinical drug supply management, from Phase I to Phase IV, for global trials of any size or length.
- [Intezyne](https://bioadvance.com/?viba_portfolio=intezyne-inc) - Developing a pipeline of oncology products, including two clinical stage compounds originated by Niiki Pharma which target pathways in the endoplasmic reticulum in cancer cells.
- [Midway Pharmaceuticals](https://bioadvance.com/?viba_portfolio=midway-pharmaceuticals) - Developing oral, high molecular weight polyethylene glycol as a medical food and dietary supplement.
- [Novira Therapeutics](https://bioadvance.com/?viba_portfolio=novira-therapeutics) - Developing first-in-class antiviral therapeutics based on a novel mechanism of action that targets viral capsid assembly. Acquired by Johnson & Johnson in December 2015.
- [Ossianix, Inc.](https://bioadvance.com/?viba_portfolio=ossianix-inc) - Developing single domain antibodies based on the shark VNAR structure, with potential applications in immunological, inflammatory, musculoskeletal, neurologic, and other disorders.
- [Gelifex](https://bioadvance.com/?viba_portfolio=gelifex) - Novel spinal nucleus replacement implants for degenerative disc disease. Acquired by Synthes, Inc. in 2004.
- [SansRosa](https://bioadvance.com/?viba_portfolio=sansrosa) - Topical agents to treat the redness associated with rosacea which was approved by the FDA in 2013. The company was acquired by CollaGenex, Inc. in 2005, which was later acquired by Galderma.
- [NuPathe](https://bioadvance.com/?viba_portfolio=nupathe) - Zecuity® transdermal patch to treat migraine headaches approved by the FDA in 2013. IPO (NASDAQ: PATH) completed in August 2010 and the company was acquired by Teva Pharmaceutical Industries Ltd. in February 2014.
- [Melior](https://bioadvance.com/?viba_portfolio=melior) - In vivo pharmacology platform to identify new therapeutic indications for pre-clinical and clinical-stage pharmaceuticals.
- [LumenVu, Inc.](https://bioadvance.com/?viba_portfolio=lumenvu-inc) - Light-embedded catheters to direct accurate placement in the body. Acquired by SonoSite, Inc. in 2007. The LumenVu™ Catheter Guidance System received FDA clearance in 2010.
- [Formae, Inc.](https://bioadvance.com/?viba_portfolio=formae-inc) - Total joint resurfacing technology based on a proprietary synthetic cartilage. BioAdvance exited through a refinancing in 2011.
- [Protez](https://bioadvance.com/?viba_portfolio=protez) - Novel antibiotic candidate (PZ-601) focused on drug resistance in difficult to treat infections. Acquired by Novartis in 2008.
- [Immunome](https://bioadvance.com/?viba_portfolio=immunome) - Native human monoclonal antibody platform enables the discovery of novel targets and therapeutic antibodies against those targets, with a focus on oncology applications.
- [InfraScan](https://bioadvance.com/?viba_portfolio=infrascan) - Commercializing an FDA-approved handheld device which uses near-infrared light to screen for intracranial bleeding in patients with head trauma.
- [Acuity](https://bioadvance.com/?viba_portfolio=acuity) - RNAimolecule to treatmacular degeneration. Merged into Opko Health, Inc. in 2007. Philadelphia, PA
- [Alteris](https://bioadvance.com/?viba_portfolio=alteris) - Therapeutics and vaccines (CDX-110) against novel, proprietary cancer targets. Acquired by Celldex Therapeutics in 2005, which merged with Avant Immunotherapeutics in 2008.

## Categories

- [General](https://bioadvance.com/category/general/)
- [BioAdvance News](https://bioadvance.com/category/bioadvance-news/)
- [Portfolio News](https://bioadvance.com/category/portfolio-news/)
- [Accelerated Biosciences](https://bioadvance.com/category/portfolio-news/accelerated-biosciences/)
- [Acuity Pharmaceuticals](https://bioadvance.com/category/portfolio-news/acuity-pharmaceuticals/)
- [HueDx](https://bioadvance.com/category/portfolio-news/huedx/)
- [Latus](https://bioadvance.com/category/portfolio-news/latus/)
- [Tolerance Bio](https://bioadvance.com/category/portfolio-news/tolerance-bio/)
- [Wellsheet](https://bioadvance.com/category/portfolio-news/wellsheet/)
- [Strados](https://bioadvance.com/category/portfolio-news/strados/)
- [Phrase Health](https://bioadvance.com/category/portfolio-news/phrase-health/)
- [Ossianix](https://bioadvance.com/category/portfolio-news/ossianix/)
- [Vesteck](https://bioadvance.com/category/portfolio-news/vesteck/)
- [Mebias Discovery](https://bioadvance.com/category/portfolio-news/mebias-discovery/)
- [Senzo](https://bioadvance.com/category/portfolio-news/senzo/)
- [Venatorx Pharmaceuticals](https://bioadvance.com/category/portfolio-news/venatorx-pharmaceuticals/)
- [Palvella Therapeutics](https://bioadvance.com/category/portfolio-news/palvella-therapeutics/)
- [Immunome](https://bioadvance.com/category/portfolio-news/immunome/)
- [Annovis](https://bioadvance.com/category/portfolio-news/annovis/)
- [Relmada Therapeutics](https://bioadvance.com/category/portfolio-news/relmada-therapeutics/)
- [CrossBridge](https://bioadvance.com/category/portfolio-news/crossbridge/)
- [Hanimune Therapeutics](https://bioadvance.com/category/portfolio-news/hanimune-therapeutics/)
- [ENB Therapeutics](https://bioadvance.com/category/portfolio-news/enb-therapeutics/)
- [InfraScan](https://bioadvance.com/category/portfolio-news/infrascan/)
- [iView Therapeutics](https://bioadvance.com/category/portfolio-news/iview-therapeutics/)
- [Ride Health](https://bioadvance.com/category/portfolio-news/ride-health/)
- [SIRPant](https://bioadvance.com/category/portfolio-news/sirpant/)
- [ImmunoGenesis](https://bioadvance.com/category/portfolio-news/immunogenesis/)
- [Kayothera](https://bioadvance.com/category/portfolio-news/kayothera-portfolio-news/)
- [Halo Labs](https://bioadvance.com/category/portfolio-news/halo-labs/)
- [Oncora Medical](https://bioadvance.com/category/portfolio-news/oncora-medical/)
- [Vittoria Biotherapeutics](https://bioadvance.com/category/portfolio-news/vittoria-biotherapeutics/)
- [Opsidio](https://bioadvance.com/category/portfolio-news/opsidio/)
- [Renovacor](https://bioadvance.com/category/portfolio-news/renovacor/)
- [Eliksa Therapeutics](https://bioadvance.com/category/portfolio-news/eliksa-therapeutics/)
- [KaloCyte](https://bioadvance.com/category/portfolio-news/kalocyte/)
- [Concarlo Therapeutics](https://bioadvance.com/category/portfolio-news/concarlo-therapeutics/)
- [Innervace](https://bioadvance.com/category/portfolio-news/innervace/)
- [Bainbridge Health](https://bioadvance.com/category/portfolio-news/bainbridge-health/)
- [Allevi](https://bioadvance.com/category/portfolio-news/allevi/)
- [NuPathe](https://bioadvance.com/category/portfolio-news/nupathe/)
- [Novira Therapeutics](https://bioadvance.com/category/portfolio-news/novira-therapeutics/)
- [Melior Discovery](https://bioadvance.com/category/portfolio-news/melior-discovery/)
- [Ceptaris](https://bioadvance.com/category/portfolio-news/ceptaris/)
- [Intezyne](https://bioadvance.com/category/portfolio-news/intezyne/)
- [HealthQx](https://bioadvance.com/category/portfolio-news/healthqx/)
- [Treventis Corporation](https://bioadvance.com/category/portfolio-news/treventis-corporation/)
- [Cohero Health](https://bioadvance.com/category/portfolio-news/cohero-health/)
- [The One Health Company](https://bioadvance.com/category/portfolio-news/the-one-health-company/)
- [Keriton](https://bioadvance.com/category/portfolio-news/keriton/)
- [Pillo Health](https://bioadvance.com/category/portfolio-news/pillo-health/)
- [Onspira Therapeutics](https://bioadvance.com/category/portfolio-news/onspira-therapeutics/)
- [Avid Radiopharmaceuticals](https://bioadvance.com/category/portfolio-news/avid-radiopharmaceuticals/)
- [PST](https://bioadvance.com/category/portfolio-news/pst/)
- [LumenVu](https://bioadvance.com/category/portfolio-news/lumenvu/)
- [Protez Pharmaceuticals](https://bioadvance.com/category/portfolio-news/protez-pharmaceuticals/)
- [Alteris](https://bioadvance.com/category/portfolio-news/alteris/)
- [Midway Pharmaceuticals](https://bioadvance.com/category/portfolio-news/midway-pharmaceuticals/)
- [Atalan](https://bioadvance.com/category/portfolio-news/atalan/)

## Tags

- [Investments](https://bioadvance.com/tag/investments/)
- [Life Science](https://bioadvance.com/tag/life-science/)
- [Portfolio](https://bioadvance.com/tag/portfolio/)
- [Biotechnology](https://bioadvance.com/tag/biotechnology/)
- [AI](https://bioadvance.com/tag/ai/)
- [Mid-Atlantic](https://bioadvance.com/tag/mid-atlantic/)
- [Life Sciences](https://bioadvance.com/tag/life-sciences/)
- [Acquisition](https://bioadvance.com/tag/acquisition/)
- [Venture](https://bioadvance.com/tag/venture/)
- [Innovation](https://bioadvance.com/tag/innovation/)
- [Respiratory Disease](https://bioadvance.com/tag/respiratory-disease/)
- [COPD](https://bioadvance.com/tag/copd/)
- [Gene Therapy](https://bioadvance.com/tag/gene-therapy/)
- [Clinical Trials](https://bioadvance.com/tag/clinical-trials/)
- [Venture Capital](https://bioadvance.com/tag/venture-capital/)
- [Ocular Disease](https://bioadvance.com/tag/ocular-disease/)
- [Eyes](https://bioadvance.com/tag/eyes/)
- [Artificial Blood](https://bioadvance.com/tag/artificial-blood/)
- [genetic skin diseases](https://bioadvance.com/tag/genetic-skin-diseases/)
- [Drug Development](https://bioadvance.com/tag/drug-development/)
- [Antibodies](https://bioadvance.com/tag/antibodies/)
- [Parkinson’s disease](https://bioadvance.com/tag/parkinsons-disease/)
- [CAR T](https://bioadvance.com/tag/car-t/)
- [immunotherapy](https://bioadvance.com/tag/immunotherapy/)
- [T cell lymphoma](https://bioadvance.com/tag/t-cell-lymphoma/)
- [Cancer](https://bioadvance.com/tag/cancer/)
- [immune-mediated diseases](https://bioadvance.com/tag/immune-mediated-diseases/)
- [Funding](https://bioadvance.com/tag/funding/)
- [Board appointment](https://bioadvance.com/tag/board-appointment/)
- [Stem Cells](https://bioadvance.com/tag/stem-cells/)
- [Strategic Partnership](https://bioadvance.com/tag/strategic-partnership/)
- [Appointments](https://bioadvance.com/tag/appointments/)
- [Clinician Resignation](https://bioadvance.com/tag/clinician-resignation/)
- [Healthcare Innovation](https://bioadvance.com/tag/healthcare-innovation/)
- [Clinician Retention](https://bioadvance.com/tag/clinician-retention/)
- [Digital Health](https://bioadvance.com/tag/digital-health/)
- [Healthcare](https://bioadvance.com/tag/healthcare/)
- [Hospitals](https://bioadvance.com/tag/hospitals/)
- [Pharma](https://bioadvance.com/tag/pharma/)